id	sid	tid	token	lemma	pos
ajst-32485	1	1	119	119	NUM
ajst-32485	1	2	neoantigen	neoantigen	PROPN
ajst-32485	1	3	vaccine	vaccine	NOUN
ajst-32485	1	4	for	for	ADP
ajst-32485	1	5	pancreatic	pancreatic	ADJ
ajst-32485	1	6	cancer	cancer	NOUN
ajst-32485	1	7	:	:	PUNCT
ajst-32485	1	8	current	current	ADJ
ajst-32485	1	9	limitations	limitation	NOUN
ajst-32485	1	10	and	and	CCONJ
ajst-32485	1	11	targeted	target	VERB
ajst-32485	1	12	strategies	strategy	NOUN
ajst-32485	1	13	for	for	ADP
ajst-32485	1	14	enhancing	enhance	VERB
ajst-32485	1	15	immune	immune	ADJ
ajst-32485	1	16	response	response	NOUN
ajst-32485	1	17	ziyu	ziyu	PROPN
ajst-32485	1	18	xu	xu	PROPN
ajst-32485	1	19	1	1	NUM
ajst-32485	1	20	,	,	PUNCT
ajst-32485	1	21	a	a	PRON
ajst-32485	1	22	,	,	PUNCT
ajst-32485	1	23	xinran	xinran	NOUN
ajst-32485	1	24	zhao	zhao	PROPN
ajst-32485	1	25	2	2	NUM
ajst-32485	1	26	,	,	PUNCT
ajst-32485	1	27	b	b	PROPN
ajst-32485	1	28	1	1	NUM
ajst-32485	1	29	guanghua	guanghua	PROPN
ajst-32485	1	30	cambridge	cambridge	PROPN
ajst-32485	1	31	international	international	PROPN
ajst-32485	1	32	school	school	PROPN
ajst-32485	1	33	,	,	PUNCT
ajst-32485	1	34	shanghai	shanghai	PROPN
ajst-32485	1	35	,	,	PUNCT
ajst-32485	1	36	china	china	PROPN
ajst-32485	1	37	2	2	NUM
ajst-32485	1	38	shenzhen	shenzhen	PROPN
ajst-32485	1	39	college	college	PROPN
ajst-32485	1	40	of	of	ADP
ajst-32485	1	41	international	international	ADJ
ajst-32485	1	42	education	education	NOUN
ajst-32485	1	43	,	,	PUNCT
ajst-32485	1	44	shenzhen	shenzhen	PROPN
ajst-32485	1	45	,	,	PUNCT
ajst-32485	1	46	guangdong	guangdong	PROPN
ajst-32485	1	47	,	,	PUNCT
ajst-32485	1	48	china	china	PROPN
ajst-32485	1	49	a	a	DET
ajst-32485	1	50	shirley_zhao_19@outlook.com	shirley_zhao_19@outlook.com	PROPN
ajst-32485	1	51	,	,	PUNCT
ajst-32485	1	52	b	b	PROPN
ajst-32485	1	53	1074803366@qq.com	1074803366@qq.com	NUM
ajst-32485	1	54	abstract	abstract	NOUN
ajst-32485	1	55	.	.	PUNCT
ajst-32485	2	1	pancreatic	pancreatic	ADJ
ajst-32485	2	2	cancer	cancer	NOUN
ajst-32485	2	3	is	be	AUX
ajst-32485	2	4	a	a	DET
ajst-32485	2	5	form	form	NOUN
ajst-32485	2	6	of	of	ADP
ajst-32485	2	7	cancer	cancer	NOUN
ajst-32485	2	8	regarded	regard	VERB
ajst-32485	2	9	as	as	ADP
ajst-32485	2	10	the	the	DET
ajst-32485	2	11	most	most	ADV
ajst-32485	2	12	fatal	fatal	ADJ
ajst-32485	2	13	malignant	malignant	ADJ
ajst-32485	2	14	tumor	tumor	NOUN
ajst-32485	2	15	,	,	PUNCT
ajst-32485	2	16	facing	face	VERB
ajst-32485	2	17	challenges	challenge	NOUN
ajst-32485	2	18	due	due	ADP
ajst-32485	2	19	to	to	ADP
ajst-32485	2	20	its	its	PRON
ajst-32485	2	21	strong	strong	ADJ
ajst-32485	2	22	invasiveness	invasiveness	NOUN
ajst-32485	2	23	and	and	CCONJ
ajst-32485	2	24	limited	limited	ADJ
ajst-32485	2	25	response	response	NOUN
ajst-32485	2	26	to	to	ADP
ajst-32485	2	27	traditional	traditional	ADJ
ajst-32485	2	28	treatment	treatment	NOUN
ajst-32485	2	29	methods	method	NOUN
ajst-32485	2	30	.	.	PUNCT
ajst-32485	3	1	a	a	DET
ajst-32485	3	2	neoantigen	neoantigen	PROPN
ajst-32485	3	3	vaccine	vaccine	NOUN
ajst-32485	3	4	is	be	AUX
ajst-32485	3	5	a	a	DET
ajst-32485	3	6	newly	newly	ADV
ajst-32485	3	7	developed	develop	VERB
ajst-32485	3	8	treatment	treatment	NOUN
ajst-32485	3	9	method	method	NOUN
ajst-32485	3	10	that	that	PRON
ajst-32485	3	11	stimulates	stimulate	VERB
ajst-32485	3	12	cytotoxic	cytotoxic	ADJ
ajst-32485	3	13	t	t	NOUN
ajst-32485	3	14	-	-	PUNCT
ajst-32485	3	15	cell	cell	NOUN
ajst-32485	3	16	response	response	NOUN
ajst-32485	3	17	by	by	ADP
ajst-32485	3	18	inducing	induce	VERB
ajst-32485	3	19	tumor	tumor	NOUN
ajst-32485	3	20	-	-	PUNCT
ajst-32485	3	21	specific	specific	ADJ
ajst-32485	3	22	antigens	antigen	NOUN
ajst-32485	3	23	.	.	PUNCT
ajst-32485	4	1	although	although	SCONJ
ajst-32485	4	2	neoantigen	neoantigen	PROPN
ajst-32485	4	3	vaccine	vaccine	NOUN
ajst-32485	4	4	theoretically	theoretically	ADV
ajst-32485	4	5	possesses	possess	VERB
ajst-32485	4	6	advantages	advantage	NOUN
ajst-32485	4	7	of	of	ADP
ajst-32485	4	8	strong	strong	ADJ
ajst-32485	4	9	individualization	individualization	NOUN
ajst-32485	4	10	and	and	CCONJ
ajst-32485	4	11	high	high	ADJ
ajst-32485	4	12	immunogenicity	immunogenicity	NOUN
ajst-32485	4	13	,	,	PUNCT
ajst-32485	4	14	their	their	PRON
ajst-32485	4	15	therapeutic	therapeutic	ADJ
ajst-32485	4	16	effect	effect	NOUN
ajst-32485	4	17	is	be	AUX
ajst-32485	4	18	limited	limit	VERB
ajst-32485	4	19	in	in	ADP
ajst-32485	4	20	pancreatic	pancreatic	ADJ
ajst-32485	4	21	cancer	cancer	NOUN
ajst-32485	4	22	caused	cause	VERB
ajst-32485	4	23	by	by	ADP
ajst-32485	4	24	mechanisms	mechanism	NOUN
ajst-32485	4	25	in	in	ADP
ajst-32485	4	26	the	the	DET
ajst-32485	4	27	tumor	tumor	NOUN
ajst-32485	4	28	microenvironment	microenvironment	NOUN
ajst-32485	4	29	,	,	PUNCT
ajst-32485	4	30	physical	physical	ADJ
ajst-32485	4	31	barriers	barrier	NOUN
ajst-32485	4	32	,	,	PUNCT
ajst-32485	4	33	immunosuppressive	immunosuppressive	ADJ
ajst-32485	4	34	cells	cell	NOUN
ajst-32485	4	35	,	,	PUNCT
ajst-32485	4	36	and	and	CCONJ
ajst-32485	4	37	immune	immune	ADJ
ajst-32485	4	38	checkpoints	checkpoint	NOUN
ajst-32485	4	39	,	,	PUNCT
ajst-32485	4	40	insufficient	insufficient	ADJ
ajst-32485	4	41	quantity	quantity	NOUN
ajst-32485	4	42	,	,	PUNCT
ajst-32485	4	43	and	and	CCONJ
ajst-32485	4	44	function	function	NOUN
ajst-32485	4	45	of	of	ADP
ajst-32485	4	46	apcs	apc	NOUN
ajst-32485	4	47	,	,	PUNCT
ajst-32485	4	48	leading	lead	VERB
ajst-32485	4	49	to	to	ADP
ajst-32485	4	50	poor	poor	ADJ
ajst-32485	4	51	antigen	antigen	ADJ
ajst-32485	4	52	presentation	presentation	NOUN
ajst-32485	4	53	.	.	PUNCT
ajst-32485	5	1	a	a	DET
ajst-32485	5	2	delivery	delivery	NOUN
ajst-32485	5	3	strategy	strategy	NOUN
ajst-32485	5	4	targeting	target	VERB
ajst-32485	5	5	mesothelin	mesothelin	PROPN
ajst-32485	5	6	is	be	AUX
ajst-32485	5	7	believed	believe	VERB
ajst-32485	5	8	to	to	PART
ajst-32485	5	9	enhance	enhance	VERB
ajst-32485	5	10	antigen	antigen	ADJ
ajst-32485	5	11	presentation	presentation	NOUN
ajst-32485	5	12	and	and	CCONJ
ajst-32485	5	13	break	break	VERB
ajst-32485	5	14	through	through	ADP
ajst-32485	5	15	immune	immune	ADJ
ajst-32485	5	16	tolerance	tolerance	NOUN
ajst-32485	5	17	due	due	ADP
ajst-32485	5	18	to	to	ADP
ajst-32485	5	19	its	its	PRON
ajst-32485	5	20	characteristic	characteristic	ADJ
ajst-32485	5	21	high	high	ADJ
ajst-32485	5	22	expression	expression	NOUN
ajst-32485	5	23	in	in	ADP
ajst-32485	5	24	pancreatic	pancreatic	ADJ
ajst-32485	5	25	cancer	cancer	NOUN
ajst-32485	5	26	cells	cell	NOUN
ajst-32485	5	27	.	.	PUNCT
ajst-32485	6	1	according	accord	VERB
ajst-32485	6	2	to	to	ADP
ajst-32485	6	3	the	the	DET
ajst-32485	6	4	latest	late	ADJ
ajst-32485	6	5	clinical	clinical	ADJ
ajst-32485	6	6	trials	trial	NOUN
ajst-32485	6	7	,	,	PUNCT
ajst-32485	6	8	only	only	ADV
ajst-32485	6	9	half	half	NOUN
ajst-32485	6	10	of	of	ADP
ajst-32485	6	11	the	the	DET
ajst-32485	6	12	patients	patient	NOUN
ajst-32485	6	13	showed	show	VERB
ajst-32485	6	14	a	a	DET
ajst-32485	6	15	tcell	tcell	NOUN
ajst-32485	6	16	response	response	NOUN
ajst-32485	6	17	,	,	PUNCT
ajst-32485	6	18	suggesting	suggest	VERB
ajst-32485	6	19	the	the	DET
ajst-32485	6	20	tme	tme	NOUN
ajst-32485	6	21	barrier	barrier	NOUN
ajst-32485	6	22	has	have	VERB
ajst-32485	6	23	to	to	PART
ajst-32485	6	24	be	be	AUX
ajst-32485	6	25	conquered	conquer	VERB
ajst-32485	6	26	.	.	PUNCT
ajst-32485	7	1	based	base	VERB
ajst-32485	7	2	on	on	ADP
ajst-32485	7	3	this	this	DET
ajst-32485	7	4	result	result	NOUN
ajst-32485	7	5	,	,	PUNCT
ajst-32485	7	6	the	the	DET
ajst-32485	7	7	delivery	delivery	NOUN
ajst-32485	7	8	system	system	NOUN
ajst-32485	7	9	targeting	target	VERB
ajst-32485	7	10	the	the	DET
ajst-32485	7	11	highly	highly	ADV
ajst-32485	7	12	expressed	express	VERB
ajst-32485	7	13	tumor	tumor	NOUN
ajst-32485	7	14	marker	marker	NOUN
ajst-32485	7	15	mesothelin	mesothelin	PROPN
ajst-32485	7	16	significantly	significantly	ADV
ajst-32485	7	17	enhanced	enhance	VERB
ajst-32485	7	18	antigen	antigen	ADP
ajst-32485	7	19	uptake	uptake	NOUN
ajst-32485	7	20	and	and	CCONJ
ajst-32485	7	21	cd8⁺	cd8⁺	NOUN
ajst-32485	7	22	t	t	PROPN
ajst-32485	7	23	-	-	PUNCT
ajst-32485	7	24	cell	cell	NOUN
ajst-32485	7	25	infiltration	infiltration	NOUN
ajst-32485	7	26	in	in	ADP
ajst-32485	7	27	the	the	DET
ajst-32485	7	28	mouse	mouse	NOUN
ajst-32485	7	29	model	model	NOUN
ajst-32485	7	30	.	.	PUNCT
ajst-32485	8	1	this	this	DET
ajst-32485	8	2	essay	essay	NOUN
ajst-32485	8	3	focuses	focus	VERB
ajst-32485	8	4	on	on	ADP
ajst-32485	8	5	the	the	DET
ajst-32485	8	6	clinical	clinical	ADJ
ajst-32485	8	7	application	application	NOUN
ajst-32485	8	8	limitations	limitation	NOUN
ajst-32485	8	9	and	and	CCONJ
ajst-32485	8	10	optimization	optimization	NOUN
ajst-32485	8	11	strategies	strategy	NOUN
ajst-32485	8	12	of	of	ADP
ajst-32485	8	13	neoantigen	neoantigen	NOUN
ajst-32485	8	14	vaccine	vaccine	NOUN
ajst-32485	8	15	treatment	treatment	NOUN
ajst-32485	8	16	for	for	ADP
ajst-32485	8	17	pancreatic	pancreatic	ADJ
ajst-32485	8	18	cancer	cancer	NOUN
ajst-32485	8	19	.	.	PUNCT
ajst-32485	9	1	keywords	keyword	NOUN
ajst-32485	9	2	:	:	PUNCT
ajst-32485	9	3	neoantigen	neoantigen	PROPN
ajst-32485	9	4	vaccine	vaccine	NOUN
ajst-32485	9	5	;	;	PUNCT
ajst-32485	9	6	cancer	cancer	NOUN
ajst-32485	9	7	vaccine	vaccine	NOUN
ajst-32485	9	8	;	;	PUNCT
ajst-32485	9	9	immune	immune	ADJ
ajst-32485	9	10	response	response	NOUN
ajst-32485	9	11	;	;	PUNCT
ajst-32485	9	12	pancreatic	pancreatic	ADJ
ajst-32485	9	13	cancer	cancer	NOUN
ajst-32485	9	14	.	.	PUNCT
ajst-32485	10	1	1	1	X
ajst-32485	10	2	.	.	X
ajst-32485	10	3	introduction	introduction	NOUN
ajst-32485	10	4	pancreatic	pancreatic	ADJ
ajst-32485	10	5	cancer	cancer	NOUN
ajst-32485	10	6	is	be	AUX
ajst-32485	10	7	one	one	NUM
ajst-32485	10	8	of	of	ADP
ajst-32485	10	9	the	the	DET
ajst-32485	10	10	deadliest	deadly	ADJ
ajst-32485	10	11	forms	form	NOUN
ajst-32485	10	12	of	of	ADP
ajst-32485	10	13	cancer	cancer	NOUN
ajst-32485	10	14	in	in	ADP
ajst-32485	10	15	the	the	DET
ajst-32485	10	16	entire	entire	ADJ
ajst-32485	10	17	globe	globe	NOUN
ajst-32485	10	18	.	.	PUNCT
ajst-32485	11	1	in	in	ADP
ajst-32485	11	2	2020	2020	NUM
ajst-32485	11	3	,	,	PUNCT
ajst-32485	11	4	newly	newly	ADV
ajst-32485	11	5	diagnosed	diagnose	VERB
ajst-32485	11	6	cases	case	NOUN
ajst-32485	11	7	reached	reach	VERB
ajst-32485	11	8	495,000	495,000	NUM
ajst-32485	11	9	,	,	PUNCT
ajst-32485	11	10	along	along	ADP
ajst-32485	11	11	with	with	ADP
ajst-32485	11	12	466,000	466,000	NUM
ajst-32485	11	13	deaths	death	NOUN
ajst-32485	11	14	.	.	PUNCT
ajst-32485	12	1	91	91	NUM
ajst-32485	12	2	%	%	NOUN
ajst-32485	12	3	is	be	AUX
ajst-32485	12	4	the	the	DET
ajst-32485	12	5	latest	late	ADJ
ajst-32485	12	6	diagnosed	diagnose	VERB
ajst-32485	12	7	/	/	SYM
ajst-32485	12	8	death	death	NOUN
ajst-32485	12	9	rate	rate	NOUN
ajst-32485	12	10	of	of	ADP
ajst-32485	12	11	pancreatic	pancreatic	ADJ
ajst-32485	12	12	cancer	cancer	NOUN
ajst-32485	12	13	in	in	ADP
ajst-32485	12	14	2022	2022	NUM
ajst-32485	12	15	(	(	PUNCT
ajst-32485	12	16	who	who	PRON
ajst-32485	12	17	,	,	PUNCT
ajst-32485	12	18	2025	2025	NUM
ajst-32485	12	19	)	)	PUNCT
ajst-32485	12	20	.	.	PUNCT
ajst-32485	13	1	between	between	ADP
ajst-32485	13	2	1992	1992	NUM
ajst-32485	13	3	and	and	CCONJ
ajst-32485	13	4	2022	2022	NUM
ajst-32485	13	5	,	,	PUNCT
ajst-32485	13	6	the	the	DET
ajst-32485	13	7	percentage	percentage	NOUN
ajst-32485	13	8	of	of	ADP
ajst-32485	13	9	new	new	ADJ
ajst-32485	13	10	cases	case	NOUN
ajst-32485	13	11	found	find	VERB
ajst-32485	13	12	among	among	ADP
ajst-32485	13	13	death	death	NOUN
ajst-32485	13	14	numbers	number	NOUN
ajst-32485	13	15	remained	remain	VERB
ajst-32485	13	16	approximately	approximately	ADV
ajst-32485	13	17	85	85	NUM
ajst-32485	13	18	-	-	SYM
ajst-32485	13	19	90	90	NUM
ajst-32485	13	20	%	%	NOUN
ajst-32485	13	21	(	(	PUNCT
ajst-32485	13	22	nci	nci	PROPN
ajst-32485	13	23	,	,	PUNCT
ajst-32485	13	24	2018	2018	NUM
ajst-32485	13	25	)	)	PUNCT
ajst-32485	13	26	.	.	PUNCT
ajst-32485	14	1	current	current	ADJ
ajst-32485	14	2	mainstream	mainstream	NOUN
ajst-32485	14	3	treatment	treatment	NOUN
ajst-32485	14	4	methods	method	NOUN
ajst-32485	14	5	for	for	ADP
ajst-32485	14	6	pancreatic	pancreatic	ADJ
ajst-32485	14	7	cancer	cancer	NOUN
ajst-32485	14	8	include	include	VERB
ajst-32485	14	9	surgery	surgery	NOUN
ajst-32485	14	10	,	,	PUNCT
ajst-32485	14	11	chemotherapy	chemotherapy	NOUN
ajst-32485	14	12	,	,	PUNCT
ajst-32485	14	13	and	and	CCONJ
ajst-32485	14	14	radionuclide	radionuclide	NOUN
ajst-32485	14	15	therapy	therapy	NOUN
ajst-32485	14	16	.	.	PUNCT
ajst-32485	15	1	the	the	DET
ajst-32485	15	2	5	5	NUM
ajst-32485	15	3	-	-	PUNCT
ajst-32485	15	4	year	year	NOUN
ajst-32485	15	5	survival	survival	NOUN
ajst-32485	15	6	rate	rate	NOUN
ajst-32485	15	7	of	of	ADP
ajst-32485	15	8	pancreatic	pancreatic	ADJ
ajst-32485	15	9	cancer	cancer	NOUN
ajst-32485	15	10	patients	patient	NOUN
ajst-32485	15	11	was	be	AUX
ajst-32485	15	12	below	below	ADP
ajst-32485	15	13	10	10	NUM
ajst-32485	15	14	%	%	NOUN
ajst-32485	15	15	before	before	ADP
ajst-32485	15	16	2012	2012	NUM
ajst-32485	15	17	,	,	PUNCT
ajst-32485	15	18	regardless	regardless	ADV
ajst-32485	15	19	of	of	ADP
ajst-32485	15	20	the	the	DET
ajst-32485	15	21	treatment	treatment	NOUN
ajst-32485	15	22	received	receive	VERB
ajst-32485	15	23	and	and	CCONJ
ajst-32485	15	24	the	the	DET
ajst-32485	15	25	stage	stage	NOUN
ajst-32485	15	26	diagnosed	diagnose	VERB
ajst-32485	15	27	.	.	PUNCT
ajst-32485	16	1	the	the	DET
ajst-32485	16	2	number	number	NOUN
ajst-32485	16	3	increased	increase	VERB
ajst-32485	16	4	slightly	slightly	ADV
ajst-32485	16	5	above	above	ADP
ajst-32485	16	6	10	10	NUM
ajst-32485	16	7	%	%	NOUN
ajst-32485	16	8	after	after	ADP
ajst-32485	16	9	2012	2012	NUM
ajst-32485	16	10	,	,	PUNCT
ajst-32485	16	11	though	though	SCONJ
ajst-32485	16	12	still	still	ADV
ajst-32485	16	13	low	low	ADJ
ajst-32485	16	14	compared	compare	VERB
ajst-32485	16	15	with	with	ADP
ajst-32485	16	16	other	other	ADJ
ajst-32485	16	17	forms	form	NOUN
ajst-32485	16	18	of	of	ADP
ajst-32485	16	19	cancer	cancer	NOUN
ajst-32485	16	20	,	,	PUNCT
ajst-32485	16	21	for	for	ADP
ajst-32485	16	22	example	example	NOUN
ajst-32485	16	23	,	,	PUNCT
ajst-32485	16	24	leukemia	leukemia	NOUN
ajst-32485	16	25	.	.	PUNCT
ajst-32485	17	1	pancreatic	pancreatic	ADJ
ajst-32485	17	2	cancer	cancer	NOUN
ajst-32485	17	3	is	be	AUX
ajst-32485	17	4	hard	hard	ADJ
ajst-32485	17	5	to	to	PART
ajst-32485	17	6	cure	cure	VERB
ajst-32485	17	7	mainly	mainly	ADV
ajst-32485	17	8	because	because	SCONJ
ajst-32485	17	9	of	of	ADP
ajst-32485	17	10	its	its	PRON
ajst-32485	17	11	difficulty	difficulty	NOUN
ajst-32485	17	12	in	in	ADP
ajst-32485	17	13	diagnosis	diagnosis	NOUN
ajst-32485	17	14	,	,	PUNCT
ajst-32485	17	15	as	as	SCONJ
ajst-32485	17	16	its	its	PRON
ajst-32485	17	17	early	early	ADJ
ajst-32485	17	18	symptoms	symptom	NOUN
ajst-32485	17	19	are	be	AUX
ajst-32485	17	20	concealed	conceal	VERB
ajst-32485	17	21	,	,	PUNCT
ajst-32485	17	22	and	and	CCONJ
ajst-32485	17	23	most	most	ADJ
ajst-32485	17	24	patients	patient	NOUN
ajst-32485	17	25	are	be	AUX
ajst-32485	17	26	diagnosed	diagnose	VERB
ajst-32485	17	27	at	at	ADP
ajst-32485	17	28	an	an	DET
ajst-32485	17	29	advanced	advanced	ADJ
ajst-32485	17	30	stage	stage	NOUN
ajst-32485	17	31	,	,	PUNCT
ajst-32485	17	32	when	when	SCONJ
ajst-32485	17	33	cancer	cancer	NOUN
ajst-32485	17	34	cells	cell	NOUN
ajst-32485	17	35	have	have	AUX
ajst-32485	17	36	already	already	ADV
ajst-32485	17	37	spread	spread	VERB
ajst-32485	17	38	widely	widely	ADV
ajst-32485	17	39	.	.	PUNCT
ajst-32485	18	1	meanwhile	meanwhile	ADV
ajst-32485	18	2	,	,	PUNCT
ajst-32485	18	3	pancreatic	pancreatic	ADJ
ajst-32485	18	4	cancer	cancer	NOUN
ajst-32485	18	5	is	be	AUX
ajst-32485	18	6	not	not	PART
ajst-32485	18	7	sensitive	sensitive	ADJ
ajst-32485	18	8	to	to	ADP
ajst-32485	18	9	radiotherapy	radiotherapy	NOUN
ajst-32485	18	10	and	and	CCONJ
ajst-32485	18	11	chemotherapy	chemotherapy	NOUN
ajst-32485	18	12	,	,	PUNCT
ajst-32485	18	13	and	and	CCONJ
ajst-32485	18	14	a	a	DET
ajst-32485	18	15	lack	lack	NOUN
ajst-32485	18	16	of	of	ADP
ajst-32485	18	17	effective	effective	ADJ
ajst-32485	18	18	targeted	target	VERB
ajst-32485	18	19	therapeutic	therapeutic	ADJ
ajst-32485	18	20	drugs	drug	NOUN
ajst-32485	18	21	makes	make	VERB
ajst-32485	18	22	pancreatic	pancreatic	ADJ
ajst-32485	18	23	cancer	cancer	NOUN
ajst-32485	18	24	deadly	deadly	ADJ
ajst-32485	18	25	(	(	PUNCT
ajst-32485	18	26	nci	nci	NOUN
ajst-32485	18	27	,	,	PUNCT
ajst-32485	18	28	2022	2022	NUM
ajst-32485	18	29	)	)	PUNCT
ajst-32485	18	30	.	.	PUNCT
ajst-32485	19	1	against	against	ADP
ajst-32485	19	2	the	the	DET
ajst-32485	19	3	backdrop	backdrop	NOUN
ajst-32485	19	4	of	of	ADP
ajst-32485	19	5	the	the	DET
ajst-32485	19	6	limited	limited	ADJ
ajst-32485	19	7	efficacy	efficacy	NOUN
ajst-32485	19	8	of	of	ADP
ajst-32485	19	9	conventional	conventional	ADJ
ajst-32485	19	10	cancer	cancer	NOUN
ajst-32485	19	11	treatments	treatment	NOUN
ajst-32485	19	12	and	and	CCONJ
ajst-32485	19	13	the	the	DET
ajst-32485	19	14	extremely	extremely	ADV
ajst-32485	19	15	low	low	ADJ
ajst-32485	19	16	response	response	NOUN
ajst-32485	19	17	rate	rate	NOUN
ajst-32485	19	18	of	of	ADP
ajst-32485	19	19	immune	immune	ADJ
ajst-32485	19	20	checkpoint	checkpoint	NOUN
ajst-32485	19	21	inhibitors	inhibitor	NOUN
ajst-32485	19	22	(	(	PUNCT
ajst-32485	19	23	icis	icis	NOUN
ajst-32485	19	24	)	)	PUNCT
ajst-32485	19	25	in	in	ADP
ajst-32485	19	26	pancreatic	pancreatic	ADJ
ajst-32485	19	27	cancer	cancer	NOUN
ajst-32485	19	28	,	,	PUNCT
ajst-32485	19	29	various	various	ADJ
ajst-32485	19	30	immunotherapy	immunotherapy	NOUN
ajst-32485	19	31	approaches	approach	NOUN
ajst-32485	19	32	have	have	AUX
ajst-32485	19	33	gradually	gradually	ADV
ajst-32485	19	34	emerged	emerge	VERB
ajst-32485	19	35	as	as	ADP
ajst-32485	19	36	new	new	ADJ
ajst-32485	19	37	strategies	strategy	NOUN
ajst-32485	19	38	to	to	PART
ajst-32485	19	39	tackle	tackle	VERB
ajst-32485	19	40	pancreatic	pancreatic	ADJ
ajst-32485	19	41	cancer	cancer	NOUN
ajst-32485	19	42	.	.	PUNCT
ajst-32485	20	1	among	among	ADP
ajst-32485	20	2	them	they	PRON
ajst-32485	20	3	,	,	PUNCT
ajst-32485	20	4	personalized	personalize	VERB
ajst-32485	20	5	neoantigen	neoantigen	NOUN
ajst-32485	20	6	vaccines	vaccine	NOUN
ajst-32485	20	7	have	have	AUX
ajst-32485	20	8	attracted	attract	VERB
ajst-32485	20	9	considerable	considerable	ADJ
ajst-32485	20	10	attention	attention	NOUN
ajst-32485	20	11	in	in	ADP
ajst-32485	20	12	recent	recent	ADJ
ajst-32485	20	13	years	year	NOUN
ajst-32485	20	14	(	(	PUNCT
ajst-32485	20	15	rojas	rojas	PROPN
ajst-32485	20	16	et	et	PROPN
ajst-32485	20	17	al	al	PROPN
ajst-32485	20	18	.	.	PROPN
ajst-32485	20	19	,	,	PUNCT
ajst-32485	20	20	2023	2023	NUM
ajst-32485	20	21	)	)	PUNCT
ajst-32485	20	22	.	.	PUNCT
ajst-32485	21	1	neoantigens	neoantigen	NOUN
ajst-32485	21	2	,	,	PUNCT
ajst-32485	21	3	defined	define	VERB
ajst-32485	21	4	as	as	ADP
ajst-32485	21	5	non	non	ADJ
ajst-32485	21	6	-	-	ADJ
ajst-32485	21	7	autologous	autologous	ADJ
ajst-32485	21	8	proteins	protein	NOUN
ajst-32485	21	9	with	with	ADP
ajst-32485	21	10	individual	individual	ADJ
ajst-32485	21	11	specificity	specificity	NOUN
ajst-32485	21	12	generated	generate	VERB
ajst-32485	21	13	by	by	ADP
ajst-32485	21	14	non	non	ADJ
ajst-32485	21	15	-	-	ADJ
ajst-32485	21	16	synonymous	synonymous	ADJ
ajst-32485	21	17	mutations	mutation	NOUN
ajst-32485	21	18	in	in	ADP
ajst-32485	21	19	the	the	DET
ajst-32485	21	20	tumor	tumor	NOUN
ajst-32485	21	21	cell	cell	NOUN
ajst-32485	21	22	genome	genome	NOUN
ajst-32485	21	23	,	,	PUNCT
ajst-32485	21	24	have	have	AUX
ajst-32485	21	25	been	be	AUX
ajst-32485	21	26	recognized	recognize	VERB
ajst-32485	21	27	as	as	ADP
ajst-32485	21	28	ideal	ideal	ADJ
ajst-32485	21	29	targets	target	NOUN
ajst-32485	21	30	for	for	ADP
ajst-32485	21	31	cancer	cancer	NOUN
ajst-32485	21	32	immunotherapy	immunotherapy	NOUN
ajst-32485	21	33	due	due	ADP
ajst-32485	21	34	to	to	ADP
ajst-32485	21	35	their	their	PRON
ajst-32485	21	36	strong	strong	ADJ
ajst-32485	21	37	immunogenicity	immunogenicity	NOUN
ajst-32485	21	38	and	and	CCONJ
ajst-32485	21	39	lack	lack	NOUN
ajst-32485	21	40	of	of	ADP
ajst-32485	21	41	expression	expression	NOUN
ajst-32485	21	42	in	in	ADP
ajst-32485	21	43	normal	normal	ADJ
ajst-32485	21	44	tissues	tissue	NOUN
ajst-32485	21	45	.	.	PUNCT
ajst-32485	22	1	different	different	ADJ
ajst-32485	22	2	from	from	ADP
ajst-32485	22	3	the	the	DET
ajst-32485	22	4	traditional	traditional	ADJ
ajst-32485	22	5	tumor	tumor	NOUN
ajst-32485	22	6	-	-	PUNCT
ajst-32485	22	7	associated	associate	VERB
ajst-32485	22	8	antigens	antigen	NOUN
ajst-32485	22	9	(	(	PUNCT
ajst-32485	22	10	taas	taas	NOUN
ajst-32485	22	11	)	)	PUNCT
ajst-32485	22	12	,	,	PUNCT
ajst-32485	22	13	neoantigens	neoantigen	NOUN
ajst-32485	22	14	possess	possess	VERB
ajst-32485	22	15	stronger	strong	ADJ
ajst-32485	22	16	immunogenicity	immunogenicity	NOUN
ajst-32485	22	17	and	and	CCONJ
ajst-32485	22	18	higher	high	ADJ
ajst-32485	22	19	affinity	affinity	NOUN
ajst-32485	22	20	toward	toward	ADP
ajst-32485	22	21	major	major	ADJ
ajst-32485	22	22	histocompatibility	histocompatibility	NOUN
ajst-32485	22	23	complex	complex	NOUN
ajst-32485	22	24	(	(	PUNCT
ajst-32485	22	25	mhc	mhc	PROPN
ajst-32485	22	26	)	)	PUNCT
ajst-32485	22	27	molecules	molecule	NOUN
ajst-32485	22	28	and	and	CCONJ
ajst-32485	22	29	are	be	AUX
ajst-32485	22	30	not	not	PART
ajst-32485	22	31	affected	affect	VERB
ajst-32485	22	32	by	by	ADP
ajst-32485	22	33	central	central	ADJ
ajst-32485	22	34	immunological	immunological	ADJ
ajst-32485	22	35	tolerance	tolerance	NOUN
ajst-32485	22	36	.	.	PUNCT
ajst-32485	23	1	the	the	DET
ajst-32485	23	2	unique	unique	ADJ
ajst-32485	23	3	characteristics	characteristic	NOUN
ajst-32485	23	4	of	of	ADP
ajst-32485	23	5	high	high	ADJ
ajst-32485	23	6	individual	individual	ADJ
ajst-32485	23	7	specificity	specificity	NOUN
ajst-32485	23	8	and	and	CCONJ
ajst-32485	23	9	immunogenicity	immunogenicity	NOUN
ajst-32485	23	10	position	position	NOUN
ajst-32485	23	11	neoantigen	neoantigen	NOUN
ajst-32485	23	12	vaccines	vaccine	NOUN
ajst-32485	23	13	as	as	ADP
ajst-32485	23	14	an	an	DET
ajst-32485	23	15	ideal	ideal	ADJ
ajst-32485	23	16	strategy	strategy	NOUN
ajst-32485	23	17	to	to	ADP
ajst-32485	23	18	120	120	NUM
ajst-32485	23	19	overcome	overcome	VERB
ajst-32485	23	20	the	the	DET
ajst-32485	23	21	limitations	limitation	NOUN
ajst-32485	23	22	of	of	ADP
ajst-32485	23	23	the	the	DET
ajst-32485	23	24	immunosuppressive	immunosuppressive	ADJ
ajst-32485	23	25	microenvironment	microenvironment	NOUN
ajst-32485	23	26	in	in	ADP
ajst-32485	23	27	pancreatic	pancreatic	ADJ
ajst-32485	23	28	cancer	cancer	NOUN
ajst-32485	23	29	(	(	PUNCT
ajst-32485	23	30	peng	peng	PROPN
ajst-32485	23	31	et	et	PROPN
ajst-32485	23	32	al	al	PROPN
ajst-32485	23	33	.	.	PROPN
ajst-32485	23	34	,	,	PUNCT
ajst-32485	23	35	2019	2019	NUM
ajst-32485	23	36	)	)	PUNCT
ajst-32485	23	37	.	.	PUNCT
ajst-32485	24	1	2	2	X
ajst-32485	24	2	.	.	X
ajst-32485	24	3	neoantigen	neoantigen	PROPN
ajst-32485	24	4	vaccine	vaccine	NOUN
ajst-32485	24	5	action	action	NOUN
ajst-32485	24	6	2.1	2.1	NUM
ajst-32485	24	7	mechanism	mechanism	NOUN
ajst-32485	24	8	neoantigen	neoantigen	PRON
ajst-32485	24	9	refers	refer	VERB
ajst-32485	24	10	to	to	ADP
ajst-32485	24	11	a	a	DET
ajst-32485	24	12	specific	specific	ADJ
ajst-32485	24	13	protein	protein	NOUN
ajst-32485	24	14	fragment	fragment	NOUN
ajst-32485	24	15	produced	produce	VERB
ajst-32485	24	16	by	by	ADP
ajst-32485	24	17	a	a	DET
ajst-32485	24	18	tumor	tumor	NOUN
ajst-32485	24	19	cell	cell	NOUN
ajst-32485	24	20	due	due	ADP
ajst-32485	24	21	to	to	ADP
ajst-32485	24	22	mutations	mutation	NOUN
ajst-32485	24	23	,	,	PUNCT
ajst-32485	24	24	which	which	PRON
ajst-32485	24	25	is	be	AUX
ajst-32485	24	26	recognized	recognize	VERB
ajst-32485	24	27	by	by	ADP
ajst-32485	24	28	the	the	DET
ajst-32485	24	29	immune	immune	ADJ
ajst-32485	24	30	system	system	NOUN
ajst-32485	24	31	as	as	ADP
ajst-32485	24	32	a	a	DET
ajst-32485	24	33	non	non	ADJ
ajst-32485	24	34	-	-	ADJ
ajst-32485	24	35	self	self	NOUN
ajst-32485	24	36	-	-	PUNCT
ajst-32485	24	37	antigen	antigen	NOUN
ajst-32485	24	38	,	,	PUNCT
ajst-32485	24	39	triggering	trigger	VERB
ajst-32485	24	40	an	an	DET
ajst-32485	24	41	immune	immune	ADJ
ajst-32485	24	42	response	response	NOUN
ajst-32485	24	43	.	.	PUNCT
ajst-32485	25	1	a	a	DET
ajst-32485	25	2	neoantigen	neoantigen	PROPN
ajst-32485	25	3	vaccine	vaccine	NOUN
ajst-32485	25	4	aims	aim	VERB
ajst-32485	25	5	to	to	PART
ajst-32485	25	6	target	target	VERB
ajst-32485	25	7	these	these	DET
ajst-32485	25	8	mutated	mutate	VERB
ajst-32485	25	9	antigens	antigen	NOUN
ajst-32485	25	10	on	on	ADP
ajst-32485	25	11	the	the	DET
ajst-32485	25	12	cell	cell	NOUN
ajst-32485	25	13	surface	surface	NOUN
ajst-32485	25	14	to	to	PART
ajst-32485	25	15	activate	activate	VERB
ajst-32485	25	16	the	the	DET
ajst-32485	25	17	patient	patient	NOUN
ajst-32485	25	18	’s	’s	PART
ajst-32485	25	19	t	t	PROPN
ajst-32485	25	20	-	-	PUNCT
ajst-32485	25	21	cell	cell	NOUN
ajst-32485	25	22	immune	immune	ADJ
ajst-32485	25	23	response	response	NOUN
ajst-32485	25	24	to	to	PART
ajst-32485	25	25	attack	attack	VERB
ajst-32485	25	26	the	the	DET
ajst-32485	25	27	tumor	tumor	NOUN
ajst-32485	25	28	cells	cell	NOUN
ajst-32485	25	29	(	(	PUNCT
ajst-32485	25	30	rojas	rojas	PROPN
ajst-32485	25	31	et	et	PROPN
ajst-32485	25	32	al	al	PROPN
ajst-32485	25	33	.	.	PROPN
ajst-32485	25	34	,	,	PUNCT
ajst-32485	25	35	2023	2023	NUM
ajst-32485	25	36	)	)	PUNCT
ajst-32485	25	37	.	.	PUNCT
ajst-32485	26	1	to	to	PART
ajst-32485	26	2	produce	produce	VERB
ajst-32485	26	3	a	a	DET
ajst-32485	26	4	neoantigen	neoantigen	NOUN
ajst-32485	26	5	vaccine	vaccine	NOUN
ajst-32485	26	6	,	,	PUNCT
ajst-32485	26	7	several	several	ADJ
ajst-32485	26	8	steps	step	NOUN
ajst-32485	26	9	have	have	VERB
ajst-32485	26	10	to	to	PART
ajst-32485	26	11	be	be	AUX
ajst-32485	26	12	processed	process	VERB
ajst-32485	26	13	.	.	PUNCT
ajst-32485	27	1	to	to	PART
ajst-32485	27	2	begin	begin	VERB
ajst-32485	27	3	with	with	ADP
ajst-32485	27	4	,	,	PUNCT
ajst-32485	27	5	neoantigen	neoantigen	PROPN
ajst-32485	27	6	has	have	VERB
ajst-32485	27	7	to	to	PART
ajst-32485	27	8	be	be	AUX
ajst-32485	27	9	screened	screen	VERB
ajst-32485	27	10	by	by	ADP
ajst-32485	27	11	tumor	tumor	NOUN
ajst-32485	27	12	sequencing	sequence	VERB
ajst-32485	27	13	to	to	PART
ajst-32485	27	14	perform	perform	VERB
ajst-32485	27	15	whole	whole	ADJ
ajst-32485	27	16	exome	exome	NOUN
ajst-32485	27	17	or	or	CCONJ
ajst-32485	27	18	rna	rna	NOUN
ajst-32485	27	19	sequencing	sequencing	NOUN
ajst-32485	27	20	on	on	ADP
ajst-32485	27	21	the	the	DET
ajst-32485	27	22	patient	patient	NOUN
ajst-32485	27	23	’s	’s	PART
ajst-32485	27	24	tumor	tumor	NOUN
ajst-32485	27	25	tissue	tissue	NOUN
ajst-32485	27	26	to	to	PART
ajst-32485	27	27	identify	identify	VERB
ajst-32485	27	28	particular	particular	ADJ
ajst-32485	27	29	mutations	mutation	NOUN
ajst-32485	27	30	such	such	ADJ
ajst-32485	27	31	as	as	ADP
ajst-32485	27	32	single	single	ADJ
ajst-32485	27	33	-	-	PUNCT
ajst-32485	27	34	nucleotide	nucleotide	NOUN
ajst-32485	27	35	variations	variation	NOUN
ajst-32485	27	36	,	,	PUNCT
ajst-32485	27	37	insertions	insertion	NOUN
ajst-32485	27	38	,	,	PUNCT
ajst-32485	27	39	or	or	CCONJ
ajst-32485	27	40	deletions	deletion	NOUN
ajst-32485	27	41	.	.	PUNCT
ajst-32485	28	1	besides	besides	SCONJ
ajst-32485	28	2	,	,	PUNCT
ajst-32485	28	3	prediction	prediction	NOUN
ajst-32485	28	4	is	be	AUX
ajst-32485	28	5	also	also	ADV
ajst-32485	28	6	required	require	VERB
ajst-32485	28	7	.	.	PUNCT
ajst-32485	29	1	through	through	ADP
ajst-32485	29	2	algorithms	algorithm	NOUN
ajst-32485	29	3	such	such	ADJ
ajst-32485	29	4	as	as	ADP
ajst-32485	29	5	mhc	mhc	NOUN
ajst-32485	29	6	binding	bind	VERB
ajst-32485	29	7	prediction	prediction	NOUN
ajst-32485	29	8	tools	tool	NOUN
ajst-32485	29	9	,	,	PUNCT
ajst-32485	29	10	select	select	ADJ
ajst-32485	29	11	mutant	mutant	ADJ
ajst-32485	29	12	peptide	peptide	NOUN
ajst-32485	29	13	segments	segment	NOUN
ajst-32485	29	14	that	that	PRON
ajst-32485	29	15	may	may	AUX
ajst-32485	29	16	bind	bind	VERB
ajst-32485	29	17	to	to	ADP
ajst-32485	29	18	the	the	DET
ajst-32485	29	19	patient	patient	NOUN
ajst-32485	29	20	’s	’s	PART
ajst-32485	29	21	hla	hla	PROPN
ajst-32485	29	22	molecules	molecule	NOUN
ajst-32485	29	23	(	(	PUNCT
ajst-32485	29	24	mhc	mhc	PROPN
ajst-32485	29	25	-	-	PUNCT
ajst-32485	29	26	i	i	PROPN
ajst-32485	29	27	/	/	SYM
ajst-32485	29	28	ii	ii	PROPN
ajst-32485	29	29	classes	class	NOUN
ajst-32485	29	30	)	)	PUNCT
ajst-32485	29	31	and	and	CCONJ
ajst-32485	29	32	give	give	VERB
ajst-32485	29	33	priority	priority	NOUN
ajst-32485	29	34	to	to	ADP
ajst-32485	29	35	candidate	candidate	NOUN
ajst-32485	29	36	neoantigens	neoantigen	NOUN
ajst-32485	29	37	with	with	ADP
ajst-32485	29	38	strong	strong	ADJ
ajst-32485	29	39	immunogenicity	immunogenicity	NOUN
ajst-32485	29	40	(	(	PUNCT
ajst-32485	29	41	rojas	rojas	PROPN
ajst-32485	29	42	et	et	PROPN
ajst-32485	29	43	al	al	PROPN
ajst-32485	29	44	.	.	PROPN
ajst-32485	29	45	,	,	PUNCT
ajst-32485	29	46	2023	2023	NUM
ajst-32485	29	47	)	)	PUNCT
ajst-32485	29	48	.	.	PUNCT
ajst-32485	30	1	designing	design	VERB
ajst-32485	30	2	a	a	DET
ajst-32485	30	3	vaccine	vaccine	NOUN
ajst-32485	30	4	is	be	AUX
ajst-32485	30	5	the	the	DET
ajst-32485	30	6	step	step	NOUN
ajst-32485	30	7	following	follow	VERB
ajst-32485	30	8	neoantigen	neoantigen	PROPN
ajst-32485	30	9	screening	screening	NOUN
ajst-32485	30	10	.	.	PUNCT
ajst-32485	31	1	the	the	DET
ajst-32485	31	2	vaccine	vaccine	NOUN
ajst-32485	31	3	form	form	NOUN
ajst-32485	31	4	has	have	VERB
ajst-32485	31	5	to	to	PART
ajst-32485	31	6	be	be	AUX
ajst-32485	31	7	decided	decide	VERB
ajst-32485	31	8	at	at	ADP
ajst-32485	31	9	first	first	ADV
ajst-32485	31	10	,	,	PUNCT
ajst-32485	31	11	for	for	ADP
ajst-32485	31	12	example	example	NOUN
ajst-32485	31	13	,	,	PUNCT
ajst-32485	31	14	using	use	VERB
ajst-32485	31	15	synthetic	synthetic	ADJ
ajst-32485	31	16	peptide	peptide	ADJ
ajst-32485	31	17	segments	segment	NOUN
ajst-32485	31	18	,	,	PUNCT
ajst-32485	31	19	mrna	mrna	PROPN
ajst-32485	31	20	,	,	PUNCT
ajst-32485	31	21	or	or	CCONJ
ajst-32485	31	22	dna	dna	PROPN
ajst-32485	31	23	vectors	vector	NOUN
ajst-32485	31	24	to	to	PART
ajst-32485	31	25	encode	encode	VERB
ajst-32485	31	26	new	new	ADJ
ajst-32485	31	27	antigens	antigen	NOUN
ajst-32485	31	28	.	.	PUNCT
ajst-32485	32	1	besides	besides	SCONJ
ajst-32485	32	2	,	,	PUNCT
ajst-32485	32	3	adjuvants	adjuvant	NOUN
ajst-32485	32	4	and	and	CCONJ
ajst-32485	32	5	delivery	delivery	NOUN
ajst-32485	32	6	systems	system	NOUN
ajst-32485	32	7	are	be	AUX
ajst-32485	32	8	also	also	ADV
ajst-32485	32	9	factors	factor	NOUN
ajst-32485	32	10	that	that	PRON
ajst-32485	32	11	need	need	VERB
ajst-32485	32	12	to	to	PART
ajst-32485	32	13	be	be	AUX
ajst-32485	32	14	considered	consider	VERB
ajst-32485	32	15	while	while	SCONJ
ajst-32485	32	16	designing	design	VERB
ajst-32485	32	17	a	a	DET
ajst-32485	32	18	vaccine	vaccine	NOUN
ajst-32485	32	19	;	;	PUNCT
ajst-32485	32	20	they	they	PRON
ajst-32485	32	21	are	be	AUX
ajst-32485	32	22	often	often	ADV
ajst-32485	32	23	combined	combine	VERB
ajst-32485	32	24	with	with	ADP
ajst-32485	32	25	adjuvants	adjuvant	NOUN
ajst-32485	32	26	such	such	ADJ
ajst-32485	32	27	as	as	ADP
ajst-32485	32	28	tlr	tlr	PROPN
ajst-32485	32	29	agonists	agonist	NOUN
ajst-32485	32	30	or	or	CCONJ
ajst-32485	32	31	nanoparticles	nanoparticle	NOUN
ajst-32485	32	32	to	to	PART
ajst-32485	32	33	enhance	enhance	VERB
ajst-32485	32	34	immunogenicity	immunogenicity	NOUN
ajst-32485	32	35	and	and	CCONJ
ajst-32485	32	36	promote	promote	VERB
ajst-32485	32	37	antigen	antigen	ADJ
ajst-32485	32	38	presentation	presentation	NOUN
ajst-32485	32	39	(	(	PUNCT
ajst-32485	32	40	rojas	rojas	PROPN
ajst-32485	32	41	et	et	PROPN
ajst-32485	32	42	al	al	PROPN
ajst-32485	32	43	.	.	PROPN
ajst-32485	32	44	,	,	PUNCT
ajst-32485	32	45	2023	2023	NUM
ajst-32485	32	46	)	)	PUNCT
ajst-32485	32	47	.	.	PUNCT
ajst-32485	33	1	the	the	DET
ajst-32485	33	2	next	next	ADJ
ajst-32485	33	3	step	step	NOUN
ajst-32485	33	4	is	be	AUX
ajst-32485	33	5	to	to	PART
ajst-32485	33	6	ensure	ensure	VERB
ajst-32485	33	7	immune	immune	ADJ
ajst-32485	33	8	activation	activation	NOUN
ajst-32485	33	9	of	of	ADP
ajst-32485	33	10	the	the	DET
ajst-32485	33	11	vaccine	vaccine	NOUN
ajst-32485	33	12	.	.	PUNCT
ajst-32485	34	1	antigen	antigen	ADJ
ajst-32485	34	2	presentation	presentation	NOUN
ajst-32485	34	3	should	should	AUX
ajst-32485	34	4	be	be	AUX
ajst-32485	34	5	considered	consider	VERB
ajst-32485	34	6	if	if	SCONJ
ajst-32485	34	7	the	the	DET
ajst-32485	34	8	neoantigens	neoantigen	NOUN
ajst-32485	34	9	in	in	ADP
ajst-32485	34	10	the	the	DET
ajst-32485	34	11	vaccine	vaccine	NOUN
ajst-32485	34	12	are	be	AUX
ajst-32485	34	13	taken	take	VERB
ajst-32485	34	14	up	up	ADP
ajst-32485	34	15	by	by	ADP
ajst-32485	34	16	dendritic	dendritic	ADJ
ajst-32485	34	17	cells	cell	NOUN
ajst-32485	34	18	(	(	PUNCT
ajst-32485	34	19	dcs	dcs	PROPN
ajst-32485	34	20	)	)	PUNCT
ajst-32485	34	21	and	and	CCONJ
ajst-32485	34	22	presented	present	VERB
ajst-32485	34	23	to	to	ADP
ajst-32485	34	24	cd8⁺/cd4⁺	cd8⁺/cd4⁺	PROPN
ajst-32485	34	25	t	t	NOUN
ajst-32485	34	26	cells	cell	NOUN
ajst-32485	34	27	.	.	PUNCT
ajst-32485	35	1	as	as	ADV
ajst-32485	35	2	well	well	ADV
ajst-32485	35	3	as	as	ADP
ajst-32485	35	4	t	t	PROPN
ajst-32485	35	5	cell	cell	NOUN
ajst-32485	35	6	expansion	expansion	NOUN
ajst-32485	35	7	,	,	PUNCT
ajst-32485	35	8	activated	activate	VERB
ajst-32485	35	9	t	t	NOUN
ajst-32485	35	10	cells	cell	NOUN
ajst-32485	35	11	clone	clone	VERB
ajst-32485	35	12	and	and	CCONJ
ajst-32485	35	13	proliferate	proliferate	VERB
ajst-32485	35	14	,	,	PUNCT
ajst-32485	35	15	forming	form	VERB
ajst-32485	35	16	specific	specific	ADJ
ajst-32485	35	17	cytotoxic	cytotoxic	ADJ
ajst-32485	35	18	t	t	NOUN
ajst-32485	35	19	cells	cell	NOUN
ajst-32485	35	20	(	(	PUNCT
ajst-32485	35	21	ctls	ctls	PROPN
ajst-32485	35	22	)	)	PUNCT
ajst-32485	35	23	or	or	CCONJ
ajst-32485	35	24	helper	helper	NOUN
ajst-32485	35	25	t	t	PROPN
ajst-32485	35	26	cells	cell	NOUN
ajst-32485	35	27	(	(	PUNCT
ajst-32485	35	28	th	th	NOUN
ajst-32485	35	29	)	)	PUNCT
ajst-32485	35	30	.	.	PUNCT
ajst-32485	36	1	to	to	PART
ajst-32485	36	2	make	make	VERB
ajst-32485	36	3	sure	sure	ADJ
ajst-32485	36	4	the	the	DET
ajst-32485	36	5	vaccine	vaccine	NOUN
ajst-32485	36	6	works	work	VERB
ajst-32485	36	7	,	,	PUNCT
ajst-32485	36	8	designers	designer	NOUN
ajst-32485	36	9	have	have	VERB
ajst-32485	36	10	to	to	PART
ajst-32485	36	11	verify	verify	VERB
ajst-32485	36	12	if	if	SCONJ
ajst-32485	36	13	effector	effector	NOUN
ajst-32485	36	14	t	t	PROPN
ajst-32485	36	15	cells	cell	NOUN
ajst-32485	36	16	migrate	migrate	VERB
ajst-32485	36	17	to	to	ADP
ajst-32485	36	18	the	the	DET
ajst-32485	36	19	tumor	tumor	NOUN
ajst-32485	36	20	site	site	NOUN
ajst-32485	36	21	and	and	CCONJ
ajst-32485	36	22	directly	directly	ADV
ajst-32485	36	23	kill	kill	VERB
ajst-32485	36	24	tumor	tumor	NOUN
ajst-32485	36	25	cells	cell	NOUN
ajst-32485	36	26	by	by	ADP
ajst-32485	36	27	recognizing	recognize	VERB
ajst-32485	36	28	the	the	DET
ajst-32485	36	29	mhc	mhc	PROPN
ajst-32485	36	30	-	-	PUNCT
ajst-32485	36	31	neoantigen	neoantigen	PROPN
ajst-32485	36	32	complex	complex	NOUN
ajst-32485	36	33	on	on	ADP
ajst-32485	36	34	the	the	DET
ajst-32485	36	35	surface	surface	NOUN
ajst-32485	36	36	of	of	ADP
ajst-32485	36	37	tumor	tumor	NOUN
ajst-32485	36	38	cells	cell	NOUN
ajst-32485	36	39	(	(	PUNCT
ajst-32485	36	40	rojas	rojas	PROPN
ajst-32485	36	41	et	et	PROPN
ajst-32485	36	42	al	al	PROPN
ajst-32485	36	43	.	.	PROPN
ajst-32485	36	44	,	,	PUNCT
ajst-32485	36	45	2023	2023	NUM
ajst-32485	36	46	)	)	PUNCT
ajst-32485	36	47	.	.	PUNCT
ajst-32485	37	1	2.2	2.2	NUM
ajst-32485	37	2	vaccine	vaccine	NOUN
ajst-32485	37	3	response	response	NOUN
ajst-32485	37	4	and	and	CCONJ
ajst-32485	37	5	clinical	clinical	ADJ
ajst-32485	37	6	outcome	outcome	NOUN
ajst-32485	37	7	phase	phase	NOUN
ajst-32485	37	8	1	1	NUM
ajst-32485	37	9	clinical	clinical	ADJ
ajst-32485	37	10	trial	trial	NOUN
ajst-32485	37	11	of	of	ADP
ajst-32485	37	12	atezolizumab	atezolizumab	NOUN
ajst-32485	37	13	in	in	ADP
ajst-32485	37	14	treating	treat	VERB
ajst-32485	37	15	padc	padc	NOUN
ajst-32485	37	16	was	be	AUX
ajst-32485	37	17	conducted	conduct	VERB
ajst-32485	37	18	by	by	ADP
ajst-32485	37	19	providing	provide	VERB
ajst-32485	37	20	atezolizumab	atezolizumab	NOUN
ajst-32485	37	21	for	for	ADP
ajst-32485	37	22	anti	anti	ADJ
ajst-32485	37	23	-	-	ADJ
ajst-32485	37	24	pd	pd	ADJ
ajst-32485	37	25	-	-	PUNCT
ajst-32485	37	26	l1	l1	PROPN
ajst-32485	37	27	immunity	immunity	NOUN
ajst-32485	37	28	therapy	therapy	NOUN
ajst-32485	37	29	,	,	PUNCT
ajst-32485	37	30	followed	follow	VERB
ajst-32485	37	31	by	by	ADP
ajst-32485	37	32	mrna	mrna	PROPN
ajst-32485	37	33	neoantigen	neoantigen	PROPN
ajst-32485	37	34	vaccine	vaccine	PROPN
ajst-32485	37	35	autogene	autogene	NOUN
ajst-32485	37	36	cevumeran	cevumeran	VERB
ajst-32485	37	37	,	,	PUNCT
ajst-32485	37	38	and	and	CCONJ
ajst-32485	37	39	lastly	lastly	ADV
ajst-32485	37	40	with	with	ADP
ajst-32485	37	41	chemotherapy	chemotherapy	NOUN
ajst-32485	37	42	using	use	VERB
ajst-32485	37	43	mfolfirinox	mfolfirinox	NOUN
ajst-32485	37	44	(	(	PUNCT
ajst-32485	37	45	it	it	PRON
ajst-32485	37	46	contains	contain	VERB
ajst-32485	37	47	folinic	folinic	ADJ
ajst-32485	37	48	acid	acid	NOUN
ajst-32485	37	49	,	,	PUNCT
ajst-32485	37	50	fluorouracil	fluorouracil	NOUN
ajst-32485	37	51	,	,	PUNCT
ajst-32485	37	52	irinotecan	irinotecan	NOUN
ajst-32485	37	53	,	,	PUNCT
ajst-32485	37	54	and	and	CCONJ
ajst-32485	37	55	oxaliplatin	oxaliplatin	NOUN
ajst-32485	37	56	)	)	PUNCT
ajst-32485	37	57	.	.	PUNCT
ajst-32485	38	1	patients	patient	NOUN
ajst-32485	38	2	must	must	AUX
ajst-32485	38	3	undergo	undergo	VERB
ajst-32485	38	4	this	this	DET
ajst-32485	38	5	therapy	therapy	NOUN
ajst-32485	38	6	for	for	ADP
ajst-32485	38	7	4	4	NUM
ajst-32485	38	8	periods	period	NOUN
ajst-32485	38	9	.	.	PUNCT
ajst-32485	39	1	half	half	NOUN
ajst-32485	39	2	(	(	PUNCT
ajst-32485	39	3	50	50	NUM
ajst-32485	39	4	%	%	NOUN
ajst-32485	39	5	)	)	PUNCT
ajst-32485	39	6	of	of	ADP
ajst-32485	39	7	the	the	DET
ajst-32485	39	8	patients	patient	NOUN
ajst-32485	39	9	involved	involve	VERB
ajst-32485	39	10	in	in	ADP
ajst-32485	39	11	this	this	DET
ajst-32485	39	12	trial	trial	NOUN
ajst-32485	39	13	were	be	AUX
ajst-32485	39	14	detected	detect	VERB
ajst-32485	39	15	with	with	ADP
ajst-32485	39	16	a	a	DET
ajst-32485	39	17	high	high	ADJ
ajst-32485	39	18	-	-	PUNCT
ajst-32485	39	19	intensity	intensity	NOUN
ajst-32485	39	20	neoantigenspecific	neoantigenspecific	PROPN
ajst-32485	39	21	t	t	PROPN
ajst-32485	39	22	-	-	PUNCT
ajst-32485	39	23	cell	cell	NOUN
ajst-32485	39	24	response	response	NOUN
ajst-32485	39	25	,	,	PUNCT
ajst-32485	39	26	particularly	particularly	ADV
ajst-32485	39	27	cd4⁺	cd4⁺	ADJ
ajst-32485	39	28	and	and	CCONJ
ajst-32485	39	29	cd8⁺	cd8⁺	NOUN
ajst-32485	39	30	(	(	PUNCT
ajst-32485	39	31	figure	figure	NOUN
ajst-32485	39	32	1b	1b	NUM
ajst-32485	39	33	)	)	PUNCT
ajst-32485	39	34	.	.	PUNCT
ajst-32485	40	1	half	half	NOUN
ajst-32485	40	2	of	of	ADP
ajst-32485	40	3	these	these	DET
ajst-32485	40	4	patients	patient	NOUN
ajst-32485	40	5	with	with	ADP
ajst-32485	40	6	highly	highly	ADV
ajst-32485	40	7	presented	present	VERB
ajst-32485	40	8	t	t	NOUN
ajst-32485	40	9	cells	cell	NOUN
ajst-32485	40	10	had	have	VERB
ajst-32485	40	11	t	t	NOUN
ajst-32485	40	12	cells	cell	NOUN
ajst-32485	40	13	targeting	target	VERB
ajst-32485	40	14	multiple	multiple	ADJ
ajst-32485	40	15	vaccine	vaccine	NOUN
ajst-32485	40	16	neoantigens	neoantigen	NOUN
ajst-32485	40	17	,	,	PUNCT
ajst-32485	40	18	referring	refer	VERB
ajst-32485	40	19	to	to	ADP
ajst-32485	40	20	more	more	ADJ
ajst-32485	40	21	than	than	ADP
ajst-32485	40	22	one	one	NUM
ajst-32485	40	23	target	target	NOUN
ajst-32485	40	24	spot	spot	NOUN
ajst-32485	40	25	.	.	PUNCT
ajst-32485	41	1	the	the	DET
ajst-32485	41	2	amplification	amplification	NOUN
ajst-32485	41	3	of	of	ADP
ajst-32485	41	4	t	t	PROPN
ajst-32485	41	5	-	-	PUNCT
ajst-32485	41	6	cells	cell	NOUN
ajst-32485	41	7	in	in	ADP
ajst-32485	41	8	this	this	DET
ajst-32485	41	9	experiment	experiment	NOUN
ajst-32485	41	10	shows	show	VERB
ajst-32485	41	11	that	that	SCONJ
ajst-32485	41	12	they	they	PRON
ajst-32485	41	13	expanded	expand	VERB
ajst-32485	41	14	by	by	ADP
ajst-32485	41	15	the	the	DET
ajst-32485	41	16	vaccine	vaccine	NOUN
ajst-32485	41	17	,	,	PUNCT
ajst-32485	41	18	accounting	account	VERB
ajst-32485	41	19	for	for	ADP
ajst-32485	41	20	10	10	NUM
ajst-32485	41	21	%	%	NOUN
ajst-32485	41	22	of	of	ADP
ajst-32485	41	23	the	the	DET
ajst-32485	41	24	peripheral	peripheral	ADJ
ajst-32485	41	25	blood	blood	NOUN
ajst-32485	41	26	t	t	NOUN
ajst-32485	41	27	cells	cell	NOUN
ajst-32485	41	28	and	and	CCONJ
ajst-32485	41	29	re	re	VERB
ajst-32485	41	30	-	-	VERB
ajst-32485	41	31	expanded	expand	VERB
ajst-32485	41	32	after	after	ADP
ajst-32485	41	33	the	the	DET
ajst-32485	41	34	vaccine	vaccine	NOUN
ajst-32485	41	35	booster	booster	NOUN
ajst-32485	41	36	(	(	PUNCT
ajst-32485	41	37	figure	figure	NOUN
ajst-32485	41	38	1d	1d	NUM
ajst-32485	41	39	)	)	PUNCT
ajst-32485	41	40	.	.	PUNCT
ajst-32485	42	1	these	these	DET
ajst-32485	42	2	t	t	NOUN
ajst-32485	42	3	-	-	PUNCT
ajst-32485	42	4	cells	cell	NOUN
ajst-32485	42	5	are	be	AUX
ajst-32485	42	6	multipotent	multipotent	NOUN
ajst-32485	42	7	effector	effector	NOUN
ajst-32485	42	8	cd8⁺	cd8⁺	PROPN
ajst-32485	42	9	t	t	PROPN
ajst-32485	42	10	-	-	PUNCT
ajst-32485	42	11	cells	cell	NOUN
ajst-32485	42	12	and	and	CCONJ
ajst-32485	42	13	can	can	AUX
ajst-32485	42	14	survive	survive	VERB
ajst-32485	42	15	for	for	ADP
ajst-32485	42	16	a	a	DET
ajst-32485	42	17	long	long	ADJ
ajst-32485	42	18	time	time	NOUN
ajst-32485	42	19	.	.	PUNCT
ajst-32485	43	1	immune	immune	ADJ
ajst-32485	43	2	memory	memory	NOUN
ajst-32485	43	3	of	of	ADP
ajst-32485	43	4	vaccination	vaccination	NOUN
ajst-32485	43	5	was	be	AUX
ajst-32485	43	6	shown	show	VERB
ajst-32485	43	7	by	by	ADP
ajst-32485	43	8	some	some	DET
ajst-32485	43	9	patients	patient	NOUN
ajst-32485	43	10	having	have	VERB
ajst-32485	43	11	persistence	persistence	NOUN
ajst-32485	43	12	of	of	ADP
ajst-32485	43	13	long	long	ADJ
ajst-32485	43	14	-	-	PUNCT
ajst-32485	43	15	term	term	NOUN
ajst-32485	43	16	memory	memory	NOUN
ajst-32485	43	17	t	t	NOUN
ajst-32485	43	18	cells	cell	NOUN
ajst-32485	43	19	for	for	ADP
ajst-32485	43	20	more	more	ADJ
ajst-32485	43	21	than	than	ADP
ajst-32485	43	22	18	18	NUM
ajst-32485	43	23	months	month	NOUN
ajst-32485	43	24	(	(	PUNCT
ajst-32485	43	25	figure	figure	NOUN
ajst-32485	43	26	1c	1c	NOUN
ajst-32485	43	27	)	)	PUNCT
ajst-32485	43	28	(	(	PUNCT
ajst-32485	43	29	rojas	rojas	PROPN
ajst-32485	43	30	et	et	PROPN
ajst-32485	43	31	al	al	PROPN
ajst-32485	43	32	.	.	PROPN
ajst-32485	43	33	,	,	PUNCT
ajst-32485	43	34	2023	2023	NUM
ajst-32485	43	35	)	)	PUNCT
ajst-32485	43	36	.	.	PUNCT
ajst-32485	44	1	t	t	PROPN
ajst-32485	44	2	-	-	PUNCT
ajst-32485	44	3	cell	cell	NOUN
ajst-32485	44	4	responders	responder	NOUN
ajst-32485	44	5	had	have	VERB
ajst-32485	44	6	a	a	DET
ajst-32485	44	7	median	median	ADJ
ajst-32485	44	8	recurrence	recurrence	NOUN
ajst-32485	44	9	-	-	PUNCT
ajst-32485	44	10	free	free	ADJ
ajst-32485	44	11	survival	survival	NOUN
ajst-32485	44	12	(	(	PUNCT
ajst-32485	44	13	rfs	rfs	PROPN
ajst-32485	44	14	)	)	PUNCT
ajst-32485	44	15	not	not	PART
ajst-32485	44	16	reached	reach	VERB
ajst-32485	44	17	,	,	PUNCT
ajst-32485	44	18	which	which	PRON
ajst-32485	44	19	means	mean	VERB
ajst-32485	44	20	the	the	DET
ajst-32485	44	21	majority	majority	NOUN
ajst-32485	44	22	did	do	AUX
ajst-32485	44	23	not	not	PART
ajst-32485	44	24	relapse	relapse	VERB
ajst-32485	44	25	.	.	PUNCT
ajst-32485	45	1	in	in	ADP
ajst-32485	45	2	comparison	comparison	NOUN
ajst-32485	45	3	,	,	PUNCT
ajst-32485	45	4	t	t	NOUN
ajst-32485	45	5	-	-	PUNCT
ajst-32485	45	6	cell	cell	NOUN
ajst-32485	45	7	non	non	NOUN
ajst-32485	45	8	-	-	NOUN
ajst-32485	45	9	responders	responder	NOUN
ajst-32485	45	10	showed	show	VERB
ajst-32485	45	11	a	a	DET
ajst-32485	45	12	median	median	ADJ
ajst-32485	45	13	rfs	rfs	NOUN
ajst-32485	45	14	of	of	ADP
ajst-32485	45	15	13.4	13.4	NUM
ajst-32485	45	16	months	month	NOUN
ajst-32485	45	17	.	.	PUNCT
ajst-32485	46	1	the	the	DET
ajst-32485	46	2	two	two	NUM
ajst-32485	46	3	groups	group	NOUN
ajst-32485	46	4	showed	show	VERB
ajst-32485	46	5	a	a	DET
ajst-32485	46	6	large	large	ADJ
ajst-32485	46	7	difference	difference	NOUN
ajst-32485	46	8	in	in	ADP
ajst-32485	46	9	rfs	rfs	PROPN
ajst-32485	46	10	value	value	NOUN
ajst-32485	46	11	(	(	PUNCT
ajst-32485	46	12	figure	figure	NOUN
ajst-32485	46	13	1e	1e	PROPN
ajst-32485	46	14	)	)	PUNCT
ajst-32485	46	15	;	;	PUNCT
ajst-32485	46	16	this	this	DET
ajst-32485	46	17	result	result	NOUN
ajst-32485	46	18	is	be	AUX
ajst-32485	46	19	not	not	PART
ajst-32485	46	20	affected	affect	VERB
ajst-32485	46	21	by	by	ADP
ajst-32485	46	22	the	the	DET
ajst-32485	46	23	patients	patient	NOUN
ajst-32485	46	24	’	'	PUNCT
ajst-32485	46	25	basic	basic	ADJ
ajst-32485	46	26	immune	immune	ADJ
ajst-32485	46	27	status	status	NOUN
ajst-32485	46	28	,	,	PUNCT
ajst-32485	46	29	as	as	SCONJ
ajst-32485	46	30	verified	verify	VERB
ajst-32485	46	31	by	by	ADP
ajst-32485	46	32	the	the	DET
ajst-32485	46	33	immune	immune	ADJ
ajst-32485	46	34	response	response	NOUN
ajst-32485	46	35	to	to	ADP
ajst-32485	46	36	the	the	DET
ajst-32485	46	37	sars	sar	NOUN
ajst-32485	46	38	-	-	PUNCT
ajst-32485	46	39	cov-2	cov-2	NOUN
ajst-32485	46	40	mrna	mrna	NOUN
ajst-32485	46	41	vaccine	vaccine	NOUN
ajst-32485	46	42	.	.	PUNCT
ajst-32485	47	1	in	in	ADP
ajst-32485	47	2	terms	term	NOUN
ajst-32485	47	3	of	of	ADP
ajst-32485	47	4	vaccine	vaccine	NOUN
ajst-32485	47	5	safety	safety	NOUN
ajst-32485	47	6	,	,	PUNCT
ajst-32485	47	7	the	the	DET
ajst-32485	47	8	experimental	experimental	ADJ
ajst-32485	47	9	results	result	NOUN
ajst-32485	47	10	show	show	VERB
ajst-32485	47	11	that	that	SCONJ
ajst-32485	47	12	the	the	DET
ajst-32485	47	13	vaccine	vaccine	NOUN
ajst-32485	47	14	is	be	AUX
ajst-32485	47	15	well	well	ADV
ajst-32485	47	16	tolerated	tolerate	VERB
ajst-32485	47	17	:	:	PUNCT
ajst-32485	47	18	no	no	DET
ajst-32485	47	19	dose	dose	NOUN
ajst-32485	47	20	-	-	PUNCT
ajst-32485	47	21	limiting	limit	VERB
ajst-32485	47	22	toxicity	toxicity	NOUN
ajst-32485	47	23	(	(	PUNCT
ajst-32485	47	24	dlt	dlt	PROPN
ajst-32485	47	25	)	)	PUNCT
ajst-32485	47	26	or	or	CCONJ
ajst-32485	47	27	serious	serious	ADJ
ajst-32485	47	28	vaccine	vaccine	NOUN
ajst-32485	47	29	-	-	PUNCT
ajst-32485	47	30	related	relate	VERB
ajst-32485	47	31	adverse	adverse	ADJ
ajst-32485	47	32	events	event	NOUN
ajst-32485	47	33	were	be	AUX
ajst-32485	47	34	reported	report	VERB
ajst-32485	47	35	.	.	PUNCT
ajst-32485	48	1	the	the	DET
ajst-32485	48	2	main	main	ADJ
ajst-32485	48	3	adverse	adverse	ADJ
ajst-32485	48	4	reactions	reaction	NOUN
ajst-32485	48	5	were	be	AUX
ajst-32485	48	6	grade	grade	NOUN
ajst-32485	48	7	1	1	NUM
ajst-32485	48	8	-	-	SYM
ajst-32485	48	9	2	2	NUM
ajst-32485	48	10	,	,	PUNCT
ajst-32485	48	11	including	include	VERB
ajst-32485	48	12	injection	injection	NOUN
ajst-32485	48	13	site	site	NOUN
ajst-32485	48	14	reaction	reaction	NOUN
ajst-32485	48	15	(	(	PUNCT
ajst-32485	48	16	58	58	NUM
ajst-32485	48	17	%	%	NOUN
ajst-32485	48	18	)	)	PUNCT
ajst-32485	48	19	,	,	PUNCT
ajst-32485	48	20	fatigue	fatigue	NOUN
ajst-32485	48	21	(	(	PUNCT
ajst-32485	48	22	33	33	NUM
ajst-32485	48	23	%	%	NOUN
ajst-32485	48	24	)	)	PUNCT
ajst-32485	48	25	,	,	PUNCT
ajst-32485	48	26	and	and	CCONJ
ajst-32485	48	27	low	low	ADJ
ajst-32485	48	28	fever	fever	NOUN
ajst-32485	48	29	(	(	PUNCT
ajst-32485	48	30	25	25	NUM
ajst-32485	48	31	%	%	NOUN
ajst-32485	48	32	)	)	PUNCT
ajst-32485	48	33	.	.	PUNCT
ajst-32485	49	1	no	no	DET
ajst-32485	49	2	dose	dose	NOUN
ajst-32485	49	3	-	-	PUNCT
ajst-32485	49	4	limiting	limit	VERB
ajst-32485	49	5	toxicity	toxicity	NOUN
ajst-32485	49	6	(	(	PUNCT
ajst-32485	49	7	dlt	dlt	PROPN
ajst-32485	49	8	)	)	PUNCT
ajst-32485	49	9	or	or	CCONJ
ajst-32485	49	10	vaccine	vaccine	NOUN
ajst-32485	49	11	-	-	PUNCT
ajst-32485	49	12	related	relate	VERB
ajst-32485	49	13	serious	serious	ADJ
ajst-32485	49	14	adverse	adverse	ADJ
ajst-32485	49	15	events	event	NOUN
ajst-32485	49	16	(	(	PUNCT
ajst-32485	49	17	saes	sae	NOUN
ajst-32485	49	18	)	)	PUNCT
ajst-32485	49	19	were	be	AUX
ajst-32485	49	20	detected	detect	VERB
ajst-32485	49	21	(	(	PUNCT
ajst-32485	49	22	rojas	rojas	PROPN
ajst-32485	49	23	et	et	PROPN
ajst-32485	49	24	al	al	PROPN
ajst-32485	49	25	.	.	PROPN
ajst-32485	49	26	,	,	PUNCT
ajst-32485	49	27	2023	2023	NUM
ajst-32485	49	28	)	)	PUNCT
ajst-32485	49	29	.	.	PUNCT
ajst-32485	50	1	121	121	NUM
ajst-32485	50	2	figure	figure	NOUN
ajst-32485	50	3	1	1	NUM
ajst-32485	50	4	.	.	PUNCT
ajst-32485	50	5	clinical	clinical	ADJ
ajst-32485	50	6	outcome	outcome	NOUN
ajst-32485	50	7	data	datum	NOUN
ajst-32485	50	8	.	.	PUNCT
ajst-32485	51	1	a	a	DET
ajst-32485	51	2	)	)	PUNCT
ajst-32485	51	3	trial	trial	NOUN
ajst-32485	51	4	design	design	NOUN
ajst-32485	51	5	.	.	PUNCT
ajst-32485	52	1	b	b	X
ajst-32485	52	2	)	)	PUNCT
ajst-32485	52	3	proportion	proportion	NOUN
ajst-32485	52	4	of	of	ADP
ajst-32485	52	5	vaccine	vaccine	NOUN
ajst-32485	52	6	responders	responder	NOUN
ajst-32485	52	7	and	and	CCONJ
ajst-32485	52	8	nonresponders	nonresponder	NOUN
ajst-32485	52	9	.	.	PUNCT
ajst-32485	53	1	c	c	X
ajst-32485	53	2	)	)	PUNCT
ajst-32485	53	3	vaccine	vaccine	NOUN
ajst-32485	53	4	-	-	PUNCT
ajst-32485	53	5	expanded	expand	VERB
ajst-32485	53	6	clones	clone	NOUN
ajst-32485	53	7	identified	identify	VERB
ajst-32485	53	8	by	by	ADP
ajst-32485	53	9	clonetrack	clonetrack	NOUN
ajst-32485	53	10	:	:	PUNCT
ajst-32485	53	11	longitudinal	longitudinal	ADJ
ajst-32485	53	12	aggregate	aggregate	ADJ
ajst-32485	53	13	percentage	percentage	NOUN
ajst-32485	53	14	;	;	PUNCT
ajst-32485	53	15	inverted	invert	VERB
ajst-32485	53	16	triangles	triangle	NOUN
ajst-32485	53	17	indicate	indicate	VERB
ajst-32485	53	18	collection	collection	NOUN
ajst-32485	53	19	times	time	NOUN
ajst-32485	53	20	for	for	ADP
ajst-32485	53	21	single	single	ADJ
ajst-32485	53	22	-	-	PUNCT
ajst-32485	53	23	cell	cell	NOUN
ajst-32485	53	24	sequencing	sequencing	NOUN
ajst-32485	53	25	and	and	CCONJ
ajst-32485	53	26	circles	circle	NOUN
ajst-32485	53	27	indicate	indicate	VERB
ajst-32485	53	28	vaccine	vaccine	NOUN
ajst-32485	53	29	booster	booster	NOUN
ajst-32485	53	30	.	.	PUNCT
ajst-32485	54	1	d	d	X
ajst-32485	54	2	)	)	PUNCT
ajst-32485	54	3	cd8⁺	cd8⁺	NOUN
ajst-32485	54	4	t	t	NOUN
ajst-32485	54	5	cells	cell	NOUN
ajst-32485	54	6	in	in	ADP
ajst-32485	54	7	the	the	DET
ajst-32485	54	8	peripheral	peripheral	ADJ
ajst-32485	54	9	blood	blood	NOUN
ajst-32485	54	10	of	of	ADP
ajst-32485	54	11	autogene	autogene	NOUN
ajst-32485	54	12	cevumeran	cevumeran	VERB
ajst-32485	54	13	responders	responder	NOUN
ajst-32485	54	14	and	and	CCONJ
ajst-32485	54	15	non	non	NOUN
ajst-32485	54	16	-	-	NOUN
ajst-32485	54	17	responders	responder	NOUN
ajst-32485	54	18	during	during	ADP
ajst-32485	54	19	vaccination	vaccination	NOUN
ajst-32485	54	20	.	.	PUNCT
ajst-32485	55	1	analyses	analysis	NOUN
ajst-32485	55	2	in	in	ADP
ajst-32485	55	3	n	n	CCONJ
ajst-32485	55	4	 	 	SPACE
ajst-32485	55	5	=	=	NOUN
ajst-32485	55	6	 	 	SPACE
ajst-32485	55	7	13	13	NUM
ajst-32485	55	8	patients	patient	NOUN
ajst-32485	55	9	with	with	ADP
ajst-32485	55	10	identical	identical	ADJ
ajst-32485	55	11	study	study	NOUN
ajst-32485	55	12	-	-	PUNCT
ajst-32485	55	13	specified	specify	VERB
ajst-32485	55	14	treatment	treatment	NOUN
ajst-32485	55	15	schedules	schedule	NOUN
ajst-32485	55	16	and	and	CCONJ
ajst-32485	55	17	thus	thus	ADV
ajst-32485	55	18	eligible	eligible	ADJ
ajst-32485	55	19	for	for	ADP
ajst-32485	55	20	direct	direct	ADJ
ajst-32485	55	21	comparison	comparison	NOUN
ajst-32485	55	22	.	.	PUNCT
ajst-32485	56	1	circle	circle	NOUN
ajst-32485	56	2	=	=	PUNCT
ajst-32485	57	1	mean	mean	VERB
ajst-32485	57	2	,	,	PUNCT
ajst-32485	57	3	error	error	NOUN
ajst-32485	57	4	bars	bar	NOUN
ajst-32485	57	5	=	=	SYM
ajst-32485	57	6	standard	standard	ADJ
ajst-32485	57	7	error	error	NOUN
ajst-32485	57	8	of	of	ADP
ajst-32485	57	9	the	the	DET
ajst-32485	57	10	mean	mean	NOUN
ajst-32485	57	11	;	;	PUNCT
ajst-32485	57	12	n	n	CCONJ
ajst-32485	57	13	=	=	VERB
ajst-32485	57	14	individual	individual	ADJ
ajst-32485	57	15	patients	patient	NOUN
ajst-32485	57	16	.	.	PUNCT
ajst-32485	58	1	p	p	NOUN
ajst-32485	58	2	values	value	NOUN
ajst-32485	58	3	by	by	ADP
ajst-32485	58	4	the	the	DET
ajst-32485	58	5	two	two	NUM
ajst-32485	58	6	-	-	PUNCT
ajst-32485	58	7	tailed	tail	VERB
ajst-32485	58	8	mann	mann	PROPN
ajst-32485	58	9	-	-	PUNCT
ajst-32485	58	10	whitney	whitney	PROPN
ajst-32485	58	11	test	test	NOUN
ajst-32485	58	12	.	.	PUNCT
ajst-32485	59	1	e	e	X
ajst-32485	59	2	)	)	PUNCT
ajst-32485	59	3	os	os	NOUN
ajst-32485	59	4	and	and	CCONJ
ajst-32485	59	5	rfs	rfs	VERB
ajst-32485	59	6	in	in	ADP
ajst-32485	59	7	n	n	CCONJ
ajst-32485	59	8	 	 	SPACE
ajst-32485	59	9	=	=	NOUN
ajst-32485	59	10	 	 	SPACE
ajst-32485	59	11	19	19	NUM
ajst-32485	59	12	patients	patient	NOUN
ajst-32485	59	13	in	in	ADP
ajst-32485	59	14	the	the	DET
ajst-32485	59	15	safety	safety	NOUN
ajst-32485	59	16	-	-	PUNCT
ajst-32485	59	17	evaluable	evaluable	ADJ
ajst-32485	59	18	cohort	cohort	NOUN
ajst-32485	59	19	.	.	PUNCT
ajst-32485	60	1	b	b	X
ajst-32485	60	2	,	,	PUNCT
ajst-32485	60	3	rfs	rf	VERB
ajst-32485	60	4	from	from	ADP
ajst-32485	60	5	surgery	surgery	NOUN
ajst-32485	60	6	and	and	CCONJ
ajst-32485	60	7	from	from	ADP
ajst-32485	60	8	landmark	landmark	ADJ
ajst-32485	60	9	time	time	NOUN
ajst-32485	60	10	(	(	PUNCT
ajst-32485	60	11	date	date	NOUN
ajst-32485	60	12	of	of	ADP
ajst-32485	60	13	the	the	DET
ajst-32485	60	14	last	last	ADJ
ajst-32485	60	15	vaccine	vaccine	NOUN
ajst-32485	60	16	priming	prime	VERB
ajst-32485	60	17	dose	dose	NOUN
ajst-32485	60	18	)	)	PUNCT
ajst-32485	60	19	stratified	stratify	VERB
ajst-32485	60	20	by	by	ADP
ajst-32485	60	21	vaccine	vaccine	NOUN
ajst-32485	60	22	response	response	NOUN
ajst-32485	60	23	in	in	ADP
ajst-32485	60	24	patients	patient	NOUN
ajst-32485	60	25	in	in	ADP
ajst-32485	60	26	the	the	DET
ajst-32485	60	27	biomarkerevaluable	biomarkerevaluable	NOUN
ajst-32485	60	28	cohort	cohort	NOUN
ajst-32485	60	29	.	.	PUNCT
ajst-32485	61	1	n	n	PRON
ajst-32485	61	2	indicates	indicate	VERB
ajst-32485	61	3	individual	individual	ADJ
ajst-32485	61	4	patients	patient	NOUN
ajst-32485	61	5	.	.	PUNCT
ajst-32485	62	1	hr	hr	NOUN
ajst-32485	62	2	indicates	indicate	VERB
ajst-32485	62	3	hazard	hazard	NOUN
ajst-32485	62	4	ratio	ratio	NOUN
ajst-32485	62	5	with	with	ADP
ajst-32485	62	6	95	95	NUM
ajst-32485	62	7	%	%	NOUN
ajst-32485	62	8	ci	ci	NOUN
ajst-32485	62	9	.	.	PUNCT
ajst-32485	63	1	p	p	X
ajst-32485	63	2	  	  	SPACE
ajst-32485	63	3	values	value	NOUN
ajst-32485	63	4	calculated	calculate	VERB
ajst-32485	63	5	using	use	VERB
ajst-32485	63	6	a	a	DET
ajst-32485	63	7	two	two	NUM
ajst-32485	63	8	-	-	PUNCT
ajst-32485	63	9	tailed	tail	VERB
ajst-32485	63	10	log	log	NOUN
ajst-32485	63	11	-	-	PUNCT
ajst-32485	63	12	rank	rank	NOUN
ajst-32485	63	13	test	test	NOUN
ajst-32485	63	14	.	.	PUNCT
ajst-32485	64	1	(	(	PUNCT
ajst-32485	64	2	rojas	rojas	PROPN
ajst-32485	64	3	et	et	PROPN
ajst-32485	64	4	al	al	PROPN
ajst-32485	64	5	.	.	PROPN
ajst-32485	64	6	,	,	PUNCT
ajst-32485	64	7	2023	2023	NUM
ajst-32485	64	8	)	)	PUNCT
ajst-32485	64	9	.	.	PUNCT
ajst-32485	65	1	this	this	DET
ajst-32485	65	2	trial	trial	NOUN
ajst-32485	65	3	still	still	ADV
ajst-32485	65	4	has	have	VERB
ajst-32485	65	5	several	several	ADJ
ajst-32485	65	6	limitations	limitation	NOUN
ajst-32485	65	7	;	;	PUNCT
ajst-32485	65	8	the	the	DET
ajst-32485	65	9	first	first	ADJ
ajst-32485	65	10	is	be	AUX
ajst-32485	65	11	the	the	DET
ajst-32485	65	12	small	small	ADJ
ajst-32485	65	13	sample	sample	NOUN
ajst-32485	65	14	size	size	NOUN
ajst-32485	65	15	due	due	ADP
ajst-32485	65	16	to	to	ADP
ajst-32485	65	17	only	only	ADV
ajst-32485	65	18	12	12	NUM
ajst-32485	65	19	patients	patient	NOUN
ajst-32485	65	20	being	be	AUX
ajst-32485	65	21	evaluated	evaluate	VERB
ajst-32485	65	22	,	,	PUNCT
ajst-32485	65	23	and	and	CCONJ
ajst-32485	65	24	larger	large	ADJ
ajst-32485	65	25	-	-	PUNCT
ajst-32485	65	26	scale	scale	NOUN
ajst-32485	65	27	validation	validation	NOUN
ajst-32485	65	28	is	be	AUX
ajst-32485	65	29	required	require	VERB
ajst-32485	65	30	.	.	PUNCT
ajst-32485	66	1	more	more	ADJ
ajst-32485	66	2	than	than	ADP
ajst-32485	66	3	that	that	PRON
ajst-32485	66	4	,	,	PUNCT
ajst-32485	66	5	combination	combination	NOUN
ajst-32485	66	6	therapy	therapy	NOUN
ajst-32485	66	7	interference	interference	NOUN
ajst-32485	66	8	means	mean	VERB
ajst-32485	66	9	it	it	PRON
ajst-32485	66	10	is	be	AUX
ajst-32485	66	11	difficult	difficult	ADJ
ajst-32485	66	12	to	to	PART
ajst-32485	66	13	distinguish	distinguish	VERB
ajst-32485	66	14	the	the	DET
ajst-32485	66	15	effect	effect	NOUN
ajst-32485	66	16	of	of	ADP
ajst-32485	66	17	the	the	DET
ajst-32485	66	18	vaccine	vaccine	NOUN
ajst-32485	66	19	alone	alone	ADV
ajst-32485	66	20	(	(	PUNCT
ajst-32485	66	21	chemotherapy	chemotherapy	NOUN
ajst-32485	66	22	and	and	CCONJ
ajst-32485	66	23	pd	pd	PROPN
ajst-32485	66	24	-	-	PUNCT
ajst-32485	66	25	l1	l1	PROPN
ajst-32485	66	26	inhibitors	inhibitor	NOUN
ajst-32485	66	27	may	may	AUX
ajst-32485	66	28	synergistically	synergistically	ADV
ajst-32485	66	29	enhance	enhance	VERB
ajst-32485	66	30	the	the	DET
ajst-32485	66	31	effect	effect	NOUN
ajst-32485	66	32	)	)	PUNCT
ajst-32485	66	33	.	.	PUNCT
ajst-32485	67	1	immunosuppressive	immunosuppressive	ADJ
ajst-32485	67	2	pancreatic	pancreatic	ADJ
ajst-32485	67	3	cancer	cancer	NOUN
ajst-32485	67	4	is	be	AUX
ajst-32485	67	5	also	also	ADV
ajst-32485	67	6	an	an	DET
ajst-32485	67	7	issue	issue	NOUN
ajst-32485	67	8	,	,	PUNCT
ajst-32485	67	9	as	as	SCONJ
ajst-32485	67	10	122	122	NUM
ajst-32485	67	11	some	some	DET
ajst-32485	67	12	patients	patient	NOUN
ajst-32485	67	13	still	still	ADV
ajst-32485	67	14	show	show	VERB
ajst-32485	67	15	no	no	DET
ajst-32485	67	16	response	response	NOUN
ajst-32485	67	17	,	,	PUNCT
ajst-32485	67	18	suggesting	suggest	VERB
ajst-32485	67	19	the	the	DET
ajst-32485	67	20	need	need	NOUN
ajst-32485	67	21	for	for	ADP
ajst-32485	67	22	combined	combine	VERB
ajst-32485	67	23	therapy	therapy	NOUN
ajst-32485	67	24	targeting	target	VERB
ajst-32485	67	25	the	the	DET
ajst-32485	67	26	microenvironment	microenvironment	NOUN
ajst-32485	67	27	,	,	PUNCT
ajst-32485	67	28	including	include	VERB
ajst-32485	67	29	cd40	cd40	PROPN
ajst-32485	67	30	agonists	agonist	NOUN
ajst-32485	67	31	(	(	PUNCT
ajst-32485	67	32	rojas	rojas	PROPN
ajst-32485	67	33	et	et	PROPN
ajst-32485	67	34	al	al	PROPN
ajst-32485	67	35	.	.	PROPN
ajst-32485	67	36	,	,	PUNCT
ajst-32485	67	37	2023	2023	NUM
ajst-32485	67	38	;	;	PUNCT
ajst-32485	67	39	program	program	NOUN
ajst-32485	67	40	guide	guide	NOUN
ajst-32485	67	41	–	–	PUNCT
ajst-32485	67	42	asco	asco	NOUN
ajst-32485	67	43	meeting	meeting	NOUN
ajst-32485	67	44	program	program	NOUN
ajst-32485	67	45	guide	guide	NOUN
ajst-32485	67	46	,	,	PUNCT
ajst-32485	67	47	2025	2025	NUM
ajst-32485	67	48	;	;	PUNCT
ajst-32485	67	49	memorial	memorial	ADJ
ajst-32485	67	50	sloan	sloan	PROPN
ajst-32485	67	51	kettering	kettering	PROPN
ajst-32485	67	52	cancer	cancer	PROPN
ajst-32485	67	53	center	center	PROPN
ajst-32485	67	54	&	&	CCONJ
ajst-32485	67	55	genentech	genentech	PROPN
ajst-32485	67	56	,	,	PUNCT
ajst-32485	67	57	inc	inc	PROPN
ajst-32485	67	58	.	.	PROPN
ajst-32485	67	59	,	,	PUNCT
ajst-32485	67	60	2023	2023	NUM
ajst-32485	67	61	)	)	PUNCT
ajst-32485	67	62	.	.	PUNCT
ajst-32485	68	1	current	current	ADJ
ajst-32485	68	2	developments	development	NOUN
ajst-32485	68	3	of	of	ADP
ajst-32485	68	4	neoantigen	neoantigen	PROPN
ajst-32485	68	5	vaccines	vaccine	NOUN
ajst-32485	68	6	show	show	VERB
ajst-32485	68	7	several	several	ADJ
ajst-32485	68	8	advantages	advantage	NOUN
ajst-32485	68	9	,	,	PUNCT
ajst-32485	68	10	including	include	VERB
ajst-32485	68	11	being	be	AUX
ajst-32485	68	12	highly	highly	ADV
ajst-32485	68	13	personalized	personalize	VERB
ajst-32485	68	14	,	,	PUNCT
ajst-32485	68	15	targeting	target	VERB
ajst-32485	68	16	patient	patient	NOUN
ajst-32485	68	17	-	-	PUNCT
ajst-32485	68	18	specific	specific	ADJ
ajst-32485	68	19	mutations	mutation	NOUN
ajst-32485	68	20	to	to	PART
ajst-32485	68	21	reduce	reduce	VERB
ajst-32485	68	22	the	the	DET
ajst-32485	68	23	risk	risk	NOUN
ajst-32485	68	24	of	of	ADP
ajst-32485	68	25	off	off	ADP
ajst-32485	68	26	-	-	PUNCT
ajst-32485	68	27	target	target	NOUN
ajst-32485	68	28	,	,	PUNCT
ajst-32485	68	29	reducing	reduce	VERB
ajst-32485	68	30	the	the	DET
ajst-32485	68	31	risk	risk	NOUN
ajst-32485	68	32	of	of	ADP
ajst-32485	68	33	targeting	target	VERB
ajst-32485	68	34	other	other	ADJ
ajst-32485	68	35	surrounding	surround	VERB
ajst-32485	68	36	target	target	NOUN
ajst-32485	68	37	spots	spot	NOUN
ajst-32485	68	38	,	,	PUNCT
ajst-32485	68	39	accelerating	accelerate	VERB
ajst-32485	68	40	mutation	mutation	NOUN
ajst-32485	68	41	,	,	PUNCT
ajst-32485	68	42	and	and	CCONJ
ajst-32485	68	43	hence	hence	ADV
ajst-32485	68	44	the	the	DET
ajst-32485	68	45	development	development	NOUN
ajst-32485	68	46	of	of	ADP
ajst-32485	68	47	the	the	DET
ajst-32485	68	48	tumor	tumor	NOUN
ajst-32485	68	49	.	.	PUNCT
ajst-32485	69	1	the	the	DET
ajst-32485	69	2	vaccine	vaccine	NOUN
ajst-32485	69	3	also	also	ADV
ajst-32485	69	4	provides	provide	VERB
ajst-32485	69	5	immune	immune	ADJ
ajst-32485	69	6	memory	memory	NOUN
ajst-32485	69	7	,	,	PUNCT
ajst-32485	69	8	which	which	PRON
ajst-32485	69	9	may	may	AUX
ajst-32485	69	10	induce	induce	VERB
ajst-32485	69	11	long	long	ADJ
ajst-32485	69	12	-	-	PUNCT
ajst-32485	69	13	term	term	NOUN
ajst-32485	69	14	anti	anti	ADJ
ajst-32485	69	15	-	-	ADJ
ajst-32485	69	16	tumor	tumor	ADJ
ajst-32485	69	17	immune	immune	ADJ
ajst-32485	69	18	memory	memory	NOUN
ajst-32485	69	19	and	and	CCONJ
ajst-32485	69	20	prevent	prevent	NOUN
ajst-32485	69	21	recurrence	recurrence	NOUN
ajst-32485	69	22	.	.	PUNCT
ajst-32485	70	1	3	3	X
ajst-32485	70	2	.	.	X
ajst-32485	70	3	mesothelin	mesothelin	NOUN
ajst-32485	70	4	targeted	target	VERB
ajst-32485	70	5	delivery	delivery	NOUN
ajst-32485	70	6	strategy	strategy	NOUN
ajst-32485	70	7	3.1	3.1	NUM
ajst-32485	70	8	biological	biological	ADJ
ajst-32485	70	9	characteristics	characteristic	NOUN
ajst-32485	70	10	of	of	ADP
ajst-32485	70	11	mesothelin	mesothelin	NOUN
ajst-32485	70	12	due	due	ADP
ajst-32485	70	13	to	to	ADP
ajst-32485	70	14	numerous	numerous	ADJ
ajst-32485	70	15	challenges	challenge	NOUN
ajst-32485	70	16	in	in	ADP
ajst-32485	70	17	pancreatic	pancreatic	ADJ
ajst-32485	70	18	cancer	cancer	NOUN
ajst-32485	70	19	treatment	treatment	NOUN
ajst-32485	70	20	,	,	PUNCT
ajst-32485	70	21	enhancing	enhance	VERB
ajst-32485	70	22	the	the	DET
ajst-32485	70	23	infiltration	infiltration	NOUN
ajst-32485	70	24	and	and	CCONJ
ajst-32485	70	25	function	function	NOUN
ajst-32485	70	26	of	of	ADP
ajst-32485	70	27	tumor	tumor	NOUN
ajst-32485	70	28	-	-	PUNCT
ajst-32485	70	29	specific	specific	ADJ
ajst-32485	70	30	t	t	NOUN
ajst-32485	70	31	cells	cell	NOUN
ajst-32485	70	32	is	be	AUX
ajst-32485	70	33	considered	consider	VERB
ajst-32485	70	34	a	a	DET
ajst-32485	70	35	critical	critical	ADJ
ajst-32485	70	36	focus	focus	NOUN
ajst-32485	70	37	for	for	ADP
ajst-32485	70	38	boosting	boost	VERB
ajst-32485	70	39	the	the	DET
ajst-32485	70	40	success	success	NOUN
ajst-32485	70	41	of	of	ADP
ajst-32485	70	42	neoantigen	neoantigen	PROPN
ajst-32485	70	43	vaccines	vaccine	NOUN
ajst-32485	70	44	.	.	PUNCT
ajst-32485	71	1	in	in	ADP
ajst-32485	71	2	recent	recent	ADJ
ajst-32485	71	3	years	year	NOUN
ajst-32485	71	4	,	,	PUNCT
ajst-32485	71	5	mesothelin	mesothelin	NOUN
ajst-32485	71	6	(	(	PUNCT
ajst-32485	71	7	msln	msln	NOUN
ajst-32485	71	8	)	)	PUNCT
ajst-32485	71	9	,	,	PUNCT
ajst-32485	71	10	a	a	DET
ajst-32485	71	11	40	40	NUM
ajst-32485	71	12	-	-	PUNCT
ajst-32485	71	13	kda	kda	NOUN
ajst-32485	71	14	glycosylphosphatidylinositol	glycosylphosphatidylinositol	NOUN
ajst-32485	71	15	(	(	PUNCT
ajst-32485	71	16	gpi)-anchored	gpi)-anchored	ADJ
ajst-32485	71	17	protein	protein	NOUN
ajst-32485	71	18	,	,	PUNCT
ajst-32485	71	19	has	have	AUX
ajst-32485	71	20	gained	gain	VERB
ajst-32485	71	21	attention	attention	NOUN
ajst-32485	71	22	because	because	SCONJ
ajst-32485	71	23	of	of	ADP
ajst-32485	71	24	its	its	PRON
ajst-32485	71	25	distinctive	distinctive	ADJ
ajst-32485	71	26	expression	expression	NOUN
ajst-32485	71	27	profile	profile	NOUN
ajst-32485	71	28	.	.	PUNCT
ajst-32485	72	1	this	this	DET
ajst-32485	72	2	protein	protein	NOUN
ajst-32485	72	3	is	be	AUX
ajst-32485	72	4	highly	highly	ADV
ajst-32485	72	5	expressed	express	VERB
ajst-32485	72	6	in	in	ADP
ajst-32485	72	7	many	many	ADJ
ajst-32485	72	8	solid	solid	ADJ
ajst-32485	72	9	tumors	tumor	NOUN
ajst-32485	72	10	,	,	PUNCT
ajst-32485	72	11	including	include	VERB
ajst-32485	72	12	pancreatic	pancreatic	ADJ
ajst-32485	72	13	cancer	cancer	NOUN
ajst-32485	72	14	,	,	PUNCT
ajst-32485	72	15	while	while	SCONJ
ajst-32485	72	16	remaining	remain	VERB
ajst-32485	72	17	at	at	ADP
ajst-32485	72	18	low	low	ADJ
ajst-32485	72	19	expression	expression	NOUN
ajst-32485	72	20	levels	level	NOUN
ajst-32485	72	21	in	in	ADP
ajst-32485	72	22	normal	normal	ADJ
ajst-32485	72	23	tissues	tissue	NOUN
ajst-32485	72	24	such	such	ADJ
ajst-32485	72	25	as	as	ADP
ajst-32485	72	26	the	the	DET
ajst-32485	72	27	pleura	pleura	NOUN
ajst-32485	72	28	,	,	PUNCT
ajst-32485	72	29	peritoneum	peritoneum	NOUN
ajst-32485	72	30	,	,	PUNCT
ajst-32485	72	31	and	and	CCONJ
ajst-32485	72	32	pericardium	pericardium	NOUN
ajst-32485	72	33	.	.	PUNCT
ajst-32485	73	1	this	this	DET
ajst-32485	73	2	contrasting	contrast	VERB
ajst-32485	73	3	expression	expression	NOUN
ajst-32485	73	4	pattern	pattern	NOUN
ajst-32485	73	5	makes	make	VERB
ajst-32485	73	6	mesothelin	mesothelin	PROPN
ajst-32485	73	7	an	an	DET
ajst-32485	73	8	attractive	attractive	ADJ
ajst-32485	73	9	target	target	NOUN
ajst-32485	73	10	for	for	ADP
ajst-32485	73	11	tumor	tumor	NOUN
ajst-32485	73	12	-	-	PUNCT
ajst-32485	73	13	specific	specific	ADJ
ajst-32485	73	14	delivery	delivery	NOUN
ajst-32485	73	15	strategies	strategy	NOUN
ajst-32485	73	16	,	,	PUNCT
ajst-32485	73	17	enabling	enable	VERB
ajst-32485	73	18	the	the	DET
ajst-32485	73	19	selective	selective	ADJ
ajst-32485	73	20	targeting	targeting	NOUN
ajst-32485	73	21	of	of	ADP
ajst-32485	73	22	malignant	malignant	ADJ
ajst-32485	73	23	cells	cell	NOUN
ajst-32485	73	24	while	while	SCONJ
ajst-32485	73	25	preserving	preserve	VERB
ajst-32485	73	26	healthy	healthy	ADJ
ajst-32485	73	27	tissues	tissue	NOUN
ajst-32485	73	28	.	.	PUNCT
ajst-32485	74	1	additionally	additionally	ADV
ajst-32485	74	2	,	,	PUNCT
ajst-32485	74	3	the	the	DET
ajst-32485	74	4	localization	localization	NOUN
ajst-32485	74	5	of	of	ADP
ajst-32485	74	6	mesothelin	mesothelin	PROPN
ajst-32485	74	7	on	on	ADP
ajst-32485	74	8	the	the	DET
ajst-32485	74	9	surface	surface	NOUN
ajst-32485	74	10	of	of	ADP
ajst-32485	74	11	tumor	tumor	NOUN
ajst-32485	74	12	cells	cell	NOUN
ajst-32485	74	13	promotes	promote	VERB
ajst-32485	74	14	the	the	DET
ajst-32485	74	15	effective	effective	ADJ
ajst-32485	74	16	binding	binding	NOUN
ajst-32485	74	17	of	of	ADP
ajst-32485	74	18	therapeutic	therapeutic	ADJ
ajst-32485	74	19	ligands	ligand	NOUN
ajst-32485	74	20	,	,	PUNCT
ajst-32485	74	21	hence	hence	ADV
ajst-32485	74	22	enhancing	enhance	VERB
ajst-32485	74	23	the	the	DET
ajst-32485	74	24	success	success	NOUN
ajst-32485	74	25	of	of	ADP
ajst-32485	74	26	targeted	target	VERB
ajst-32485	74	27	delivery	delivery	NOUN
ajst-32485	74	28	and	and	CCONJ
ajst-32485	74	29	reducing	reduce	VERB
ajst-32485	74	30	the	the	DET
ajst-32485	74	31	risk	risk	NOUN
ajst-32485	74	32	of	of	ADP
ajst-32485	74	33	affecting	affect	VERB
ajst-32485	74	34	healthy	healthy	ADJ
ajst-32485	74	35	tissues	tissue	NOUN
ajst-32485	74	36	.	.	PUNCT
ajst-32485	75	1	3.2	3.2	NUM
ajst-32485	75	2	response	response	NOUN
ajst-32485	75	3	in	in	ADP
ajst-32485	75	4	mouse	mouse	NOUN
ajst-32485	75	5	model	model	NOUN
ajst-32485	75	6	in	in	ADP
ajst-32485	75	7	recent	recent	ADJ
ajst-32485	75	8	years	year	NOUN
ajst-32485	75	9	,	,	PUNCT
ajst-32485	75	10	optimizing	optimize	VERB
ajst-32485	75	11	antigen	antigen	ADJ
ajst-32485	75	12	delivery	delivery	NOUN
ajst-32485	75	13	to	to	PART
ajst-32485	75	14	break	break	VERB
ajst-32485	75	15	through	through	ADP
ajst-32485	75	16	the	the	DET
ajst-32485	75	17	immunosuppressive	immunosuppressive	ADJ
ajst-32485	75	18	microenvironment	microenvironment	NOUN
ajst-32485	75	19	in	in	ADP
ajst-32485	75	20	pancreatic	pancreatic	ADJ
ajst-32485	75	21	ductal	ductal	ADJ
ajst-32485	75	22	adenocarcinoma	adenocarcinoma	NOUN
ajst-32485	75	23	(	(	PUNCT
ajst-32485	75	24	pdac	pdac	NOUN
ajst-32485	75	25	)	)	PUNCT
ajst-32485	75	26	has	have	AUX
ajst-32485	75	27	become	become	VERB
ajst-32485	75	28	a	a	DET
ajst-32485	75	29	key	key	ADJ
ajst-32485	75	30	direction	direction	NOUN
ajst-32485	75	31	for	for	ADP
ajst-32485	75	32	augmenting	augment	VERB
ajst-32485	75	33	the	the	DET
ajst-32485	75	34	effectiveness	effectiveness	NOUN
ajst-32485	75	35	of	of	ADP
ajst-32485	75	36	immunotherapy	immunotherapy	NOUN
ajst-32485	75	37	.	.	PUNCT
ajst-32485	76	1	against	against	ADP
ajst-32485	76	2	this	this	DET
ajst-32485	76	3	backdrop	backdrop	NOUN
ajst-32485	76	4	,	,	PUNCT
ajst-32485	76	5	zhixiong	zhixiong	PROPN
ajst-32485	76	6	cai	cai	PROPN
ajst-32485	76	7	et	et	PROPN
ajst-32485	76	8	al	al	PROPN
ajst-32485	76	9	developed	develop	VERB
ajst-32485	76	10	a	a	DET
ajst-32485	76	11	nanoparticle	nanoparticle	NOUN
ajst-32485	76	12	delivery	delivery	NOUN
ajst-32485	76	13	system	system	NOUN
ajst-32485	76	14	targeting	target	VERB
ajst-32485	76	15	mesothelin	mesothelin	NOUN
ajst-32485	76	16	,	,	PUNCT
ajst-32485	76	17	aiming	aim	VERB
ajst-32485	76	18	to	to	PART
ajst-32485	76	19	raise	raise	VERB
ajst-32485	76	20	the	the	DET
ajst-32485	76	21	uptake	uptake	ADJ
ajst-32485	76	22	efficiency	efficiency	NOUN
ajst-32485	76	23	of	of	ADP
ajst-32485	76	24	tumorspecific	tumorspecific	ADJ
ajst-32485	76	25	antigens	antigen	NOUN
ajst-32485	76	26	by	by	ADP
ajst-32485	76	27	antigen	antigen	ADV
ajst-32485	76	28	-	-	PUNCT
ajst-32485	76	29	presenting	present	VERB
ajst-32485	76	30	cells	cell	NOUN
ajst-32485	76	31	(	(	PUNCT
ajst-32485	76	32	apcs	apc	NOUN
ajst-32485	76	33	)	)	PUNCT
ajst-32485	76	34	,	,	PUNCT
ajst-32485	76	35	thereby	thereby	ADV
ajst-32485	76	36	activating	activate	VERB
ajst-32485	76	37	the	the	DET
ajst-32485	76	38	t	t	NOUN
ajst-32485	76	39	-	-	PUNCT
ajst-32485	76	40	cell	cell	NOUN
ajst-32485	76	41	-	-	PUNCT
ajst-32485	76	42	mediated	mediate	VERB
ajst-32485	76	43	antitumor	antitumor	PROPN
ajst-32485	76	44	immune	immune	ADJ
ajst-32485	76	45	responses	response	NOUN
ajst-32485	76	46	(	(	PUNCT
ajst-32485	76	47	cai	cai	X
ajst-32485	76	48	et	et	PROPN
ajst-32485	76	49	al	al	PROPN
ajst-32485	76	50	.	.	PROPN
ajst-32485	76	51	,	,	PUNCT
ajst-32485	76	52	2025	2025	NUM
ajst-32485	76	53	)	)	PUNCT
ajst-32485	76	54	.	.	PUNCT
ajst-32485	77	1	regarding	regard	VERB
ajst-32485	77	2	the	the	DET
ajst-32485	77	3	delivery	delivery	NOUN
ajst-32485	77	4	system	system	NOUN
ajst-32485	77	5	,	,	PUNCT
ajst-32485	77	6	the	the	DET
ajst-32485	77	7	mesothelin	mesothelin	NOUN
ajst-32485	77	8	-	-	PUNCT
ajst-32485	77	9	targeted	target	VERB
ajst-32485	77	10	delivery	delivery	NOUN
ajst-32485	77	11	system	system	NOUN
ajst-32485	77	12	achieves	achieve	VERB
ajst-32485	77	13	tumor	tumor	NOUN
ajst-32485	77	14	-	-	PUNCT
ajst-32485	77	15	specific	specific	ADJ
ajst-32485	77	16	accumulation	accumulation	NOUN
ajst-32485	77	17	through	through	ADP
ajst-32485	77	18	the	the	DET
ajst-32485	77	19	selective	selective	ADJ
ajst-32485	77	20	recognition	recognition	NOUN
ajst-32485	77	21	of	of	ADP
ajst-32485	77	22	mesothelin	mesothelin	NOUN
ajst-32485	77	23	.	.	PUNCT
ajst-32485	78	1	when	when	SCONJ
ajst-32485	78	2	administered	administer	VERB
ajst-32485	78	3	systemically	systemically	ADV
ajst-32485	78	4	,	,	PUNCT
ajst-32485	78	5	the	the	DET
ajst-32485	78	6	delivery	delivery	NOUN
ajst-32485	78	7	system	system	NOUN
ajst-32485	78	8	binds	bind	VERB
ajst-32485	78	9	to	to	ADP
ajst-32485	78	10	tumor	tumor	NOUN
ajst-32485	78	11	cells	cell	NOUN
ajst-32485	78	12	with	with	ADP
ajst-32485	78	13	high	high	ADJ
ajst-32485	78	14	levels	level	NOUN
ajst-32485	78	15	of	of	ADP
ajst-32485	78	16	mesothelin	mesothelin	NOUN
ajst-32485	78	17	expression	expression	NOUN
ajst-32485	78	18	,	,	PUNCT
ajst-32485	78	19	thereby	thereby	ADV
ajst-32485	78	20	promoting	promote	VERB
ajst-32485	78	21	the	the	DET
ajst-32485	78	22	localized	localized	ADJ
ajst-32485	78	23	release	release	NOUN
ajst-32485	78	24	of	of	ADP
ajst-32485	78	25	neoantigen	neoantigen	NOUN
ajst-32485	78	26	payloads	payload	NOUN
ajst-32485	78	27	in	in	ADP
ajst-32485	78	28	proximity	proximity	NOUN
ajst-32485	78	29	to	to	ADP
ajst-32485	78	30	antigen	antigen	NOUN
ajst-32485	78	31	-	-	PUNCT
ajst-32485	78	32	presenting	present	VERB
ajst-32485	78	33	cells	cell	NOUN
ajst-32485	78	34	(	(	PUNCT
ajst-32485	78	35	apcs	apc	NOUN
ajst-32485	78	36	)	)	PUNCT
ajst-32485	78	37	,	,	PUNCT
ajst-32485	78	38	particularly	particularly	ADV
ajst-32485	78	39	dendritic	dendritic	ADJ
ajst-32485	78	40	cells	cell	NOUN
ajst-32485	78	41	(	(	PUNCT
ajst-32485	78	42	dcs	dcs	PROPN
ajst-32485	78	43	)	)	PUNCT
ajst-32485	78	44	.	.	PUNCT
ajst-32485	79	1	this	this	DET
ajst-32485	79	2	targeted	target	VERB
ajst-32485	79	3	accumulation	accumulation	NOUN
ajst-32485	79	4	enhances	enhance	VERB
ajst-32485	79	5	the	the	DET
ajst-32485	79	6	efficiency	efficiency	NOUN
ajst-32485	79	7	of	of	ADP
ajst-32485	79	8	antigen	antigen	ADJ
ajst-32485	79	9	uptake	uptake	NOUN
ajst-32485	79	10	and	and	CCONJ
ajst-32485	79	11	processing	processing	NOUN
ajst-32485	79	12	by	by	ADP
ajst-32485	79	13	dcs	dcs	PROPN
ajst-32485	79	14	,	,	PUNCT
ajst-32485	79	15	which	which	PRON
ajst-32485	79	16	leads	lead	VERB
ajst-32485	79	17	to	to	ADP
ajst-32485	79	18	cross	cross	NOUN
ajst-32485	79	19	-	-	NOUN
ajst-32485	79	20	presentation	presentation	NOUN
ajst-32485	79	21	of	of	ADP
ajst-32485	79	22	neoantigens	neoantigen	NOUN
ajst-32485	79	23	via	via	ADP
ajst-32485	79	24	mhc	mhc	PROPN
ajst-32485	79	25	class	class	PROPN
ajst-32485	79	26	i	i	PROPN
ajst-32485	79	27	molecules	molecule	NOUN
ajst-32485	79	28	(	(	PUNCT
ajst-32485	79	29	cai	cai	X
ajst-32485	79	30	et	et	PROPN
ajst-32485	79	31	al	al	PROPN
ajst-32485	79	32	.	.	PROPN
ajst-32485	79	33	,	,	PUNCT
ajst-32485	79	34	2025	2025	NUM
ajst-32485	79	35	)	)	PUNCT
ajst-32485	79	36	.	.	PUNCT
ajst-32485	80	1	in	in	ADP
ajst-32485	80	2	this	this	DET
ajst-32485	80	3	case	case	NOUN
ajst-32485	80	4	,	,	PUNCT
ajst-32485	80	5	the	the	DET
ajst-32485	80	6	enhanced	enhanced	ADJ
ajst-32485	80	7	antigen	antigen	ADJ
ajst-32485	80	8	presentation	presentation	NOUN
ajst-32485	80	9	promotes	promote	VERB
ajst-32485	80	10	the	the	DET
ajst-32485	80	11	activation	activation	NOUN
ajst-32485	80	12	and	and	CCONJ
ajst-32485	80	13	tumor	tumor	NOUN
ajst-32485	80	14	infiltration	infiltration	NOUN
ajst-32485	80	15	of	of	ADP
ajst-32485	80	16	cytotoxic	cytotoxic	ADJ
ajst-32485	80	17	t	t	NOUN
ajst-32485	80	18	lymphocytes	lymphocyte	NOUN
ajst-32485	80	19	(	(	PUNCT
ajst-32485	80	20	ctls	ctls	PROPN
ajst-32485	80	21	)	)	PUNCT
ajst-32485	80	22	,	,	PUNCT
ajst-32485	80	23	performing	perform	VERB
ajst-32485	80	24	its	its	PRON
ajst-32485	80	25	characteristic	characteristic	NOUN
ajst-32485	80	26	of	of	ADP
ajst-32485	80	27	greater	great	ADJ
ajst-32485	80	28	cd8⁺	cd8⁺	NOUN
ajst-32485	80	29	t	t	NOUN
ajst-32485	80	30	cell	cell	NOUN
ajst-32485	80	31	infiltration	infiltration	NOUN
ajst-32485	80	32	and	and	CCONJ
ajst-32485	80	33	the	the	DET
ajst-32485	80	34	increased	increase	VERB
ajst-32485	80	35	expression	expression	NOUN
ajst-32485	80	36	levels	level	NOUN
ajst-32485	80	37	of	of	ADP
ajst-32485	80	38	effector	effector	NOUN
ajst-32485	80	39	molecules	molecule	NOUN
ajst-32485	80	40	such	such	ADJ
ajst-32485	80	41	as	as	ADP
ajst-32485	80	42	ifn	ifn	NOUN
ajst-32485	80	43	-	-	PUNCT
ajst-32485	80	44	γ	γ	NOUN
ajst-32485	80	45	and	and	CCONJ
ajst-32485	80	46	granzyme	granzyme	PROPN
ajst-32485	80	47	b.	b.	PROPN
ajst-32485	80	48	by	by	ADP
ajst-32485	80	49	taking	take	VERB
ajst-32485	80	50	advantage	advantage	NOUN
ajst-32485	80	51	of	of	ADP
ajst-32485	80	52	the	the	DET
ajst-32485	80	53	specific	specific	ADJ
ajst-32485	80	54	expression	expression	NOUN
ajst-32485	80	55	pattern	pattern	NOUN
ajst-32485	80	56	of	of	ADP
ajst-32485	80	57	mesothelin	mesothelin	PROPN
ajst-32485	80	58	in	in	ADP
ajst-32485	80	59	the	the	DET
ajst-32485	80	60	tumor	tumor	NOUN
ajst-32485	80	61	region	region	NOUN
ajst-32485	80	62	,	,	PUNCT
ajst-32485	80	63	the	the	DET
ajst-32485	80	64	strategy	strategy	NOUN
ajst-32485	80	65	not	not	PART
ajst-32485	80	66	only	only	ADV
ajst-32485	80	67	improves	improve	VERB
ajst-32485	80	68	the	the	DET
ajst-32485	80	69	accuracy	accuracy	NOUN
ajst-32485	80	70	of	of	ADP
ajst-32485	80	71	antigen	antigen	ADJ
ajst-32485	80	72	delivery	delivery	NOUN
ajst-32485	80	73	,	,	PUNCT
ajst-32485	80	74	but	but	CCONJ
ajst-32485	80	75	also	also	ADV
ajst-32485	80	76	strengthens	strengthen	VERB
ajst-32485	80	77	the	the	DET
ajst-32485	80	78	intensity	intensity	NOUN
ajst-32485	80	79	of	of	ADP
ajst-32485	80	80	the	the	DET
ajst-32485	80	81	tumor	tumor	NOUN
ajst-32485	80	82	-	-	PUNCT
ajst-32485	80	83	specific	specific	ADJ
ajst-32485	80	84	immune	immune	ADJ
ajst-32485	80	85	responses	response	NOUN
ajst-32485	80	86	while	while	SCONJ
ajst-32485	80	87	minimizing	minimize	VERB
ajst-32485	80	88	off	off	ADP
ajst-32485	80	89	-	-	PUNCT
ajst-32485	80	90	target	target	NOUN
ajst-32485	80	91	effects	effect	NOUN
ajst-32485	80	92	(	(	PUNCT
ajst-32485	80	93	cai	cai	X
ajst-32485	80	94	et	et	PROPN
ajst-32485	80	95	al	al	PROPN
ajst-32485	80	96	.	.	PROPN
ajst-32485	80	97	,	,	PUNCT
ajst-32485	80	98	2025	2025	NUM
ajst-32485	80	99	)	)	PUNCT
ajst-32485	80	100	to	to	PART
ajst-32485	80	101	prove	prove	VERB
ajst-32485	80	102	the	the	DET
ajst-32485	80	103	role	role	NOUN
ajst-32485	80	104	of	of	ADP
ajst-32485	80	105	mesothelin	mesothelin	PROPN
ajst-32485	80	106	(	(	PUNCT
ajst-32485	80	107	msln	msln	NOUN
ajst-32485	80	108	)	)	PUNCT
ajst-32485	80	109	targeting	target	VERB
ajst-32485	80	110	strategy	strategy	NOUN
ajst-32485	80	111	in	in	ADP
ajst-32485	80	112	enhancing	enhance	VERB
ajst-32485	80	113	efficacy	efficacy	NOUN
ajst-32485	80	114	of	of	ADP
ajst-32485	80	115	personalized	personalized	ADJ
ajst-32485	80	116	neoantigen	neoantigen	NOUN
ajst-32485	80	117	vaccines	vaccine	NOUN
ajst-32485	80	118	,	,	PUNCT
ajst-32485	80	119	the	the	DET
ajst-32485	80	120	research	research	NOUN
ajst-32485	80	121	team	team	NOUN
ajst-32485	80	122	conducted	conduct	VERB
ajst-32485	80	123	a	a	DET
ajst-32485	80	124	systematic	systematic	ADJ
ajst-32485	80	125	experiment	experiment	NOUN
ajst-32485	80	126	in	in	ADP
ajst-32485	80	127	an	an	DET
ajst-32485	80	128	orthotopic	orthotopic	ADJ
ajst-32485	80	129	pancreatic	pancreatic	ADJ
ajst-32485	80	130	cancer	cancer	NOUN
ajst-32485	80	131	mouse	mouse	NOUN
ajst-32485	80	132	model	model	NOUN
ajst-32485	80	133	.	.	PUNCT
ajst-32485	81	1	the	the	DET
ajst-32485	81	2	results	result	NOUN
ajst-32485	81	3	indicated	indicate	VERB
ajst-32485	81	4	that	that	SCONJ
ajst-32485	81	5	both	both	CCONJ
ajst-32485	81	6	the	the	DET
ajst-32485	81	7	αmsln	αmsln	NOUN
ajst-32485	81	8	antibody	antibody	NOUN
ajst-32485	81	9	and	and	CCONJ
ajst-32485	81	10	the	the	DET
ajst-32485	81	11	neoantigen	neoantigen	PROPN
ajst-32485	81	12	vaccine	vaccine	NOUN
ajst-32485	81	13	(	(	PUNCT
ajst-32485	81	14	pannv	pannv	NOUN
ajst-32485	81	15	)	)	PUNCT
ajst-32485	81	16	could	could	AUX
ajst-32485	81	17	inhibit	inhibit	VERB
ajst-32485	81	18	tumor	tumor	NOUN
ajst-32485	81	19	growth	growth	NOUN
ajst-32485	81	20	to	to	ADP
ajst-32485	81	21	a	a	DET
ajst-32485	81	22	certain	certain	ADJ
ajst-32485	81	23	extent	extent	NOUN
ajst-32485	81	24	independently	independently	ADV
ajst-32485	81	25	.	.	PUNCT
ajst-32485	82	1	yet	yet	ADV
ajst-32485	82	2	,	,	PUNCT
ajst-32485	82	3	the	the	DET
ajst-32485	82	4	combination	combination	NOUN
ajst-32485	82	5	therapy	therapy	NOUN
ajst-32485	82	6	exhibited	exhibit	VERB
ajst-32485	82	7	the	the	DET
ajst-32485	82	8	most	most	ADV
ajst-32485	82	9	significant	significant	ADJ
ajst-32485	82	10	tumor	tumor	NOUN
ajst-32485	82	11	suppression	suppression	NOUN
ajst-32485	82	12	.	.	PUNCT
ajst-32485	83	1	by	by	ADP
ajst-32485	83	2	day	day	NOUN
ajst-32485	83	3	28	28	NUM
ajst-32485	83	4	,	,	PUNCT
ajst-32485	83	5	the	the	DET
ajst-32485	83	6	combined	combined	ADJ
ajst-32485	83	7	treatment	treatment	NOUN
ajst-32485	83	8	group	group	NOUN
ajst-32485	83	9	displayed	display	VERB
ajst-32485	83	10	a	a	DET
ajst-32485	83	11	significant	significant	ADJ
ajst-32485	83	12	regression	regression	NOUN
ajst-32485	83	13	in	in	ADP
ajst-32485	83	14	tumor	tumor	NOUN
ajst-32485	83	15	burden	burden	NOUN
ajst-32485	83	16	,	,	PUNCT
ajst-32485	83	17	with	with	ADP
ajst-32485	83	18	some	some	DET
ajst-32485	83	19	mice	mouse	NOUN
ajst-32485	83	20	reaching	reach	VERB
ajst-32485	83	21	partial	partial	ADJ
ajst-32485	83	22	response	response	NOUN
ajst-32485	83	23	(	(	PUNCT
ajst-32485	83	24	pr	pr	NOUN
ajst-32485	83	25	)	)	PUNCT
ajst-32485	83	26	(	(	PUNCT
ajst-32485	83	27	p	p	X
ajst-32485	83	28	=	=	NOUN
ajst-32485	83	29	0.0255	0.0255	NUM
ajst-32485	83	30	)	)	PUNCT
ajst-32485	83	31	,	,	PUNCT
ajst-32485	83	32	which	which	PRON
ajst-32485	83	33	was	be	AUX
ajst-32485	83	34	significantly	significantly	ADV
ajst-32485	83	35	different	different	ADJ
ajst-32485	83	36	from	from	ADP
ajst-32485	83	37	the	the	DET
ajst-32485	83	38	other	other	ADJ
ajst-32485	83	39	three	three	NUM
ajst-32485	83	40	groups	group	NOUN
ajst-32485	83	41	(	(	PUNCT
ajst-32485	83	42	pbs	pbs	PROPN
ajst-32485	83	43	,	,	PUNCT
ajst-32485	83	44	αmsln	αmsln	NOUN
ajst-32485	83	45	,	,	PUNCT
ajst-32485	83	46	pannv	pannv	NOUN
ajst-32485	83	47	)	)	PUNCT
ajst-32485	83	48	(	(	PUNCT
ajst-32485	83	49	p	p	X
ajst-32485	83	50	<	<	X
ajst-32485	83	51	0.0001	0.0001	NUM
ajst-32485	83	52	)	)	PUNCT
ajst-32485	83	53	(	(	PUNCT
ajst-32485	83	54	figure	figure	NOUN
ajst-32485	83	55	2a	2a	NUM
ajst-32485	83	56	)	)	PUNCT
ajst-32485	83	57	(	(	PUNCT
ajst-32485	83	58	cai	cai	X
ajst-32485	83	59	et	et	PROPN
ajst-32485	83	60	al	al	PROPN
ajst-32485	83	61	.	.	PROPN
ajst-32485	83	62	,	,	PUNCT
ajst-32485	83	63	2025	2025	NUM
ajst-32485	83	64	)	)	PUNCT
ajst-32485	83	65	123	123	NUM
ajst-32485	83	66	further	further	ADJ
ajst-32485	83	67	immunological	immunological	ADJ
ajst-32485	83	68	analysis	analysis	NOUN
ajst-32485	83	69	discovered	discover	VERB
ajst-32485	83	70	that	that	SCONJ
ajst-32485	83	71	in	in	ADP
ajst-32485	83	72	the	the	DET
ajst-32485	83	73	combined	combined	ADJ
ajst-32485	83	74	treatment	treatment	NOUN
ajst-32485	83	75	group	group	NOUN
ajst-32485	83	76	,	,	PUNCT
ajst-32485	83	77	the	the	DET
ajst-32485	83	78	infiltration	infiltration	NOUN
ajst-32485	83	79	of	of	ADP
ajst-32485	83	80	cd8⁺	cd8⁺	NOUN
ajst-32485	83	81	t	t	NOUN
ajst-32485	83	82	cells	cell	NOUN
ajst-32485	83	83	in	in	ADP
ajst-32485	83	84	tumor	tumor	NOUN
ajst-32485	83	85	tissues	tissue	NOUN
ajst-32485	83	86	had	have	VERB
ajst-32485	83	87	a	a	DET
ajst-32485	83	88	significant	significant	ADJ
ajst-32485	83	89	increase	increase	NOUN
ajst-32485	83	90	(	(	PUNCT
ajst-32485	83	91	p	p	X
ajst-32485	83	92	<	<	X
ajst-32485	83	93	0.001	0.001	NUM
ajst-32485	83	94	)	)	PUNCT
ajst-32485	83	95	,	,	PUNCT
ajst-32485	83	96	with	with	ADP
ajst-32485	83	97	the	the	DET
ajst-32485	83	98	proportion	proportion	NOUN
ajst-32485	83	99	of	of	ADP
ajst-32485	83	100	neoantigen	neoantigen	NOUN
ajst-32485	83	101	-	-	PUNCT
ajst-32485	83	102	specific	specific	ADJ
ajst-32485	83	103	t	t	NOUN
ajst-32485	83	104	cells	cell	NOUN
ajst-32485	83	105	(	(	PUNCT
ajst-32485	83	106	slc16a13	slc16a13	NOUN
ajst-32485	83	107	-	-	PUNCT
ajst-32485	83	108	specific	specific	ADJ
ajst-32485	83	109	cd8⁺	cd8⁺	NOUN
ajst-32485	83	110	t	t	NOUN
ajst-32485	83	111	cells	cell	NOUN
ajst-32485	83	112	)	)	PUNCT
ajst-32485	83	113	reaching	reach	VERB
ajst-32485	83	114	a	a	DET
ajst-32485	83	115	peak	peak	NOUN
ajst-32485	83	116	(	(	PUNCT
ajst-32485	83	117	p	p	X
ajst-32485	83	118	<	<	X
ajst-32485	83	119	0.0001	0.0001	NUM
ajst-32485	83	120	)	)	PUNCT
ajst-32485	83	121	(	(	PUNCT
ajst-32485	83	122	figure	figure	NOUN
ajst-32485	83	123	2b	2b	NOUN
ajst-32485	83	124	)	)	PUNCT
ajst-32485	83	125	.	.	PUNCT
ajst-32485	84	1	besides	besides	SCONJ
ajst-32485	84	2	,	,	PUNCT
ajst-32485	84	3	the	the	DET
ajst-32485	84	4	proportion	proportion	NOUN
ajst-32485	84	5	of	of	ADP
ajst-32485	84	6	cd69⁺	cd69⁺	NOUN
ajst-32485	84	7	cd8⁺	cd8⁺	NOUN
ajst-32485	84	8	t	t	PROPN
ajst-32485	84	9	cells	cell	NOUN
ajst-32485	84	10	a	a	DET
ajst-32485	84	11	type	type	NOUN
ajst-32485	84	12	of	of	ADP
ajst-32485	84	13	activated	activated	ADJ
ajst-32485	84	14	tissue	tissue	NOUN
ajst-32485	84	15	-	-	PUNCT
ajst-32485	84	16	resident	resident	NOUN
ajst-32485	84	17	t	t	NOUN
ajst-32485	84	18	cells	cell	NOUN
ajst-32485	84	19	was	be	AUX
ajst-32485	84	20	markedly	markedly	ADV
ajst-32485	84	21	elevated	elevate	VERB
ajst-32485	84	22	in	in	ADP
ajst-32485	84	23	the	the	DET
ajst-32485	84	24	group	group	NOUN
ajst-32485	84	25	(	(	PUNCT
ajst-32485	84	26	p	p	NOUN
ajst-32485	84	27	=	=	NOUN
ajst-32485	84	28	0.0037	0.0037	NUM
ajst-32485	84	29	)	)	PUNCT
ajst-32485	84	30	(	(	PUNCT
ajst-32485	84	31	figure	figure	NOUN
ajst-32485	84	32	2c	2c	NUM
ajst-32485	84	33	)	)	PUNCT
ajst-32485	84	34	,	,	PUNCT
ajst-32485	84	35	and	and	CCONJ
ajst-32485	84	36	is	be	AUX
ajst-32485	84	37	considered	consider	VERB
ajst-32485	84	38	to	to	PART
ajst-32485	84	39	be	be	AUX
ajst-32485	84	40	vaccine	vaccine	NOUN
ajst-32485	84	41	-	-	PUNCT
ajst-32485	84	42	induced	induce	VERB
ajst-32485	84	43	tumor	tumor	NOUN
ajst-32485	84	44	-	-	PUNCT
ajst-32485	84	45	specific	specific	ADJ
ajst-32485	84	46	t	t	NOUN
ajst-32485	84	47	cells	cell	NOUN
ajst-32485	84	48	(	(	PUNCT
ajst-32485	84	49	cai	cai	X
ajst-32485	84	50	et	et	PROPN
ajst-32485	84	51	al	al	PROPN
ajst-32485	84	52	.	.	PROPN
ajst-32485	84	53	,	,	PUNCT
ajst-32485	84	54	2025	2025	NUM
ajst-32485	84	55	)	)	PUNCT
ajst-32485	84	56	tumor	tumor	NOUN
ajst-32485	84	57	cytotoxicity	cytotoxicity	NOUN
ajst-32485	84	58	assays	assay	NOUN
ajst-32485	84	59	confirmed	confirm	VERB
ajst-32485	84	60	the	the	DET
ajst-32485	84	61	enhancement	enhancement	NOUN
ajst-32485	84	62	of	of	ADP
ajst-32485	84	63	the	the	DET
ajst-32485	84	64	combined	combine	VERB
ajst-32485	84	65	treatment	treatment	NOUN
ajst-32485	84	66	group	group	NOUN
ajst-32485	84	67	on	on	ADP
ajst-32485	84	68	t	t	PROPN
ajst-32485	84	69	cell	cell	NOUN
ajst-32485	84	70	effector	effector	NOUN
ajst-32485	84	71	function	function	NOUN
ajst-32485	84	72	.	.	PUNCT
ajst-32485	85	1	the	the	DET
ajst-32485	85	2	tumor	tumor	NOUN
ajst-32485	85	3	-	-	PUNCT
ajst-32485	85	4	killing	kill	VERB
ajst-32485	85	5	efficiency	efficiency	NOUN
ajst-32485	85	6	of	of	ADP
ajst-32485	85	7	cd69⁺	cd69⁺	NOUN
ajst-32485	85	8	cd8⁺	cd8⁺	NOUN
ajst-32485	85	9	t	t	PROPN
ajst-32485	85	10	cells	cell	NOUN
ajst-32485	85	11	isolated	isolate	VERB
ajst-32485	85	12	from	from	ADP
ajst-32485	85	13	the	the	DET
ajst-32485	85	14	combined	combine	VERB
ajst-32485	85	15	treatment	treatment	NOUN
ajst-32485	85	16	group	group	NOUN
ajst-32485	85	17	against	against	ADP
ajst-32485	85	18	tumor	tumor	NOUN
ajst-32485	85	19	cells	cell	NOUN
ajst-32485	85	20	was	be	AUX
ajst-32485	85	21	8	8	NUM
ajst-32485	85	22	times	time	NOUN
ajst-32485	85	23	that	that	DET
ajst-32485	85	24	of	of	ADP
ajst-32485	85	25	the	the	DET
ajst-32485	85	26	pbs	pbs	PROPN
ajst-32485	85	27	group	group	NOUN
ajst-32485	85	28	and	and	CCONJ
ajst-32485	85	29	2	2	NUM
ajst-32485	85	30	times	time	NOUN
ajst-32485	85	31	that	that	PRON
ajst-32485	85	32	of	of	ADP
ajst-32485	85	33	the	the	DET
ajst-32485	85	34	pannv	pannv	PROPN
ajst-32485	85	35	monotherapy	monotherapy	NOUN
ajst-32485	85	36	group	group	NOUN
ajst-32485	85	37	(	(	PUNCT
ajst-32485	85	38	p	p	X
ajst-32485	85	39	<	<	X
ajst-32485	85	40	0.0001	0.0001	NUM
ajst-32485	85	41	)	)	PUNCT
ajst-32485	85	42	(	(	PUNCT
ajst-32485	85	43	figure	figure	NOUN
ajst-32485	85	44	2d	2d	NUM
ajst-32485	85	45	)	)	PUNCT
ajst-32485	85	46	.	.	PUNCT
ajst-32485	86	1	moreover	moreover	ADV
ajst-32485	86	2	,	,	PUNCT
ajst-32485	86	3	the	the	DET
ajst-32485	86	4	proportion	proportion	NOUN
ajst-32485	86	5	of	of	ADP
ajst-32485	86	6	mature	mature	ADJ
ajst-32485	86	7	dendritic	dendritic	ADJ
ajst-32485	86	8	cells	cell	NOUN
ajst-32485	86	9	(	(	PUNCT
ajst-32485	86	10	cd80⁺	cd80⁺	NOUN
ajst-32485	86	11	cd86⁺	cd86⁺	ADJ
ajst-32485	86	12	)	)	PUNCT
ajst-32485	86	13	in	in	ADP
ajst-32485	86	14	the	the	DET
ajst-32485	86	15	lymph	lymph	NOUN
ajst-32485	86	16	nodes	node	NOUN
ajst-32485	86	17	and	and	CCONJ
ajst-32485	86	18	effector	effector	NOUN
ajst-32485	86	19	memory	memory	NOUN
ajst-32485	86	20	cd8⁺	cd8⁺	PROPN
ajst-32485	86	21	t	t	PROPN
ajst-32485	86	22	cells	cell	NOUN
ajst-32485	86	23	(	(	PUNCT
ajst-32485	86	24	cd44⁺	cd44⁺	NOUN
ajst-32485	86	25	cd62l-	cd62l-	PROPN
ajst-32485	86	26	)	)	PUNCT
ajst-32485	86	27	in	in	ADP
ajst-32485	86	28	the	the	DET
ajst-32485	86	29	spleen	spleen	NOUN
ajst-32485	86	30	also	also	ADV
ajst-32485	86	31	underwent	undergo	VERB
ajst-32485	86	32	a	a	DET
ajst-32485	86	33	significant	significant	ADJ
ajst-32485	86	34	increase	increase	NOUN
ajst-32485	86	35	in	in	ADP
ajst-32485	86	36	the	the	DET
ajst-32485	86	37	combined	combined	ADJ
ajst-32485	86	38	treatment	treatment	NOUN
ajst-32485	86	39	group	group	NOUN
ajst-32485	86	40	(	(	PUNCT
ajst-32485	86	41	p	p	NOUN
ajst-32485	86	42	=	=	NOUN
ajst-32485	86	43	0.0001	0.0001	NUM
ajst-32485	86	44	and	and	CCONJ
ajst-32485	86	45	p	p	NOUN
ajst-32485	86	46	=	=	PROPN
ajst-32485	86	47	0.0318	0.0318	NUM
ajst-32485	86	48	,	,	PUNCT
ajst-32485	86	49	respectively	respectively	ADV
ajst-32485	86	50	)	)	PUNCT
ajst-32485	86	51	(	(	PUNCT
ajst-32485	86	52	figure	figure	NOUN
ajst-32485	86	53	2e	2e	NUM
ajst-32485	86	54	,	,	PUNCT
ajst-32485	86	55	f	f	X
ajst-32485	86	56	)	)	PUNCT
ajst-32485	86	57	(	(	PUNCT
ajst-32485	86	58	cai	cai	X
ajst-32485	86	59	et	et	PROPN
ajst-32485	86	60	al	al	PROPN
ajst-32485	86	61	.	.	PROPN
ajst-32485	86	62	,	,	PUNCT
ajst-32485	86	63	2025	2025	NUM
ajst-32485	86	64	)	)	PUNCT
ajst-32485	86	65	.	.	PUNCT
ajst-32485	87	1	figure	figure	NOUN
ajst-32485	87	2	2	2	NUM
ajst-32485	87	3	.	.	PUNCT
ajst-32485	88	1	the	the	DET
ajst-32485	88	2	antitumor	antitumor	PROPN
ajst-32485	88	3	effects	effect	NOUN
ajst-32485	88	4	of	of	ADP
ajst-32485	88	5	the	the	DET
ajst-32485	88	6	combined	combine	VERB
ajst-32485	88	7	treatment	treatment	NOUN
ajst-32485	88	8	of	of	ADP
ajst-32485	88	9	pannv	pannv	NOUN
ajst-32485	88	10	plus	plus	CCONJ
ajst-32485	88	11	αmsln	αmsln	NOUN
ajst-32485	88	12	in	in	ADP
ajst-32485	88	13	orthotopic	orthotopic	ADJ
ajst-32485	88	14	pancreatic	pancreatic	ADJ
ajst-32485	88	15	cancer	cancer	NOUN
ajst-32485	88	16	.	.	PUNCT
ajst-32485	89	1	a	a	DET
ajst-32485	89	2	)	)	PUNCT
ajst-32485	89	3	statistical	statistical	ADJ
ajst-32485	89	4	analysis	analysis	NOUN
ajst-32485	89	5	of	of	ADP
ajst-32485	89	6	pbs	pbs	PROPN
ajst-32485	89	7	,	,	PUNCT
ajst-32485	89	8	αmsln	αmsln	NOUN
ajst-32485	89	9	,	,	PUNCT
ajst-32485	89	10	pannv	pannv	PROPN
ajst-32485	89	11	,	,	PUNCT
ajst-32485	89	12	and	and	CCONJ
ajst-32485	89	13	αmsln	αmsln	NOUN
ajst-32485	89	14	plus	plus	CCONJ
ajst-32485	89	15	pannv	pannv	PROPN
ajst-32485	89	16	(	(	PUNCT
ajst-32485	89	17	combination	combination	NOUN
ajst-32485	89	18	)	)	PUNCT
ajst-32485	89	19	treated	treat	VERB
ajst-32485	89	20	mice	mouse	NOUN
ajst-32485	89	21	.	.	PUNCT
ajst-32485	90	1	b	b	X
ajst-32485	90	2	)	)	PUNCT
ajst-32485	90	3	in	in	ADP
ajst-32485	90	4	tumor	tumor	NOUN
ajst-32485	90	5	tissues	tissue	NOUN
ajst-32485	90	6	by	by	ADP
ajst-32485	90	7	flow	flow	NOUN
ajst-32485	90	8	cytometry	cytometry	NOUN
ajst-32485	90	9	(	(	PUNCT
ajst-32485	90	10	n	n	NOUN
ajst-32485	90	11	=	=	SYM
ajst-32485	90	12	3	3	NUM
ajst-32485	90	13	;	;	PUNCT
ajst-32485	90	14	one	one	NUM
ajst-32485	90	15	-	-	PUNCT
ajst-32485	90	16	way	way	NOUN
ajst-32485	90	17	anova	anova	PROPN
ajst-32485	90	18	)	)	PUNCT
ajst-32485	90	19	.	.	PUNCT
ajst-32485	91	1	c	c	X
ajst-32485	91	2	)	)	PUNCT
ajst-32485	91	3	the	the	DET
ajst-32485	91	4	percentage	percentage	NOUN
ajst-32485	91	5	of	of	ADP
ajst-32485	91	6	cd8+cd69	cd8+cd69	PROPN
ajst-32485	91	7	+	+	PROPN
ajst-32485	91	8	t	t	NOUN
ajst-32485	91	9	cells	cell	NOUN
ajst-32485	91	10	detected	detect	VERB
ajst-32485	91	11	in	in	ADP
ajst-32485	91	12	tumor	tumor	NOUN
ajst-32485	91	13	tissue	tissue	NOUN
ajst-32485	91	14	by	by	ADP
ajst-32485	91	15	flow	flow	NOUN
ajst-32485	91	16	cytometry	cytometry	NOUN
ajst-32485	91	17	(	(	PUNCT
ajst-32485	91	18	n	n	NOUN
ajst-32485	91	19	=	=	SYM
ajst-32485	91	20	5	5	NUM
ajst-32485	91	21	;	;	PUNCT
ajst-32485	91	22	one	one	NUM
ajst-32485	91	23	-	-	PUNCT
ajst-32485	91	24	way	way	NOUN
ajst-32485	91	25	anova	anova	PROPN
ajst-32485	91	26	)	)	PUNCT
ajst-32485	91	27	.	.	PUNCT
ajst-32485	92	1	d	d	X
ajst-32485	92	2	)	)	PUNCT
ajst-32485	92	3	in	in	ADP
ajst-32485	92	4	vitro	vitro	X
ajst-32485	92	5	cytotoxicity	cytotoxicity	NOUN
ajst-32485	92	6	analysis	analysis	NOUN
ajst-32485	92	7	induced	induce	VERB
ajst-32485	92	8	by	by	ADP
ajst-32485	92	9	cd8	cd8	PROPN
ajst-32485	92	10	+	+	PROPN
ajst-32485	92	11	cd69	cd69	PROPN
ajst-32485	92	12	+	+	PROPN
ajst-32485	92	13	t	t	NOUN
ajst-32485	92	14	cells	cell	NOUN
ajst-32485	92	15	against	against	ADP
ajst-32485	92	16	panc02	panc02	NOUN
ajst-32485	92	17	cells	cell	NOUN
ajst-32485	92	18	determined	determine	VERB
ajst-32485	92	19	by	by	ADP
ajst-32485	92	20	ldh	ldh	PROPN
ajst-32485	92	21	assay	assay	PROPN
ajst-32485	92	22	(	(	PUNCT
ajst-32485	92	23	n=3	n=3	NOUN
ajst-32485	92	24	)	)	PUNCT
ajst-32485	92	25	.	.	PUNCT
ajst-32485	93	1	e	e	X
ajst-32485	93	2	)	)	PUNCT
ajst-32485	93	3	the	the	DET
ajst-32485	93	4	percentage	percentage	NOUN
ajst-32485	93	5	of	of	ADP
ajst-32485	93	6	matured	matured	ADJ
ajst-32485	93	7	dcs	dcs	PROPN
ajst-32485	93	8	with	with	ADP
ajst-32485	93	9	cd80	cd80	PROPN
ajst-32485	93	10	and	and	CCONJ
ajst-32485	93	11	cd86	cd86	PROPN
ajst-32485	93	12	co	co	NOUN
ajst-32485	93	13	-	-	NOUN
ajst-32485	93	14	expression	expression	NOUN
ajst-32485	93	15	in	in	ADP
ajst-32485	93	16	the	the	DET
ajst-32485	93	17	lymph	lymph	NOUN
ajst-32485	93	18	nodes	node	NOUN
ajst-32485	93	19	detected	detect	VERB
ajst-32485	93	20	by	by	ADP
ajst-32485	93	21	flow	flow	NOUN
ajst-32485	93	22	cytometry	cytometry	NOUN
ajst-32485	93	23	(	(	PUNCT
ajst-32485	93	24	n	n	NOUN
ajst-32485	93	25	=	=	SYM
ajst-32485	93	26	5	5	NUM
ajst-32485	93	27	;	;	PUNCT
ajst-32485	93	28	one	one	NUM
ajst-32485	93	29	-	-	PUNCT
ajst-32485	93	30	way	way	NOUN
ajst-32485	93	31	anova	anova	PROPN
ajst-32485	93	32	)	)	PUNCT
ajst-32485	93	33	.	.	PUNCT
ajst-32485	94	1	f	f	X
ajst-32485	94	2	)	)	PUNCT
ajst-32485	94	3	the	the	DET
ajst-32485	94	4	percentage	percentage	NOUN
ajst-32485	94	5	of	of	ADP
ajst-32485	94	6	effector	effector	NOUN
ajst-32485	94	7	memory	memory	NOUN
ajst-32485	94	8	t	t	NOUN
ajst-32485	94	9	cells	cell	NOUN
ajst-32485	94	10	in	in	ADP
ajst-32485	94	11	splenic	splenic	PROPN
ajst-32485	94	12	cd8	cd8	PROPN
ajst-32485	94	13	+	+	PROPN
ajst-32485	94	14	t	t	PROPN
ajst-32485	94	15	cells	cell	NOUN
ajst-32485	94	16	detected	detect	VERB
ajst-32485	94	17	by	by	ADP
ajst-32485	94	18	flow	flow	NOUN
ajst-32485	94	19	cytometry	cytometry	NOUN
ajst-32485	94	20	(	(	PUNCT
ajst-32485	94	21	n	n	NOUN
ajst-32485	94	22	=	=	SYM
ajst-32485	94	23	5	5	NUM
ajst-32485	94	24	;	;	PUNCT
ajst-32485	94	25	one	one	NUM
ajst-32485	94	26	-	-	PUNCT
ajst-32485	94	27	way	way	NOUN
ajst-32485	94	28	anova	anova	PROPN
ajst-32485	94	29	)	)	PUNCT
ajst-32485	94	30	(	(	PUNCT
ajst-32485	94	31	cai	cai	X
ajst-32485	94	32	et	et	PROPN
ajst-32485	94	33	al	al	PROPN
ajst-32485	94	34	.	.	PROPN
ajst-32485	94	35	,	,	PUNCT
ajst-32485	94	36	2025	2025	NUM
ajst-32485	94	37	)	)	PUNCT
ajst-32485	94	38	.	.	PUNCT
ajst-32485	95	1	3.3	3.3	NUM
ajst-32485	95	2	advantages	advantage	NOUN
ajst-32485	95	3	the	the	DET
ajst-32485	95	4	combination	combination	NOUN
ajst-32485	95	5	of	of	ADP
ajst-32485	95	6	anti	anti	ADJ
ajst-32485	95	7	-	-	ADJ
ajst-32485	95	8	mesothelin	mesothelin	ADJ
ajst-32485	95	9	(	(	PUNCT
ajst-32485	95	10	msln	msln	NOUN
ajst-32485	95	11	)	)	PUNCT
ajst-32485	95	12	antibody	antibody	NOUN
ajst-32485	95	13	and	and	CCONJ
ajst-32485	95	14	personalized	personalize	VERB
ajst-32485	95	15	neoantigen	neoantigen	NOUN
ajst-32485	95	16	vaccines	vaccine	NOUN
ajst-32485	95	17	has	have	VERB
ajst-32485	95	18	several	several	ADJ
ajst-32485	95	19	advantages	advantage	NOUN
ajst-32485	95	20	in	in	ADP
ajst-32485	95	21	enhancing	enhance	VERB
ajst-32485	95	22	anti	anti	ADJ
ajst-32485	95	23	-	-	ADJ
ajst-32485	95	24	tumor	tumor	ADJ
ajst-32485	95	25	immune	immune	ADJ
ajst-32485	95	26	responses	response	NOUN
ajst-32485	95	27	.	.	PUNCT
ajst-32485	96	1	firstly	firstly	ADV
ajst-32485	96	2	,	,	PUNCT
ajst-32485	96	3	mesothelin	mesothelin	PROPN
ajst-32485	96	4	antibodies	antibodie	VERB
ajst-32485	96	5	can	can	AUX
ajst-32485	96	6	specifically	specifically	ADV
ajst-32485	96	7	target	target	VERB
ajst-32485	96	8	and	and	CCONJ
ajst-32485	96	9	eliminate	eliminate	VERB
ajst-32485	96	10	tumor	tumor	NOUN
ajst-32485	96	11	cells	cell	NOUN
ajst-32485	96	12	expressing	express	VERB
ajst-32485	96	13	msln	msln	NOUN
ajst-32485	96	14	,	,	PUNCT
ajst-32485	96	15	thereby	thereby	ADV
ajst-32485	96	16	reducing	reduce	VERB
ajst-32485	96	17	antigen	antigen	NOUN
ajst-32485	96	18	-	-	PUNCT
ajst-32485	96	19	presenting	present	VERB
ajst-32485	96	20	cancer	cancer	NOUN
ajst-32485	96	21	-	-	PUNCT
ajst-32485	96	22	associated	associate	VERB
ajst-32485	96	23	fibroblasts	fibroblast	NOUN
ajst-32485	96	24	(	(	PUNCT
ajst-32485	96	25	apcafs	apcafs	ADJ
ajst-32485	96	26	)	)	PUNCT
ajst-32485	96	27	cells	cell	NOUN
ajst-32485	96	28	known	know	VERB
ajst-32485	96	29	to	to	PART
ajst-32485	96	30	inhibit	inhibit	VERB
ajst-32485	96	31	t	t	PROPN
ajst-32485	96	32	-	-	PUNCT
ajst-32485	96	33	cell	cell	NOUN
ajst-32485	96	34	infiltration	infiltration	NOUN
ajst-32485	96	35	and	and	CCONJ
ajst-32485	96	36	promote	promote	VERB
ajst-32485	96	37	immune	immune	ADJ
ajst-32485	96	38	evasion	evasion	NOUN
ajst-32485	96	39	.	.	PUNCT
ajst-32485	97	1	the	the	DET
ajst-32485	97	2	targeted	target	VERB
ajst-32485	97	3	elimination	elimination	NOUN
ajst-32485	97	4	of	of	ADP
ajst-32485	97	5	apcafs	apcafs	ADJ
ajst-32485	97	6	not	not	PART
ajst-32485	97	7	only	only	ADV
ajst-32485	97	8	alleviates	alleviate	VERB
ajst-32485	97	9	physical	physical	ADJ
ajst-32485	97	10	barriers	barrier	NOUN
ajst-32485	97	11	in	in	ADP
ajst-32485	97	12	the	the	DET
ajst-32485	97	13	tme	tme	NOUN
ajst-32485	97	14	but	but	CCONJ
ajst-32485	97	15	also	also	ADV
ajst-32485	97	16	interrupts	interrupt	VERB
ajst-32485	97	17	pathological	pathological	ADJ
ajst-32485	97	18	conversion	conversion	NOUN
ajst-32485	97	19	of	of	ADP
ajst-32485	97	20	naïve	naïve	ADJ
ajst-32485	97	21	cd4⁺	cd4⁺	ADJ
ajst-32485	97	22	t	t	NOUN
ajst-32485	97	23	cells	cell	NOUN
ajst-32485	97	24	into	into	ADP
ajst-32485	97	25	regulatory	regulatory	ADJ
ajst-32485	97	26	t	t	NOUN
ajst-32485	97	27	cells	cell	NOUN
ajst-32485	97	28	(	(	PUNCT
ajst-32485	97	29	tregs	treg	NOUN
ajst-32485	97	30	)	)	PUNCT
ajst-32485	97	31	,	,	PUNCT
ajst-32485	97	32	thus	thus	ADV
ajst-32485	97	33	offering	offer	VERB
ajst-32485	97	34	a	a	DET
ajst-32485	97	35	more	more	ADV
ajst-32485	97	36	favorable	favorable	ADJ
ajst-32485	97	37	environment	environment	NOUN
ajst-32485	97	38	for	for	ADP
ajst-32485	97	39	effector	effector	NOUN
ajst-32485	97	40	immune	immune	ADJ
ajst-32485	97	41	cells	cell	NOUN
ajst-32485	97	42	to	to	PART
ajst-32485	97	43	infiltrate	infiltrate	VERB
ajst-32485	97	44	and	and	CCONJ
ajst-32485	97	45	exert	exert	VERB
ajst-32485	97	46	cytotoxic	cytotoxic	ADJ
ajst-32485	97	47	functions	function	NOUN
ajst-32485	97	48	(	(	PUNCT
ajst-32485	97	49	cai	cai	X
ajst-32485	97	50	et	et	PROPN
ajst-32485	97	51	al	al	PROPN
ajst-32485	97	52	.	.	PROPN
ajst-32485	97	53	,	,	PUNCT
ajst-32485	97	54	2025	2025	NUM
ajst-32485	97	55	)	)	PUNCT
ajst-32485	97	56	.	.	PUNCT
ajst-32485	98	1	124	124	NUM
ajst-32485	98	2	in	in	ADP
ajst-32485	98	3	addition	addition	NOUN
ajst-32485	98	4	,	,	PUNCT
ajst-32485	98	5	the	the	DET
ajst-32485	98	6	neoantigen	neoantigen	PROPN
ajst-32485	98	7	vaccine	vaccine	NOUN
ajst-32485	98	8	serves	serve	VERB
ajst-32485	98	9	to	to	PART
ajst-32485	98	10	produce	produce	VERB
ajst-32485	98	11	tumor	tumor	NOUN
ajst-32485	98	12	-	-	PUNCT
ajst-32485	98	13	specific	specific	ADJ
ajst-32485	98	14	cd8⁺	cd8⁺	NOUN
ajst-32485	98	15	t	t	NOUN
ajst-32485	98	16	cells	cell	NOUN
ajst-32485	98	17	with	with	ADP
ajst-32485	98	18	high	high	ADJ
ajst-32485	98	19	precision	precision	NOUN
ajst-32485	98	20	,	,	PUNCT
ajst-32485	98	21	ensuring	ensure	VERB
ajst-32485	98	22	that	that	SCONJ
ajst-32485	98	23	the	the	DET
ajst-32485	98	24	immune	immune	ADJ
ajst-32485	98	25	responses	response	NOUN
ajst-32485	98	26	they	they	PRON
ajst-32485	98	27	induce	induce	VERB
ajst-32485	98	28	are	be	AUX
ajst-32485	98	29	against	against	ADP
ajst-32485	98	30	specific	specific	ADJ
ajst-32485	98	31	antigens	antigen	NOUN
ajst-32485	98	32	on	on	ADP
ajst-32485	98	33	the	the	DET
ajst-32485	98	34	tumor	tumor	NOUN
ajst-32485	98	35	.	.	PUNCT
ajst-32485	99	1	the	the	DET
ajst-32485	99	2	effect	effect	NOUN
ajst-32485	99	3	of	of	ADP
ajst-32485	99	4	combining	combine	VERB
ajst-32485	99	5	these	these	DET
ajst-32485	99	6	two	two	NUM
ajst-32485	99	7	strategies	strategy	NOUN
ajst-32485	99	8	has	have	AUX
ajst-32485	99	9	been	be	AUX
ajst-32485	99	10	fully	fully	ADV
ajst-32485	99	11	verified	verify	VERB
ajst-32485	99	12	in	in	ADP
ajst-32485	99	13	orthotopic	orthotopic	ADJ
ajst-32485	99	14	pancreatic	pancreatic	ADJ
ajst-32485	99	15	cancer	cancer	NOUN
ajst-32485	99	16	mouse	mouse	NOUN
ajst-32485	99	17	models	model	NOUN
ajst-32485	99	18	,	,	PUNCT
ajst-32485	99	19	with	with	ADP
ajst-32485	99	20	a	a	DET
ajst-32485	99	21	remarkable	remarkable	ADJ
ajst-32485	99	22	increase	increase	NOUN
ajst-32485	99	23	in	in	ADP
ajst-32485	99	24	neoantigen	neoantigen	NOUN
ajst-32485	99	25	-	-	PUNCT
ajst-32485	99	26	specific	specific	ADJ
ajst-32485	99	27	cd8⁺	cd8⁺	NOUN
ajst-32485	99	28	t	t	NOUN
ajst-32485	99	29	cells	cell	NOUN
ajst-32485	99	30	’	’	PART
ajst-32485	99	31	infiltration	infiltration	NOUN
ajst-32485	99	32	and	and	CCONJ
ajst-32485	99	33	activation	activation	NOUN
ajst-32485	99	34	,	,	PUNCT
ajst-32485	99	35	which	which	PRON
ajst-32485	99	36	means	mean	VERB
ajst-32485	99	37	superior	superior	ADJ
ajst-32485	99	38	tumor	tumor	NOUN
ajst-32485	99	39	regression	regression	NOUN
ajst-32485	99	40	was	be	AUX
ajst-32485	99	41	observed	observe	VERB
ajst-32485	99	42	compared	compare	VERB
ajst-32485	99	43	to	to	ADP
ajst-32485	99	44	monotherapies	monotherapie	NOUN
ajst-32485	99	45	(	(	PUNCT
ajst-32485	99	46	cai	cai	X
ajst-32485	99	47	et	et	PROPN
ajst-32485	99	48	al	al	PROPN
ajst-32485	99	49	.	.	PROPN
ajst-32485	99	50	,	,	PUNCT
ajst-32485	99	51	2025	2025	NUM
ajst-32485	99	52	)	)	PUNCT
ajst-32485	99	53	.	.	PUNCT
ajst-32485	100	1	besides	besides	SCONJ
ajst-32485	100	2	,	,	PUNCT
ajst-32485	100	3	in	in	ADP
ajst-32485	100	4	the	the	DET
ajst-32485	100	5	preclinical	preclinical	ADJ
ajst-32485	100	6	phase	phase	NOUN
ajst-32485	100	7	of	of	ADP
ajst-32485	100	8	the	the	DET
ajst-32485	100	9	clinical	clinical	ADJ
ajst-32485	100	10	trial	trial	NOUN
ajst-32485	100	11	,	,	PUNCT
ajst-32485	100	12	the	the	DET
ajst-32485	100	13	combined	combine	VERB
ajst-32485	100	14	treatment	treatment	NOUN
ajst-32485	100	15	performed	perform	VERB
ajst-32485	100	16	well	well	ADV
ajst-32485	100	17	from	from	ADP
ajst-32485	100	18	a	a	DET
ajst-32485	100	19	safety	safety	NOUN
ajst-32485	100	20	perspective	perspective	NOUN
ajst-32485	100	21	.	.	PUNCT
ajst-32485	101	1	the	the	DET
ajst-32485	101	2	observation	observation	NOUN
ajst-32485	101	3	of	of	ADP
ajst-32485	101	4	no	no	DET
ajst-32485	101	5	noticeable	noticeable	ADJ
ajst-32485	101	6	changes	change	NOUN
ajst-32485	101	7	in	in	ADP
ajst-32485	101	8	major	major	ADJ
ajst-32485	101	9	organs	organ	NOUN
ajst-32485	101	10	or	or	CCONJ
ajst-32485	101	11	tissue	tissue	NOUN
ajst-32485	101	12	structure	structure	NOUN
ajst-32485	101	13	illustrates	illustrate	VERB
ajst-32485	101	14	a	a	DET
ajst-32485	101	15	promising	promising	ADJ
ajst-32485	101	16	potential	potential	NOUN
ajst-32485	101	17	for	for	ADP
ajst-32485	101	18	clinical	clinical	ADJ
ajst-32485	101	19	translations	translation	NOUN
ajst-32485	101	20	without	without	ADP
ajst-32485	101	21	inducing	induce	VERB
ajst-32485	101	22	any	any	DET
ajst-32485	101	23	systemic	systemic	ADJ
ajst-32485	101	24	toxicity	toxicity	NOUN
ajst-32485	101	25	(	(	PUNCT
ajst-32485	101	26	cai	cai	X
ajst-32485	101	27	et	et	PROPN
ajst-32485	101	28	al	al	PROPN
ajst-32485	101	29	.	.	PROPN
ajst-32485	101	30	,	,	PUNCT
ajst-32485	101	31	2025	2025	NUM
ajst-32485	101	32	)	)	PUNCT
ajst-32485	101	33	.	.	PUNCT
ajst-32485	102	1	however	however	ADV
ajst-32485	102	2	,	,	PUNCT
ajst-32485	102	3	the	the	DET
ajst-32485	102	4	strategy	strategy	NOUN
ajst-32485	102	5	still	still	ADV
ajst-32485	102	6	has	have	VERB
ajst-32485	102	7	several	several	ADJ
ajst-32485	102	8	limitations	limitation	NOUN
ajst-32485	102	9	that	that	PRON
ajst-32485	102	10	need	need	VERB
ajst-32485	102	11	to	to	PART
ajst-32485	102	12	be	be	AUX
ajst-32485	102	13	considered	consider	VERB
ajst-32485	102	14	.	.	PUNCT
ajst-32485	103	1	for	for	ADP
ajst-32485	103	2	instance	instance	NOUN
ajst-32485	103	3	,	,	PUNCT
ajst-32485	103	4	the	the	DET
ajst-32485	103	5	efficacy	efficacy	NOUN
ajst-32485	103	6	relies	rely	VERB
ajst-32485	103	7	on	on	ADP
ajst-32485	103	8	high	high	ADJ
ajst-32485	103	9	expression	expression	NOUN
ajst-32485	103	10	of	of	ADP
ajst-32485	103	11	msln	msln	NOUN
ajst-32485	103	12	on	on	ADP
ajst-32485	103	13	tumor	tumor	NOUN
ajst-32485	103	14	cells	cell	NOUN
ajst-32485	103	15	and	and	CCONJ
ajst-32485	103	16	stromal	stromal	ADJ
ajst-32485	103	17	cells	cell	NOUN
ajst-32485	103	18	to	to	ADP
ajst-32485	103	19	a	a	DET
ajst-32485	103	20	large	large	ADJ
ajst-32485	103	21	extent	extent	NOUN
ajst-32485	103	22	.	.	PUNCT
ajst-32485	104	1	in	in	ADP
ajst-32485	104	2	this	this	DET
ajst-32485	104	3	case	case	NOUN
ajst-32485	104	4	,	,	PUNCT
ajst-32485	104	5	the	the	DET
ajst-32485	104	6	therapeutic	therapeutic	ADJ
ajst-32485	104	7	results	result	NOUN
ajst-32485	104	8	may	may	AUX
ajst-32485	104	9	experience	experience	VERB
ajst-32485	104	10	significant	significant	ADJ
ajst-32485	104	11	falls	fall	NOUN
ajst-32485	104	12	in	in	ADP
ajst-32485	104	13	those	those	PRON
ajst-32485	104	14	who	who	PRON
ajst-32485	104	15	express	express	VERB
ajst-32485	104	16	msln	msln	NOUN
ajst-32485	104	17	at	at	ADP
ajst-32485	104	18	a	a	DET
ajst-32485	104	19	low	low	ADJ
ajst-32485	104	20	level	level	NOUN
ajst-32485	104	21	(	(	PUNCT
ajst-32485	104	22	cai	cai	X
ajst-32485	104	23	et	et	PROPN
ajst-32485	104	24	al	al	PROPN
ajst-32485	104	25	.	.	PROPN
ajst-32485	104	26	,	,	PUNCT
ajst-32485	104	27	2025	2025	NUM
ajst-32485	104	28	)	)	PUNCT
ajst-32485	104	29	.	.	PUNCT
ajst-32485	105	1	3.4	3.4	NUM
ajst-32485	105	2	comparative	comparative	ADJ
ajst-32485	105	3	evaluation	evaluation	NOUN
ajst-32485	105	4	neoantigen	neoantigen	NOUN
ajst-32485	105	5	vaccines	vaccine	NOUN
ajst-32485	105	6	exhibit	exhibit	VERB
ajst-32485	105	7	limited	limited	ADJ
ajst-32485	105	8	immunogenicity	immunogenicity	NOUN
ajst-32485	105	9	due	due	ADP
ajst-32485	105	10	to	to	ADP
ajst-32485	105	11	inefficient	inefficient	ADJ
ajst-32485	105	12	antigen	antigen	ADJ
ajst-32485	105	13	delivery	delivery	NOUN
ajst-32485	105	14	and	and	CCONJ
ajst-32485	105	15	a	a	DET
ajst-32485	105	16	complicated	complicate	VERB
ajst-32485	105	17	immunosuppressive	immunosuppressive	ADJ
ajst-32485	105	18	tme	tme	NOUN
ajst-32485	105	19	.	.	PUNCT
ajst-32485	106	1	despite	despite	SCONJ
ajst-32485	106	2	the	the	DET
ajst-32485	106	3	fact	fact	NOUN
ajst-32485	106	4	that	that	SCONJ
ajst-32485	106	5	non	non	ADJ
ajst-32485	106	6	-	-	ADJ
ajst-32485	106	7	targeted	targeted	ADJ
ajst-32485	106	8	neoantigen	neoantigen	NOUN
ajst-32485	106	9	vaccines	vaccine	NOUN
ajst-32485	106	10	are	be	AUX
ajst-32485	106	11	capable	capable	ADJ
ajst-32485	106	12	of	of	ADP
ajst-32485	106	13	inducing	induce	VERB
ajst-32485	106	14	tumor	tumor	NOUN
ajst-32485	106	15	-	-	PUNCT
ajst-32485	106	16	specific	specific	ADJ
ajst-32485	106	17	t	t	NOUN
ajst-32485	106	18	cell	cell	NOUN
ajst-32485	106	19	responses	response	NOUN
ajst-32485	106	20	,	,	PUNCT
ajst-32485	106	21	their	their	PRON
ajst-32485	106	22	therapeutic	therapeutic	ADJ
ajst-32485	106	23	effects	effect	NOUN
ajst-32485	106	24	are	be	AUX
ajst-32485	106	25	still	still	ADV
ajst-32485	106	26	unsatisfactory	unsatisfactory	ADJ
ajst-32485	106	27	.	.	PUNCT
ajst-32485	107	1	by	by	ADP
ajst-32485	107	2	combining	combine	VERB
ajst-32485	107	3	mesothelin	mesothelin	NOUN
ajst-32485	107	4	(	(	PUNCT
ajst-32485	107	5	msln)-targeted	msln)-targeted	ADJ
ajst-32485	107	6	delivery	delivery	NOUN
ajst-32485	107	7	with	with	ADP
ajst-32485	107	8	vaccine	vaccine	NOUN
ajst-32485	107	9	strategies	strategy	NOUN
ajst-32485	107	10	,	,	PUNCT
ajst-32485	107	11	some	some	PRON
ajst-32485	107	12	of	of	ADP
ajst-32485	107	13	the	the	DET
ajst-32485	107	14	current	current	ADJ
ajst-32485	107	15	problems	problem	NOUN
ajst-32485	107	16	are	be	AUX
ajst-32485	107	17	expected	expect	VERB
ajst-32485	107	18	to	to	PART
ajst-32485	107	19	be	be	AUX
ajst-32485	107	20	solved	solve	VERB
ajst-32485	107	21	because	because	SCONJ
ajst-32485	107	22	of	of	ADP
ajst-32485	107	23	improved	improve	VERB
ajst-32485	107	24	antigen	antigen	ADJ
ajst-32485	107	25	delivery	delivery	NOUN
ajst-32485	107	26	and	and	CCONJ
ajst-32485	107	27	t	t	NOUN
ajst-32485	107	28	cell	cell	NOUN
ajst-32485	107	29	infiltration	infiltration	NOUN
ajst-32485	107	30	.	.	PUNCT
ajst-32485	108	1	this	this	DET
ajst-32485	108	2	section	section	NOUN
ajst-32485	108	3	compares	compare	VERB
ajst-32485	108	4	the	the	DET
ajst-32485	108	5	immune	immune	ADJ
ajst-32485	108	6	responses	response	NOUN
ajst-32485	108	7	and	and	CCONJ
ajst-32485	108	8	therapeutic	therapeutic	ADJ
ajst-32485	108	9	outcomes	outcome	NOUN
ajst-32485	108	10	between	between	ADP
ajst-32485	108	11	msln	msln	NOUN
ajst-32485	108	12	-	-	PUNCT
ajst-32485	108	13	targeted	target	VERB
ajst-32485	108	14	and	and	CCONJ
ajst-32485	108	15	nontargeted	nontargete	VERB
ajst-32485	108	16	vaccine	vaccine	NOUN
ajst-32485	108	17	strategies	strategy	NOUN
ajst-32485	108	18	(	(	PUNCT
ajst-32485	108	19	cai	cai	X
ajst-32485	108	20	et	et	PROPN
ajst-32485	108	21	al	al	PROPN
ajst-32485	108	22	.	.	PROPN
ajst-32485	108	23	,	,	PUNCT
ajst-32485	108	24	2025	2025	NUM
ajst-32485	108	25	)	)	PUNCT
ajst-32485	108	26	.	.	PUNCT
ajst-32485	109	1	compared	compare	VERB
ajst-32485	109	2	with	with	ADP
ajst-32485	109	3	conventional	conventional	ADJ
ajst-32485	109	4	non	non	ADJ
ajst-32485	109	5	-	-	ADJ
ajst-32485	109	6	targeted	targeted	ADJ
ajst-32485	109	7	neoantigen	neoantigen	NOUN
ajst-32485	109	8	vaccines	vaccine	NOUN
ajst-32485	109	9	,	,	PUNCT
ajst-32485	109	10	the	the	DET
ajst-32485	109	11	mesothelin	mesothelin	NOUN
ajst-32485	109	12	(	(	PUNCT
ajst-32485	109	13	msln)-targeted	msln)-targeted	ADJ
ajst-32485	109	14	delivery	delivery	NOUN
ajst-32485	109	15	strategy	strategy	NOUN
ajst-32485	109	16	shows	show	VERB
ajst-32485	109	17	considerable	considerable	ADJ
ajst-32485	109	18	advantages	advantage	NOUN
ajst-32485	109	19	in	in	ADP
ajst-32485	109	20	terms	term	NOUN
ajst-32485	109	21	of	of	ADP
ajst-32485	109	22	boosting	boost	VERB
ajst-32485	109	23	antigen	antigen	ADJ
ajst-32485	109	24	delivery	delivery	NOUN
ajst-32485	109	25	and	and	CCONJ
ajst-32485	109	26	t	t	NOUN
ajst-32485	109	27	cell	cell	NOUN
ajst-32485	109	28	activation	activation	NOUN
ajst-32485	109	29	.	.	PUNCT
ajst-32485	110	1	in	in	ADP
ajst-32485	110	2	non	non	ADJ
ajst-32485	110	3	-	-	ADJ
ajst-32485	110	4	targeted	targeted	ADJ
ajst-32485	110	5	strategies	strategy	NOUN
ajst-32485	110	6	,	,	PUNCT
ajst-32485	110	7	for	for	ADP
ajst-32485	110	8	instance	instance	NOUN
ajst-32485	110	9	,	,	PUNCT
ajst-32485	110	10	the	the	DET
ajst-32485	110	11	lipoplex	lipoplex	PROPN
ajst-32485	110	12	mrna	mrna	PROPN
ajst-32485	110	13	neoantigen	neoantigen	PROPN
ajst-32485	110	14	vaccine	vaccine	NOUN
ajst-32485	110	15	studied	study	VERB
ajst-32485	110	16	by	by	ADP
ajst-32485	110	17	rojas	rojas	PROPN
ajst-32485	110	18	et	et	PROPN
ajst-32485	110	19	al	al	PROPN
ajst-32485	110	20	.	.	PROPN
ajst-32485	110	21	,	,	PUNCT
ajst-32485	110	22	only	only	ADV
ajst-32485	110	23	approximately	approximately	ADV
ajst-32485	110	24	50	50	NUM
ajst-32485	110	25	%	%	NOUN
ajst-32485	110	26	of	of	ADP
ajst-32485	110	27	patients	patient	NOUN
ajst-32485	110	28	could	could	AUX
ajst-32485	110	29	induce	induce	VERB
ajst-32485	110	30	neoantigen	neoantigen	NOUN
ajst-32485	110	31	-	-	PUNCT
ajst-32485	110	32	specific	specific	ADJ
ajst-32485	110	33	t	t	NOUN
ajst-32485	110	34	cell	cell	NOUN
ajst-32485	110	35	responses	response	NOUN
ajst-32485	110	36	,	,	PUNCT
ajst-32485	110	37	with	with	ADP
ajst-32485	110	38	the	the	DET
ajst-32485	110	39	ifn	ifn	PROPN
ajst-32485	110	40	-	-	PUNCT
ajst-32485	110	41	γ	γ	NOUN
ajst-32485	110	42	elispot	elispot	NOUN
ajst-32485	110	43	reaction	reaction	NOUN
ajst-32485	110	44	intensity	intensity	NOUN
ajst-32485	110	45	between	between	ADP
ajst-32485	110	46	100	100	NUM
ajst-32485	110	47	and	and	CCONJ
ajst-32485	110	48	2000	2000	NUM
ajst-32485	110	49	spots	spot	NOUN
ajst-32485	110	50	per	per	ADP
ajst-32485	110	51	million	million	NUM
ajst-32485	110	52	pbmcs	pbmcs	NOUN
ajst-32485	110	53	.	.	PUNCT
ajst-32485	111	1	out	out	ADP
ajst-32485	111	2	of	of	ADP
ajst-32485	111	3	16	16	NUM
ajst-32485	111	4	patients	patient	NOUN
ajst-32485	111	5	,	,	PUNCT
ajst-32485	111	6	8	8	NUM
ajst-32485	111	7	experienced	experience	VERB
ajst-32485	111	8	their	their	PRON
ajst-32485	111	9	t	t	NOUN
ajst-32485	111	10	cells	cell	NOUN
ajst-32485	111	11	expanding	expand	VERB
ajst-32485	111	12	in	in	ADP
ajst-32485	111	13	clones	clone	NOUN
ajst-32485	111	14	,	,	PUNCT
ajst-32485	111	15	and	and	CCONJ
ajst-32485	111	16	some	some	DET
ajst-32485	111	17	clones	clone	NOUN
ajst-32485	111	18	accounted	account	VERB
ajst-32485	111	19	for	for	ADP
ajst-32485	111	20	10	10	NUM
ajst-32485	111	21	%	%	NOUN
ajst-32485	111	22	of	of	ADP
ajst-32485	111	23	the	the	DET
ajst-32485	111	24	total	total	ADJ
ajst-32485	111	25	peripheral	peripheral	ADJ
ajst-32485	111	26	t	t	NOUN
ajst-32485	111	27	cells	cell	NOUN
ajst-32485	111	28	.	.	PUNCT
ajst-32485	112	1	although	although	SCONJ
ajst-32485	112	2	these	these	DET
ajst-32485	112	3	results	result	NOUN
ajst-32485	112	4	demonstrate	demonstrate	VERB
ajst-32485	112	5	the	the	DET
ajst-32485	112	6	immunogenic	immunogenic	ADJ
ajst-32485	112	7	potential	potential	NOUN
ajst-32485	112	8	of	of	ADP
ajst-32485	112	9	neoantigen	neoantigen	PROPN
ajst-32485	112	10	vaccines	vaccine	NOUN
ajst-32485	112	11	,	,	PUNCT
ajst-32485	112	12	the	the	DET
ajst-32485	112	13	overall	overall	ADJ
ajst-32485	112	14	therapeutic	therapeutic	ADJ
ajst-32485	112	15	effect	effect	NOUN
ajst-32485	112	16	is	be	AUX
ajst-32485	112	17	still	still	ADV
ajst-32485	112	18	greatly	greatly	ADV
ajst-32485	112	19	constrained	constrain	VERB
ajst-32485	112	20	due	due	ADP
ajst-32485	112	21	to	to	ADP
ajst-32485	112	22	the	the	DET
ajst-32485	112	23	low	low	ADJ
ajst-32485	112	24	efficiency	efficiency	NOUN
ajst-32485	112	25	of	of	ADP
ajst-32485	112	26	antigen	antigen	ADJ
ajst-32485	112	27	delivery	delivery	NOUN
ajst-32485	112	28	and	and	CCONJ
ajst-32485	112	29	limited	limited	ADJ
ajst-32485	112	30	infiltration	infiltration	NOUN
ajst-32485	112	31	of	of	ADP
ajst-32485	112	32	t	t	PROPN
ajst-32485	112	33	cells	cell	NOUN
ajst-32485	112	34	into	into	ADP
ajst-32485	112	35	the	the	DET
ajst-32485	112	36	tme	tme	X
ajst-32485	112	37	(	(	PUNCT
ajst-32485	112	38	cai	cai	X
ajst-32485	112	39	et	et	PROPN
ajst-32485	112	40	al	al	PROPN
ajst-32485	112	41	.	.	PROPN
ajst-32485	112	42	,	,	PUNCT
ajst-32485	112	43	2025	2025	NUM
ajst-32485	112	44	;	;	PUNCT
ajst-32485	112	45	rojas	rojas	PROPN
ajst-32485	112	46	et	et	PROPN
ajst-32485	112	47	al	al	PROPN
ajst-32485	112	48	.	.	PROPN
ajst-32485	112	49	,	,	PUNCT
ajst-32485	112	50	2023	2023	NUM
ajst-32485	112	51	)	)	PUNCT
ajst-32485	112	52	.	.	PUNCT
ajst-32485	113	1	in	in	ADP
ajst-32485	113	2	contrast	contrast	NOUN
ajst-32485	113	3	,	,	PUNCT
ajst-32485	113	4	in	in	ADP
ajst-32485	113	5	the	the	DET
ajst-32485	113	6	orthotopic	orthotopic	ADJ
ajst-32485	113	7	pancreatic	pancreatic	PROPN
ajst-32485	113	8	cancer	cancer	NOUN
ajst-32485	113	9	mouse	mouse	NOUN
ajst-32485	113	10	model	model	NOUN
ajst-32485	113	11	,	,	PUNCT
ajst-32485	113	12	the	the	DET
ajst-32485	113	13	msln	msln	NOUN
ajst-32485	113	14	-	-	PUNCT
ajst-32485	113	15	targeted	target	VERB
ajst-32485	113	16	delivery	delivery	NOUN
ajst-32485	113	17	strategy	strategy	NOUN
ajst-32485	113	18	markedly	markedly	ADV
ajst-32485	113	19	improved	improve	VERB
ajst-32485	113	20	antigen	antigen	ADJ
ajst-32485	113	21	delivery	delivery	NOUN
ajst-32485	113	22	efficiency	efficiency	NOUN
ajst-32485	113	23	and	and	CCONJ
ajst-32485	113	24	promoted	promote	VERB
ajst-32485	113	25	neoantigen	neoantigen	NOUN
ajst-32485	113	26	-	-	PUNCT
ajst-32485	113	27	specific	specific	ADJ
ajst-32485	113	28	cd8⁺	cd8⁺	NOUN
ajst-32485	113	29	t	t	NOUN
ajst-32485	113	30	cell	cell	NOUN
ajst-32485	113	31	infiltration	infiltration	NOUN
ajst-32485	113	32	and	and	CCONJ
ajst-32485	113	33	activation	activation	NOUN
ajst-32485	113	34	.	.	PUNCT
ajst-32485	114	1	the	the	DET
ajst-32485	114	2	infiltration	infiltration	NOUN
ajst-32485	114	3	level	level	NOUN
ajst-32485	114	4	of	of	ADP
ajst-32485	114	5	cd8⁺	cd8⁺	NOUN
ajst-32485	114	6	t	t	NOUN
ajst-32485	114	7	cells	cell	NOUN
ajst-32485	114	8	in	in	ADP
ajst-32485	114	9	the	the	DET
ajst-32485	114	10	tumor	tumor	NOUN
ajst-32485	114	11	tissues	tissue	NOUN
ajst-32485	114	12	of	of	ADP
ajst-32485	114	13	the	the	DET
ajst-32485	114	14	mslntargeted	mslntargete	VERB
ajst-32485	114	15	group	group	NOUN
ajst-32485	114	16	was	be	AUX
ajst-32485	114	17	much	much	ADV
ajst-32485	114	18	higher	high	ADJ
ajst-32485	114	19	than	than	ADP
ajst-32485	114	20	that	that	PRON
ajst-32485	114	21	of	of	ADP
ajst-32485	114	22	the	the	DET
ajst-32485	114	23	non	non	ADJ
ajst-32485	114	24	-	-	ADJ
ajst-32485	114	25	targeted	targeted	ADJ
ajst-32485	114	26	vaccine	vaccine	NOUN
ajst-32485	114	27	group	group	NOUN
ajst-32485	114	28	(	(	PUNCT
ajst-32485	114	29	p	p	X
ajst-32485	114	30	<	<	X
ajst-32485	114	31	0.001	0.001	NUM
ajst-32485	114	32	)	)	PUNCT
ajst-32485	114	33	,	,	PUNCT
ajst-32485	114	34	with	with	ADP
ajst-32485	114	35	a	a	DET
ajst-32485	114	36	substantial	substantial	ADJ
ajst-32485	114	37	increase	increase	NOUN
ajst-32485	114	38	in	in	ADP
ajst-32485	114	39	the	the	DET
ajst-32485	114	40	proportion	proportion	NOUN
ajst-32485	114	41	of	of	ADP
ajst-32485	114	42	cd69⁺	cd69⁺	NOUN
ajst-32485	114	43	cd8⁺	cd8⁺	NOUN
ajst-32485	114	44	activated	activate	VERB
ajst-32485	114	45	t	t	NOUN
ajst-32485	114	46	cells	cell	NOUN
ajst-32485	114	47	(	(	PUNCT
ajst-32485	114	48	p	p	NOUN
ajst-32485	114	49	=	=	NOUN
ajst-32485	114	50	0.0037	0.0037	NUM
ajst-32485	114	51	)	)	PUNCT
ajst-32485	114	52	.	.	PUNCT
ajst-32485	115	1	the	the	DET
ajst-32485	115	2	functional	functional	ADJ
ajst-32485	115	3	cytotoxicity	cytotoxicity	NOUN
ajst-32485	115	4	assays	assay	NOUN
ajst-32485	115	5	further	far	ADV
ajst-32485	115	6	revealed	reveal	VERB
ajst-32485	115	7	that	that	SCONJ
ajst-32485	115	8	the	the	DET
ajst-32485	115	9	killing	kill	VERB
ajst-32485	115	10	efficiency	efficiency	NOUN
ajst-32485	115	11	of	of	ADP
ajst-32485	115	12	t	t	NOUN
ajst-32485	115	13	cells	cell	NOUN
ajst-32485	115	14	in	in	ADP
ajst-32485	115	15	the	the	DET
ajst-32485	115	16	targeted	target	VERB
ajst-32485	115	17	group	group	NOUN
ajst-32485	115	18	was	be	AUX
ajst-32485	115	19	twice	twice	ADV
ajst-32485	115	20	as	as	ADV
ajst-32485	115	21	high	high	ADJ
ajst-32485	115	22	as	as	ADP
ajst-32485	115	23	that	that	PRON
ajst-32485	115	24	of	of	ADP
ajst-32485	115	25	the	the	DET
ajst-32485	115	26	non	non	ADJ
ajst-32485	115	27	-	-	ADJ
ajst-32485	115	28	targeted	targeted	ADJ
ajst-32485	115	29	group	group	NOUN
ajst-32485	115	30	(	(	PUNCT
ajst-32485	115	31	p	p	X
ajst-32485	115	32	<	<	X
ajst-32485	115	33	0.0001	0.0001	NUM
ajst-32485	115	34	)	)	PUNCT
ajst-32485	115	35	.	.	PUNCT
ajst-32485	116	1	nevertheless	nevertheless	ADV
ajst-32485	116	2	,	,	PUNCT
ajst-32485	116	3	the	the	DET
ajst-32485	116	4	msln	msln	NOUN
ajst-32485	116	5	-	-	PUNCT
ajst-32485	116	6	targeted	target	VERB
ajst-32485	116	7	strategy	strategy	NOUN
ajst-32485	116	8	has	have	AUX
ajst-32485	116	9	resulted	result	VERB
ajst-32485	116	10	in	in	ADP
ajst-32485	116	11	apparent	apparent	ADJ
ajst-32485	116	12	tumor	tumor	NOUN
ajst-32485	116	13	regression	regression	NOUN
ajst-32485	116	14	in	in	ADP
ajst-32485	116	15	vivo	vivo	NOUN
ajst-32485	116	16	,	,	PUNCT
ajst-32485	116	17	which	which	PRON
ajst-32485	116	18	is	be	AUX
ajst-32485	116	19	a	a	DET
ajst-32485	116	20	phenomenon	phenomenon	NOUN
ajst-32485	116	21	that	that	PRON
ajst-32485	116	22	has	have	AUX
ajst-32485	116	23	not	not	PART
ajst-32485	116	24	been	be	AUX
ajst-32485	116	25	directly	directly	ADV
ajst-32485	116	26	verified	verify	VERB
ajst-32485	116	27	in	in	ADP
ajst-32485	116	28	clinical	clinical	ADJ
ajst-32485	116	29	studies	study	NOUN
ajst-32485	116	30	of	of	ADP
ajst-32485	116	31	non	non	ADJ
ajst-32485	116	32	-	-	ADJ
ajst-32485	116	33	targeted	targeted	ADJ
ajst-32485	116	34	vaccines	vaccine	NOUN
ajst-32485	116	35	(	(	PUNCT
ajst-32485	116	36	cai	cai	X
ajst-32485	116	37	et	et	PROPN
ajst-32485	116	38	al	al	PROPN
ajst-32485	116	39	.	.	PROPN
ajst-32485	116	40	,	,	PUNCT
ajst-32485	116	41	2025	2025	NUM
ajst-32485	116	42	)	)	PUNCT
ajst-32485	116	43	.	.	PUNCT
ajst-32485	117	1	apart	apart	ADV
ajst-32485	117	2	from	from	ADP
ajst-32485	117	3	these	these	DET
ajst-32485	117	4	immunological	immunological	ADJ
ajst-32485	117	5	advantages	advantage	NOUN
ajst-32485	117	6	,	,	PUNCT
ajst-32485	117	7	the	the	DET
ajst-32485	117	8	success	success	NOUN
ajst-32485	117	9	of	of	ADP
ajst-32485	117	10	the	the	DET
ajst-32485	117	11	strategy	strategy	NOUN
ajst-32485	117	12	heavily	heavily	ADV
ajst-32485	117	13	depends	depend	VERB
ajst-32485	117	14	on	on	ADP
ajst-32485	117	15	the	the	DET
ajst-32485	117	16	expression	expression	NOUN
ajst-32485	117	17	levels	level	NOUN
ajst-32485	117	18	of	of	ADP
ajst-32485	117	19	msln	msln	NOUN
ajst-32485	117	20	in	in	ADP
ajst-32485	117	21	tumor	tumor	NOUN
ajst-32485	117	22	cells	cell	NOUN
ajst-32485	117	23	and	and	CCONJ
ajst-32485	117	24	stromal	stromal	ADJ
ajst-32485	117	25	components	component	NOUN
ajst-32485	117	26	,	,	PUNCT
ajst-32485	117	27	which	which	PRON
ajst-32485	117	28	means	mean	VERB
ajst-32485	117	29	there	there	PRON
ajst-32485	117	30	will	will	AUX
ajst-32485	117	31	be	be	AUX
ajst-32485	117	32	limitations	limitation	NOUN
ajst-32485	117	33	in	in	ADP
ajst-32485	117	34	the	the	DET
ajst-32485	117	35	treatment	treatment	NOUN
ajst-32485	117	36	of	of	ADP
ajst-32485	117	37	low	low	ADV
ajst-32485	117	38	-	-	PUNCT
ajst-32485	117	39	expressing	express	VERB
ajst-32485	117	40	msln	msln	NOUN
ajst-32485	117	41	or	or	CCONJ
ajst-32485	117	42	highly	highly	ADV
ajst-32485	117	43	specific	specific	ADJ
ajst-32485	117	44	tumors	tumor	NOUN
ajst-32485	117	45	.	.	PUNCT
ajst-32485	118	1	besides	besides	SCONJ
ajst-32485	118	2	,	,	PUNCT
ajst-32485	118	3	as	as	SCONJ
ajst-32485	118	4	the	the	DET
ajst-32485	118	5	current	current	ADJ
ajst-32485	118	6	evidence	evidence	NOUN
ajst-32485	118	7	for	for	ADP
ajst-32485	118	8	the	the	DET
ajst-32485	118	9	msln	msln	NOUN
ajst-32485	118	10	-	-	PUNCT
ajst-32485	118	11	targeted	target	VERB
ajst-32485	118	12	strategy	strategy	NOUN
ajst-32485	118	13	mainly	mainly	ADV
ajst-32485	118	14	comes	come	VERB
ajst-32485	118	15	from	from	ADP
ajst-32485	118	16	preclinical	preclinical	ADJ
ajst-32485	118	17	mouse	mouse	NOUN
ajst-32485	118	18	models	model	NOUN
ajst-32485	118	19	,	,	PUNCT
ajst-32485	118	20	its	its	PRON
ajst-32485	118	21	therapeutic	therapeutic	ADJ
ajst-32485	118	22	efficacy	efficacy	NOUN
ajst-32485	118	23	in	in	ADP
ajst-32485	118	24	humans	human	NOUN
ajst-32485	118	25	still	still	ADV
ajst-32485	118	26	requires	require	VERB
ajst-32485	118	27	further	further	ADJ
ajst-32485	118	28	clinical	clinical	ADJ
ajst-32485	118	29	verification	verification	NOUN
ajst-32485	118	30	.	.	PUNCT
ajst-32485	119	1	despite	despite	SCONJ
ajst-32485	119	2	these	these	DET
ajst-32485	119	3	shortcomings	shortcoming	NOUN
ajst-32485	119	4	,	,	PUNCT
ajst-32485	119	5	the	the	DET
ajst-32485	119	6	targeted	target	VERB
ajst-32485	119	7	delivery	delivery	NOUN
ajst-32485	119	8	strategy	strategy	NOUN
ajst-32485	119	9	has	have	VERB
ajst-32485	119	10	a	a	DET
ajst-32485	119	11	mechanism	mechanism	NOUN
ajst-32485	119	12	-	-	PUNCT
ajst-32485	119	13	based	base	VERB
ajst-32485	119	14	advantage	advantage	NOUN
ajst-32485	119	15	in	in	ADP
ajst-32485	119	16	breaking	break	VERB
ajst-32485	119	17	through	through	ADP
ajst-32485	119	18	physical	physical	ADJ
ajst-32485	119	19	and	and	CCONJ
ajst-32485	119	20	immunosuppressive	immunosuppressive	ADJ
ajst-32485	119	21	barriers	barrier	NOUN
ajst-32485	119	22	—	—	PUNCT
ajst-32485	119	23	a	a	DET
ajst-32485	119	24	key	key	ADJ
ajst-32485	119	25	issue	issue	NOUN
ajst-32485	119	26	that	that	SCONJ
ajst-32485	119	27	non	non	ADJ
ajst-32485	119	28	-	-	ADJ
ajst-32485	119	29	targeted	targeted	ADJ
ajst-32485	119	30	neoantigen	neoantigen	NOUN
ajst-32485	119	31	strategies	strategy	NOUN
ajst-32485	119	32	have	have	VERB
ajst-32485	119	33	difficulty	difficulty	NOUN
ajst-32485	119	34	resolving	resolve	VERB
ajst-32485	119	35	effectively	effectively	ADV
ajst-32485	119	36	(	(	PUNCT
ajst-32485	119	37	cai	cai	X
ajst-32485	119	38	et	et	PROPN
ajst-32485	119	39	al	al	PROPN
ajst-32485	119	40	.	.	PROPN
ajst-32485	119	41	,	,	PUNCT
ajst-32485	119	42	2025	2025	NUM
ajst-32485	119	43	;	;	PUNCT
ajst-32485	119	44	rojas	rojas	PROPN
ajst-32485	119	45	et	et	PROPN
ajst-32485	119	46	al	al	PROPN
ajst-32485	119	47	.	.	PROPN
ajst-32485	119	48	,	,	PUNCT
ajst-32485	119	49	2023	2023	NUM
ajst-32485	119	50	)	)	PUNCT
ajst-32485	119	51	.	.	PUNCT
ajst-32485	120	1	125	125	NUM
ajst-32485	120	2	4	4	NUM
ajst-32485	120	3	.	.	PUNCT
ajst-32485	120	4	key	key	ADJ
ajst-32485	120	5	limitations	limitation	NOUN
ajst-32485	120	6	to	to	PART
ajst-32485	120	7	look	look	VERB
ajst-32485	120	8	at	at	ADP
ajst-32485	120	9	the	the	DET
ajst-32485	120	10	limitations	limitation	NOUN
ajst-32485	120	11	of	of	ADP
ajst-32485	120	12	the	the	DET
ajst-32485	120	13	neoantigen	neoantigen	PROPN
ajst-32485	120	14	vaccine	vaccine	NOUN
ajst-32485	120	15	in	in	ADP
ajst-32485	120	16	pancreatic	pancreatic	ADJ
ajst-32485	120	17	cancer	cancer	NOUN
ajst-32485	120	18	,	,	PUNCT
ajst-32485	120	19	typical	typical	ADJ
ajst-32485	120	20	characteristics	characteristic	NOUN
ajst-32485	120	21	of	of	ADP
ajst-32485	120	22	pancreatic	pancreatic	ADJ
ajst-32485	120	23	cancer	cancer	NOUN
ajst-32485	120	24	should	should	AUX
ajst-32485	120	25	first	first	ADV
ajst-32485	120	26	be	be	AUX
ajst-32485	120	27	discussed	discuss	VERB
ajst-32485	120	28	.	.	PUNCT
ajst-32485	121	1	the	the	DET
ajst-32485	121	2	stroma	stroma	NOUN
ajst-32485	121	3	of	of	ADP
ajst-32485	121	4	pdac	pdac	PROPN
ajst-32485	121	5	(	(	PUNCT
ajst-32485	121	6	pancreatic	pancreatic	ADJ
ajst-32485	121	7	ductal	ductal	ADJ
ajst-32485	121	8	adenocarcinoma	adenocarcinoma	NOUN
ajst-32485	121	9	)	)	PUNCT
ajst-32485	121	10	is	be	AUX
ajst-32485	121	11	rich	rich	ADJ
ajst-32485	121	12	in	in	ADP
ajst-32485	121	13	collagen	collagen	NOUN
ajst-32485	121	14	,	,	PUNCT
ajst-32485	121	15	hyaluronic	hyaluronic	ADJ
ajst-32485	121	16	acid	acid	NOUN
ajst-32485	121	17	,	,	PUNCT
ajst-32485	121	18	and	and	CCONJ
ajst-32485	121	19	fibronectin	fibronectin	NOUN
ajst-32485	121	20	,	,	PUNCT
ajst-32485	121	21	forming	form	VERB
ajst-32485	121	22	a	a	DET
ajst-32485	121	23	physical	physical	ADJ
ajst-32485	121	24	barrier	barrier	NOUN
ajst-32485	121	25	that	that	PRON
ajst-32485	121	26	restricts	restrict	VERB
ajst-32485	121	27	the	the	DET
ajst-32485	121	28	penetration	penetration	NOUN
ajst-32485	121	29	of	of	ADP
ajst-32485	121	30	t	t	NOUN
ajst-32485	121	31	cells	cell	NOUN
ajst-32485	121	32	and	and	CCONJ
ajst-32485	121	33	drugs	drug	NOUN
ajst-32485	121	34	.	.	PUNCT
ajst-32485	122	1	current	current	ADJ
ajst-32485	122	2	clinical	clinical	ADJ
ajst-32485	122	3	trials	trial	NOUN
ajst-32485	122	4	show	show	VERB
ajst-32485	122	5	that	that	SCONJ
ajst-32485	122	6	although	although	SCONJ
ajst-32485	122	7	some	some	DET
ajst-32485	122	8	patients	patient	NOUN
ajst-32485	122	9	do	do	AUX
ajst-32485	122	10	produce	produce	VERB
ajst-32485	122	11	neoantigen	neoantigen	ADV
ajst-32485	122	12	-	-	PUNCT
ajst-32485	122	13	specific	specific	ADJ
ajst-32485	122	14	t	t	NOUN
ajst-32485	122	15	-	-	PUNCT
ajst-32485	122	16	cells	cell	NOUN
ajst-32485	122	17	,	,	PUNCT
ajst-32485	122	18	the	the	DET
ajst-32485	122	19	tumor	tumor	NOUN
ajst-32485	122	20	infiltration	infiltration	NOUN
ajst-32485	122	21	is	be	AUX
ajst-32485	122	22	still	still	ADV
ajst-32485	122	23	limited	limit	VERB
ajst-32485	122	24	,	,	PUNCT
ajst-32485	122	25	which	which	PRON
ajst-32485	122	26	may	may	AUX
ajst-32485	122	27	be	be	AUX
ajst-32485	122	28	related	relate	VERB
ajst-32485	122	29	to	to	ADP
ajst-32485	122	30	interstitial	interstitial	ADJ
ajst-32485	122	31	obstruction	obstruction	NOUN
ajst-32485	122	32	(	(	PUNCT
ajst-32485	122	33	rojas	rojas	PROPN
ajst-32485	122	34	et	et	PROPN
ajst-32485	122	35	al	al	PROPN
ajst-32485	122	36	.	.	PROPN
ajst-32485	122	37	,	,	PUNCT
ajst-32485	122	38	2023	2023	NUM
ajst-32485	122	39	)	)	PUNCT
ajst-32485	122	40	.	.	PUNCT
ajst-32485	123	1	so	so	ADV
ajst-32485	123	2	why	why	SCONJ
ajst-32485	123	3	ca	can	AUX
ajst-32485	123	4	n't	not	PART
ajst-32485	123	5	neoantigen	neoantigen	VERB
ajst-32485	123	6	vaccines	vaccine	NOUN
ajst-32485	123	7	be	be	AUX
ajst-32485	123	8	injected	inject	VERB
ajst-32485	123	9	into	into	ADP
ajst-32485	123	10	pancreatic	pancreatic	ADJ
ajst-32485	123	11	cancer	cancer	NOUN
ajst-32485	123	12	?	?	PUNCT
ajst-32485	124	1	what	what	PRON
ajst-32485	124	2	mechanisms	mechanism	NOUN
ajst-32485	124	3	in	in	ADP
ajst-32485	124	4	the	the	DET
ajst-32485	124	5	tme	tme	X
ajst-32485	124	6	hinder	hinder	NOUN
ajst-32485	124	7	this	this	DET
ajst-32485	124	8	process	process	NOUN
ajst-32485	124	9	?	?	PUNCT
ajst-32485	125	1	the	the	DET
ajst-32485	125	2	answer	answer	NOUN
ajst-32485	125	3	is	be	AUX
ajst-32485	125	4	immunosuppressive	immunosuppressive	ADJ
ajst-32485	125	5	cell	cell	NOUN
ajst-32485	125	6	infiltration	infiltration	NOUN
ajst-32485	125	7	and	and	CCONJ
ajst-32485	125	8	signaling	signal	VERB
ajst-32485	125	9	pathways	pathway	NOUN
ajst-32485	125	10	(	(	PUNCT
ajst-32485	125	11	treg	treg	PROPN
ajst-32485	125	12	,	,	PUNCT
ajst-32485	125	13	mdsc	mdsc	PROPN
ajst-32485	125	14	,	,	PUNCT
ajst-32485	125	15	pd	pd	PROPN
ajst-32485	125	16	-	-	PUNCT
ajst-32485	125	17	l1	l1	PROPN
ajst-32485	125	18	)	)	PUNCT
ajst-32485	125	19	.	.	PUNCT
ajst-32485	126	1	among	among	ADP
ajst-32485	126	2	immunosuppressive	immunosuppressive	ADJ
ajst-32485	126	3	cells	cell	NOUN
ajst-32485	126	4	,	,	PUNCT
ajst-32485	126	5	tregs	treg	NOUN
ajst-32485	126	6	(	(	PUNCT
ajst-32485	126	7	regulatory	regulatory	ADJ
ajst-32485	126	8	t	t	NOUN
ajst-32485	126	9	cells	cell	NOUN
ajst-32485	126	10	)	)	PUNCT
ajst-32485	126	11	and	and	CCONJ
ajst-32485	126	12	mdscs	mdsc	NOUN
ajst-32485	126	13	(	(	PUNCT
ajst-32485	126	14	myeloid	myeloid	NOUN
ajst-32485	126	15	-	-	PUNCT
ajst-32485	126	16	derived	derive	VERB
ajst-32485	126	17	suppressor	suppressor	NOUN
ajst-32485	126	18	cells	cell	NOUN
ajst-32485	126	19	)	)	PUNCT
ajst-32485	126	20	are	be	AUX
ajst-32485	126	21	enriched	enrich	VERB
ajst-32485	126	22	in	in	ADP
ajst-32485	126	23	pdac	pdac	NOUN
ajst-32485	126	24	,	,	PUNCT
ajst-32485	126	25	inhibiting	inhibit	VERB
ajst-32485	126	26	the	the	DET
ajst-32485	126	27	function	function	NOUN
ajst-32485	126	28	of	of	ADP
ajst-32485	126	29	cd8⁺t	cd8⁺t	NOUN
ajst-32485	126	30	cells	cell	NOUN
ajst-32485	126	31	.	.	PUNCT
ajst-32485	127	1	pdl1	pdl1	PROPN
ajst-32485	127	2	acts	act	VERB
ajst-32485	127	3	as	as	ADP
ajst-32485	127	4	an	an	DET
ajst-32485	127	5	immune	immune	ADJ
ajst-32485	127	6	checkpoint	checkpoint	NOUN
ajst-32485	127	7	;	;	PUNCT
ajst-32485	127	8	upregulation	upregulation	NOUN
ajst-32485	127	9	of	of	ADP
ajst-32485	127	10	pd	pd	PROPN
ajst-32485	127	11	-	-	PROPN
ajst-32485	127	12	l1	l1	PROPN
ajst-32485	127	13	causes	cause	VERB
ajst-32485	127	14	tumor	tumor	NOUN
ajst-32485	127	15	cells	cell	NOUN
ajst-32485	127	16	and	and	CCONJ
ajst-32485	127	17	cafs	cafs	NOUN
ajst-32485	127	18	(	(	PUNCT
ajst-32485	127	19	cancerassociated	cancerassociate	VERB
ajst-32485	127	20	fibroblasts	fibroblast	NOUN
ajst-32485	127	21	)	)	PUNCT
ajst-32485	127	22	to	to	PART
ajst-32485	127	23	highly	highly	ADV
ajst-32485	127	24	express	express	VERB
ajst-32485	127	25	pd	pd	NOUN
ajst-32485	127	26	-	-	PUNCT
ajst-32485	127	27	l1	l1	PROPN
ajst-32485	127	28	,	,	PUNCT
ajst-32485	127	29	leading	lead	VERB
ajst-32485	127	30	to	to	ADP
ajst-32485	127	31	t	t	NOUN
ajst-32485	127	32	cell	cell	NOUN
ajst-32485	127	33	exhaustion	exhaustion	NOUN
ajst-32485	127	34	.	.	PUNCT
ajst-32485	128	1	research	research	NOUN
ajst-32485	128	2	backs	back	VERB
ajst-32485	128	3	up	up	ADP
ajst-32485	128	4	this	this	DET
ajst-32485	128	5	point	point	NOUN
ajst-32485	128	6	as	as	SCONJ
ajst-32485	128	7	the	the	DET
ajst-32485	128	8	combination	combination	NOUN
ajst-32485	128	9	of	of	ADP
ajst-32485	128	10	atezolizumab	atezolizumab	NOUN
ajst-32485	128	11	(	(	PUNCT
ajst-32485	128	12	anti	anti	ADJ
ajst-32485	128	13	-	-	ADJ
ajst-32485	128	14	pd	pd	ADJ
ajst-32485	128	15	-	-	PUNCT
ajst-32485	128	16	l1	l1	NOUN
ajst-32485	128	17	)	)	PUNCT
ajst-32485	128	18	only	only	ADV
ajst-32485	128	19	partially	partially	ADV
ajst-32485	128	20	reversed	reverse	VERB
ajst-32485	128	21	the	the	DET
ajst-32485	128	22	inhibition	inhibition	NOUN
ajst-32485	128	23	,	,	PUNCT
ajst-32485	128	24	suggesting	suggest	VERB
ajst-32485	128	25	the	the	DET
ajst-32485	128	26	need	need	NOUN
ajst-32485	128	27	for	for	ADP
ajst-32485	128	28	multi	multi	ADJ
ajst-32485	128	29	-	-	ADJ
ajst-32485	128	30	target	target	ADJ
ajst-32485	128	31	intervention	intervention	NOUN
ajst-32485	128	32	(	(	PUNCT
ajst-32485	128	33	such	such	ADJ
ajst-32485	128	34	as	as	ADP
ajst-32485	128	35	the	the	DET
ajst-32485	128	36	combination	combination	NOUN
ajst-32485	128	37	with	with	ADP
ajst-32485	128	38	cd40	cd40	PROPN
ajst-32485	128	39	agonists	agonist	NOUN
ajst-32485	128	40	)	)	PUNCT
ajst-32485	128	41	(	(	PUNCT
ajst-32485	128	42	rojas	rojas	PROPN
ajst-32485	128	43	et	et	PROPN
ajst-32485	128	44	al	al	PROPN
ajst-32485	128	45	.	.	PROPN
ajst-32485	128	46	,	,	PUNCT
ajst-32485	128	47	2023	2023	NUM
ajst-32485	128	48	)	)	PUNCT
ajst-32485	128	49	.	.	PUNCT
ajst-32485	129	1	meanwhile	meanwhile	ADV
ajst-32485	129	2	,	,	PUNCT
ajst-32485	129	3	the	the	DET
ajst-32485	129	4	quantity	quantity	NOUN
ajst-32485	129	5	and	and	CCONJ
ajst-32485	129	6	function	function	NOUN
ajst-32485	129	7	of	of	ADP
ajst-32485	129	8	apcs	apc	NOUN
ajst-32485	129	9	are	be	AUX
ajst-32485	129	10	insufficient	insufficient	ADJ
ajst-32485	129	11	,	,	PUNCT
ajst-32485	129	12	resulting	result	VERB
ajst-32485	129	13	in	in	ADP
ajst-32485	129	14	poor	poor	ADJ
ajst-32485	129	15	antigen	antigen	ADJ
ajst-32485	129	16	presentation	presentation	NOUN
ajst-32485	129	17	.	.	PUNCT
ajst-32485	130	1	the	the	DET
ajst-32485	130	2	quantity	quantity	NOUN
ajst-32485	130	3	and	and	CCONJ
ajst-32485	130	4	functional	functional	ADJ
ajst-32485	130	5	defects	defect	NOUN
ajst-32485	130	6	of	of	ADP
ajst-32485	130	7	dc	dc	PROPN
ajst-32485	130	8	resulting	result	VERB
ajst-32485	130	9	in	in	ADP
ajst-32485	130	10	the	the	DET
ajst-32485	130	11	infiltration	infiltration	NOUN
ajst-32485	130	12	of	of	ADP
ajst-32485	130	13	dendritic	dendritic	ADJ
ajst-32485	130	14	cells	cell	NOUN
ajst-32485	130	15	(	(	PUNCT
ajst-32485	130	16	dcs	dcs	PROPN
ajst-32485	130	17	)	)	PUNCT
ajst-32485	130	18	in	in	ADP
ajst-32485	130	19	pdac	pdac	NOUN
ajst-32485	130	20	are	be	AUX
ajst-32485	130	21	low	low	ADJ
ajst-32485	130	22	,	,	PUNCT
ajst-32485	130	23	and	and	CCONJ
ajst-32485	130	24	their	their	PRON
ajst-32485	130	25	maturity	maturity	NOUN
ajst-32485	130	26	is	be	AUX
ajst-32485	130	27	low	low	ADJ
ajst-32485	130	28	(	(	PUNCT
ajst-32485	130	29	the	the	DET
ajst-32485	130	30	proportion	proportion	NOUN
ajst-32485	130	31	of	of	ADP
ajst-32485	130	32	cd80⁺	cd80⁺	NOUN
ajst-32485	130	33	and	and	CCONJ
ajst-32485	130	34	cd86⁺	cd86⁺	VERB
ajst-32485	130	35	dcs	dcs	PROPN
ajst-32485	130	36	is	be	AUX
ajst-32485	130	37	low	low	ADJ
ajst-32485	130	38	)	)	PUNCT
ajst-32485	130	39	,	,	PUNCT
ajst-32485	130	40	resulting	result	VERB
ajst-32485	130	41	in	in	ADP
ajst-32485	130	42	poor	poor	ADJ
ajst-32485	130	43	antigen	antigen	ADJ
ajst-32485	130	44	presentation	presentation	NOUN
ajst-32485	130	45	efficiency	efficiency	NOUN
ajst-32485	130	46	.	.	PUNCT
ajst-32485	131	1	study	study	NOUN
ajst-32485	131	2	proves	prove	VERB
ajst-32485	131	3	mrna	mrna	PROPN
ajst-32485	131	4	vaccines	vaccine	NOUN
ajst-32485	131	5	rely	rely	VERB
ajst-32485	131	6	on	on	ADP
ajst-32485	131	7	local	local	ADJ
ajst-32485	131	8	dc	dc	PROPN
ajst-32485	131	9	uptake	uptake	ADJ
ajst-32485	131	10	through	through	ADP
ajst-32485	131	11	intramuscular	intramuscular	ADJ
ajst-32485	131	12	injection	injection	NOUN
ajst-32485	131	13	,	,	PUNCT
ajst-32485	131	14	but	but	CCONJ
ajst-32485	131	15	the	the	DET
ajst-32485	131	16	pancreatic	pancreatic	ADJ
ajst-32485	131	17	tme	tme	NOUN
ajst-32485	131	18	may	may	AUX
ajst-32485	131	19	restrict	restrict	VERB
ajst-32485	131	20	dc	dc	PROPN
ajst-32485	131	21	migration	migration	NOUN
ajst-32485	131	22	to	to	ADP
ajst-32485	131	23	the	the	DET
ajst-32485	131	24	tumor	tumor	NOUN
ajst-32485	131	25	site	site	NOUN
ajst-32485	131	26	(	(	PUNCT
ajst-32485	131	27	rojas	rojas	PROPN
ajst-32485	131	28	et	et	PROPN
ajst-32485	131	29	al	al	PROPN
ajst-32485	131	30	.	.	PROPN
ajst-32485	131	31	,	,	PUNCT
ajst-32485	131	32	2023	2023	NUM
ajst-32485	131	33	)	)	PUNCT
ajst-32485	131	34	5	5	NUM
ajst-32485	131	35	.	.	PUNCT
ajst-32485	132	1	future	future	ADJ
ajst-32485	132	2	directions	direction	NOUN
ajst-32485	132	3	to	to	PART
ajst-32485	132	4	optimize	optimize	VERB
ajst-32485	132	5	efficacy	efficacy	NOUN
ajst-32485	132	6	table	table	NOUN
ajst-32485	132	7	1	1	NUM
ajst-32485	132	8	.	.	PUNCT
ajst-32485	133	1	future	future	ADJ
ajst-32485	133	2	directions	direction	NOUN
ajst-32485	133	3	to	to	PART
ajst-32485	133	4	optimize	optimize	VERB
ajst-32485	133	5	efficacy	efficacy	NOUN
ajst-32485	133	6	obstacles	obstacle	NOUN
ajst-32485	133	7	strategies	strategy	NOUN
ajst-32485	133	8	to	to	PART
ajst-32485	133	9	overcome	overcome	VERB
ajst-32485	133	10	(	(	PUNCT
ajst-32485	133	11	future	future	ADJ
ajst-32485	133	12	directions	direction	NOUN
ajst-32485	133	13	)	)	PUNCT
ajst-32485	133	14	low	low	ADJ
ajst-32485	133	15	antigen	antigen	ADJ
ajst-32485	133	16	delivery	delivery	NOUN
ajst-32485	133	17	efficiency	efficiency	NOUN
ajst-32485	133	18	,	,	PUNCT
ajst-32485	133	19	difficult	difficult	ADJ
ajst-32485	133	20	to	to	PART
ajst-32485	133	21	break	break	VERB
ajst-32485	133	22	through	through	ADP
ajst-32485	133	23	fibrotic	fibrotic	ADJ
ajst-32485	133	24	barrier	barrier	NOUN
ajst-32485	133	25	targeted	target	VERB
ajst-32485	133	26	delivery	delivery	NOUN
ajst-32485	133	27	therapy	therapy	NOUN
ajst-32485	133	28	,	,	PUNCT
ajst-32485	133	29	such	such	ADJ
ajst-32485	133	30	as	as	ADP
ajst-32485	133	31	msln	msln	NOUN
ajst-32485	133	32	-	-	PUNCT
ajst-32485	133	33	guided	guide	VERB
ajst-32485	133	34	nanoparticles	nanoparticle	NOUN
ajst-32485	133	35	.	.	PUNCT
ajst-32485	134	1	intelligent	intelligent	ADJ
ajst-32485	134	2	responsive	responsive	ADJ
ajst-32485	134	3	nanoparticles	nanoparticle	NOUN
ajst-32485	134	4	,	,	PUNCT
ajst-32485	134	5	such	such	ADJ
ajst-32485	134	6	as	as	ADP
ajst-32485	134	7	ph	ph	NOUN
ajst-32485	134	8	or	or	CCONJ
ajst-32485	134	9	enzyme	enzyme	NOUN
ajst-32485	134	10	responsive	responsive	ADJ
ajst-32485	134	11	.	.	PUNCT
ajst-32485	135	1	combined	combine	VERB
ajst-32485	135	2	immunomodulators	immunomodulator	NOUN
ajst-32485	135	3	to	to	PART
ajst-32485	135	4	enhance	enhance	VERB
ajst-32485	135	5	dc	dc	PROPN
ajst-32485	135	6	and	and	CCONJ
ajst-32485	135	7	tcell	tcell	NOUN
ajst-32485	135	8	initiation	initiation	NOUN
ajst-32485	135	9	.	.	PUNCT
ajst-32485	136	1	immunosuppressive	immunosuppressive	ADJ
ajst-32485	136	2	tme	tme	PROPN
ajst-32485	136	3	(	(	PUNCT
ajst-32485	136	4	treg	treg	PROPN
ajst-32485	136	5	,	,	PUNCT
ajst-32485	136	6	cafs	cafs	NOUN
ajst-32485	136	7	)	)	PUNCT
ajst-32485	136	8	combined	combine	VERB
ajst-32485	136	9	with	with	ADP
ajst-32485	136	10	msln	msln	NOUN
ajst-32485	136	11	-	-	PUNCT
ajst-32485	136	12	targeted	target	VERB
ajst-32485	136	13	antibodies	antibody	NOUN
ajst-32485	136	14	to	to	PART
ajst-32485	136	15	clear	clear	VERB
ajst-32485	136	16	antigen	antigen	ADJ
ajst-32485	136	17	presenting	present	VERB
ajst-32485	136	18	cafs	cafs	NOUN
ajst-32485	136	19	.	.	PUNCT
ajst-32485	137	1	reshape	reshape	VERB
ajst-32485	137	2	tme	tme	NOUN
ajst-32485	137	3	with	with	ADP
ajst-32485	137	4	cd40	cd40	PROPN
ajst-32485	137	5	agonists	agonist	NOUN
ajst-32485	137	6	or	or	CCONJ
ajst-32485	137	7	cxcr4	cxcr4	NOUN
ajst-32485	137	8	inhibitors	inhibitor	NOUN
ajst-32485	137	9	to	to	PART
ajst-32485	137	10	promote	promote	VERB
ajst-32485	137	11	t	t	PROPN
ajst-32485	137	12	cell	cell	NOUN
ajst-32485	137	13	infiltration	infiltration	NOUN
ajst-32485	137	14	.	.	PUNCT
ajst-32485	138	1	combined	combine	VERB
ajst-32485	138	2	immune	immune	ADJ
ajst-32485	138	3	checkpoint	checkpoint	NOUN
ajst-32485	138	4	inhibitors	inhibitor	NOUN
ajst-32485	138	5	.	.	PUNCT
ajst-32485	139	1	insufficient	insufficient	ADJ
ajst-32485	139	2	immunogenicity	immunogenicity	NOUN
ajst-32485	139	3	and	and	CCONJ
ajst-32485	139	4	complex	complex	ADJ
ajst-32485	139	5	development	development	NOUN
ajst-32485	139	6	of	of	ADP
ajst-32485	139	7	neoantigen	neoantigen	PROPN
ajst-32485	139	8	vaccines	vaccine	NOUN
ajst-32485	139	9	develop	develop	VERB
ajst-32485	139	10	multi	multi	ADJ
ajst-32485	139	11	-	-	ADJ
ajst-32485	139	12	epitope	epitope	ADJ
ajst-32485	139	13	vaccines	vaccine	NOUN
ajst-32485	139	14	and	and	CCONJ
ajst-32485	139	15	incorporate	incorporate	VERB
ajst-32485	139	16	shared	shared	ADJ
ajst-32485	139	17	neoantigens	neoantigen	NOUN
ajst-32485	139	18	.	.	PUNCT
ajst-32485	140	1	predict	predict	VERB
ajst-32485	140	2	new	new	ADJ
ajst-32485	140	3	antigens	antigen	NOUN
ajst-32485	140	4	with	with	ADP
ajst-32485	140	5	high	high	ADJ
ajst-32485	140	6	mhc	mhc	NOUN
ajst-32485	140	7	binding	bind	VERB
ajst-32485	140	8	affinity	affinity	NOUN
ajst-32485	140	9	.	.	PUNCT
ajst-32485	141	1	large	large	ADJ
ajst-32485	141	2	variation	variation	NOUN
ajst-32485	141	3	in	in	ADP
ajst-32485	141	4	patients	patient	NOUN
ajst-32485	141	5	’	'	PUNCT
ajst-32485	141	6	responses	response	NOUN
ajst-32485	141	7	to	to	ADP
ajst-32485	141	8	vaccines	vaccine	NOUN
ajst-32485	141	9	stratify	stratify	VERB
ajst-32485	141	10	patients	patient	NOUN
ajst-32485	141	11	by	by	ADP
ajst-32485	141	12	expression	expression	NOUN
ajst-32485	141	13	level	level	NOUN
ajst-32485	141	14	of	of	ADP
ajst-32485	141	15	msln	msln	NOUN
ajst-32485	141	16	and	and	CCONJ
ajst-32485	141	17	optimize	optimize	VERB
ajst-32485	141	18	delivery	delivery	NOUN
ajst-32485	141	19	strategy	strategy	NOUN
ajst-32485	141	20	of	of	ADP
ajst-32485	141	21	each	each	DET
ajst-32485	141	22	level	level	NOUN
ajst-32485	141	23	.	.	PUNCT
ajst-32485	142	1	dynamic	dynamic	ADJ
ajst-32485	142	2	monitor	monitor	VERB
ajst-32485	142	3	the	the	DET
ajst-32485	142	4	clonality	clonality	NOUN
ajst-32485	142	5	and	and	CCONJ
ajst-32485	142	6	memory	memory	NOUN
ajst-32485	142	7	cell	cell	NOUN
ajst-32485	142	8	formation	formation	NOUN
ajst-32485	142	9	to	to	PART
ajst-32485	142	10	adjust	adjust	VERB
ajst-32485	142	11	vaccination	vaccination	NOUN
ajst-32485	142	12	plan	plan	NOUN
ajst-32485	142	13	.	.	PUNCT
ajst-32485	143	1	small	small	ADJ
ajst-32485	143	2	sample	sample	NOUN
ajst-32485	143	3	size	size	NOUN
ajst-32485	143	4	of	of	ADP
ajst-32485	143	5	current	current	ADJ
ajst-32485	143	6	clinical	clinical	ADJ
ajst-32485	143	7	trials	trial	NOUN
ajst-32485	143	8	explore	explore	VERB
ajst-32485	143	9	reasonable	reasonable	ADJ
ajst-32485	143	10	combination	combination	NOUN
ajst-32485	143	11	therapies	therapy	NOUN
ajst-32485	143	12	.	.	PUNCT
ajst-32485	144	1	conduct	conduct	VERB
ajst-32485	144	2	large	large	ADJ
ajst-32485	144	3	-	-	PUNCT
ajst-32485	144	4	scale	scale	NOUN
ajst-32485	144	5	clinical	clinical	ADJ
ajst-32485	144	6	trial	trial	NOUN
ajst-32485	144	7	to	to	PART
ajst-32485	144	8	verify	verify	VERB
ajst-32485	144	9	safety	safety	NOUN
ajst-32485	144	10	and	and	CCONJ
ajst-32485	144	11	efficacy	efficacy	NOUN
ajst-32485	144	12	.	.	PUNCT
ajst-32485	145	1	clinical	clinical	ADJ
ajst-32485	145	2	success	success	NOUN
ajst-32485	145	3	of	of	ADP
ajst-32485	145	4	neoantigen	neoantigen	PROPN
ajst-32485	145	5	vaccines	vaccine	NOUN
ajst-32485	145	6	in	in	ADP
ajst-32485	145	7	treating	treat	VERB
ajst-32485	145	8	pancreatic	pancreatic	ADJ
ajst-32485	145	9	cancer	cancer	NOUN
ajst-32485	145	10	is	be	AUX
ajst-32485	145	11	limited	limit	VERB
ajst-32485	145	12	,	,	PUNCT
ajst-32485	145	13	as	as	SCONJ
ajst-32485	145	14	drugs	drug	NOUN
ajst-32485	145	15	are	be	AUX
ajst-32485	145	16	still	still	ADV
ajst-32485	145	17	in	in	ADP
ajst-32485	145	18	the	the	DET
ajst-32485	145	19	process	process	NOUN
ajst-32485	145	20	of	of	ADP
ajst-32485	145	21	phase	phase	NOUN
ajst-32485	145	22	three	three	NUM
ajst-32485	145	23	clinical	clinical	ADJ
ajst-32485	145	24	trials	trial	NOUN
ajst-32485	145	25	,	,	PUNCT
ajst-32485	145	26	despite	despite	SCONJ
ajst-32485	145	27	their	their	PRON
ajst-32485	145	28	strong	strong	ADJ
ajst-32485	145	29	theoretical	theoretical	ADJ
ajst-32485	145	30	potential	potential	NOUN
ajst-32485	145	31	,	,	PUNCT
ajst-32485	145	32	highlighting	highlight	VERB
ajst-32485	145	33	key	key	ADJ
ajst-32485	145	34	challenges	challenge	NOUN
ajst-32485	145	35	that	that	PRON
ajst-32485	145	36	must	must	AUX
ajst-32485	145	37	be	be	AUX
ajst-32485	145	38	addressed	address	VERB
ajst-32485	145	39	.	.	PUNCT
ajst-32485	146	1	126	126	NUM
ajst-32485	146	2	future	future	ADJ
ajst-32485	146	3	directions	direction	NOUN
ajst-32485	146	4	include	include	VERB
ajst-32485	146	5	,	,	PUNCT
ajst-32485	146	6	first	first	ADV
ajst-32485	146	7	,	,	PUNCT
ajst-32485	146	8	enhancing	enhance	VERB
ajst-32485	146	9	antigen	antigen	ADJ
ajst-32485	146	10	delivery	delivery	NOUN
ajst-32485	146	11	and	and	CCONJ
ajst-32485	146	12	uptake	uptake	NOUN
ajst-32485	146	13	.	.	PUNCT
ajst-32485	147	1	methods	method	NOUN
ajst-32485	147	2	could	could	AUX
ajst-32485	147	3	be	be	AUX
ajst-32485	147	4	targeted	target	VERB
ajst-32485	147	5	nanoparticle	nanoparticle	NOUN
ajst-32485	147	6	systems	system	NOUN
ajst-32485	147	7	,	,	PUNCT
ajst-32485	147	8	mesothelin	mesothelin	NOUN
ajst-32485	147	9	(	(	PUNCT
ajst-32485	147	10	msln)-guided	msln)-guide	VERB
ajst-32485	147	11	delivery	delivery	NOUN
ajst-32485	147	12	platforms	platform	NOUN
ajst-32485	147	13	that	that	PRON
ajst-32485	147	14	improve	improve	VERB
ajst-32485	147	15	tumor	tumor	NOUN
ajst-32485	147	16	-	-	PUNCT
ajst-32485	147	17	specific	specific	ADJ
ajst-32485	147	18	accumulation	accumulation	NOUN
ajst-32485	147	19	of	of	ADP
ajst-32485	147	20	neoantigens	neoantigen	NOUN
ajst-32485	147	21	,	,	PUNCT
ajst-32485	147	22	boosting	boost	VERB
ajst-32485	147	23	dendritic	dendritic	ADJ
ajst-32485	147	24	cell	cell	NOUN
ajst-32485	147	25	(	(	PUNCT
ajst-32485	147	26	dc	dc	PROPN
ajst-32485	147	27	)	)	PUNCT
ajst-32485	147	28	uptake	uptake	ADJ
ajst-32485	147	29	and	and	CCONJ
ajst-32485	147	30	cross	cross	NOUN
ajst-32485	147	31	-	-	NOUN
ajst-32485	147	32	presentation	presentation	NOUN
ajst-32485	147	33	.	.	PUNCT
ajst-32485	148	1	this	this	DET
ajst-32485	148	2	method	method	NOUN
ajst-32485	148	3	could	could	AUX
ajst-32485	148	4	also	also	ADV
ajst-32485	148	5	be	be	AUX
ajst-32485	148	6	used	use	VERB
ajst-32485	148	7	to	to	PART
ajst-32485	148	8	exploit	exploit	VERB
ajst-32485	148	9	other	other	ADJ
ajst-32485	148	10	tumor	tumor	NOUN
ajst-32485	148	11	-	-	PUNCT
ajst-32485	148	12	specific	specific	ADJ
ajst-32485	148	13	presentations	presentation	NOUN
ajst-32485	148	14	(	(	PUNCT
ajst-32485	148	15	cai	cai	X
ajst-32485	148	16	et	et	PROPN
ajst-32485	148	17	al	al	PROPN
ajst-32485	148	18	.	.	PROPN
ajst-32485	148	19	,	,	PUNCT
ajst-32485	148	20	2025	2025	NUM
ajst-32485	148	21	)	)	PUNCT
ajst-32485	148	22	.	.	PUNCT
ajst-32485	149	1	intelligent	intelligent	ADJ
ajst-32485	149	2	responsive	responsive	ADJ
ajst-32485	149	3	nanoparticles	nanoparticle	NOUN
ajst-32485	149	4	can	can	AUX
ajst-32485	149	5	be	be	AUX
ajst-32485	149	6	used	use	VERB
ajst-32485	149	7	,	,	PUNCT
ajst-32485	149	8	ph/	ph/	ADJ
ajst-32485	149	9	enzyme	enzyme	NOUN
ajst-32485	149	10	responsiveness	responsiveness	NOUN
ajst-32485	149	11	:	:	PUNCT
ajst-32485	149	12	the	the	DET
ajst-32485	149	13	tme	tme	NOUN
ajst-32485	149	14	of	of	ADP
ajst-32485	149	15	pancreatic	pancreatic	ADJ
ajst-32485	149	16	cancer	cancer	NOUN
ajst-32485	149	17	is	be	AUX
ajst-32485	149	18	acidic	acidic	ADJ
ajst-32485	149	19	and	and	CCONJ
ajst-32485	149	20	rich	rich	ADJ
ajst-32485	149	21	in	in	ADP
ajst-32485	149	22	matrix	matrix	NOUN
ajst-32485	149	23	metalloproteinases	metalloproteinase	NOUN
ajst-32485	149	24	(	(	PUNCT
ajst-32485	149	25	mmps	mmp	NOUN
ajst-32485	149	26	)	)	PUNCT
ajst-32485	149	27	,	,	PUNCT
ajst-32485	149	28	which	which	PRON
ajst-32485	149	29	can	can	AUX
ajst-32485	149	30	be	be	AUX
ajst-32485	149	31	designed	design	VERB
ajst-32485	149	32	to	to	PART
ajst-32485	149	33	release	release	VERB
ajst-32485	149	34	antigens	antigen	NOUN
ajst-32485	149	35	at	at	ADP
ajst-32485	149	36	the	the	DET
ajst-32485	149	37	tumor	tumor	NOUN
ajst-32485	149	38	site	site	NOUN
ajst-32485	149	39	specifically	specifically	ADV
ajst-32485	149	40	.	.	PUNCT
ajst-32485	150	1	studies	study	NOUN
ajst-32485	150	2	show	show	VERB
ajst-32485	150	3	msln	msln	NOUN
ajst-32485	150	4	-	-	PUNCT
ajst-32485	150	5	targeted	target	VERB
ajst-32485	150	6	nanoparticles	nanoparticle	NOUN
ajst-32485	150	7	significantly	significantly	ADV
ajst-32485	150	8	enhance	enhance	VERB
ajst-32485	150	9	antigen	antigen	ADJ
ajst-32485	150	10	delivery	delivery	NOUN
ajst-32485	150	11	to	to	ADP
ajst-32485	150	12	dcs	dcs	PROPN
ajst-32485	150	13	and	and	CCONJ
ajst-32485	150	14	increase	increase	VERB
ajst-32485	150	15	cd8⁺	cd8⁺	NOUN
ajst-32485	150	16	t	t	NOUN
ajst-32485	150	17	cell	cell	NOUN
ajst-32485	150	18	infiltration	infiltration	NOUN
ajst-32485	150	19	in	in	ADP
ajst-32485	150	20	the	the	DET
ajst-32485	150	21	pdac	pdac	NOUN
ajst-32485	150	22	model	model	NOUN
ajst-32485	150	23	(	(	PUNCT
ajst-32485	150	24	p	p	NOUN
ajst-32485	150	25	=	=	NOUN
ajst-32485	150	26	0.001	0.001	NUM
ajst-32485	150	27	)	)	PUNCT
ajst-32485	150	28	.	.	PUNCT
ajst-32485	151	1	combination	combination	NOUN
ajst-32485	151	2	with	with	ADP
ajst-32485	151	3	immune	immune	ADJ
ajst-32485	151	4	modulators	modulator	NOUN
ajst-32485	151	5	,	,	PUNCT
ajst-32485	151	6	referring	refer	VERB
ajst-32485	151	7	to	to	ADP
ajst-32485	151	8	co	co	NOUN
ajst-32485	151	9	-	-	NOUN
ajst-32485	151	10	delivery	delivery	NOUN
ajst-32485	151	11	of	of	ADP
ajst-32485	151	12	adjuvants	adjuvant	NOUN
ajst-32485	151	13	(	(	PUNCT
ajst-32485	151	14	e.g.	e.g.	ADV
ajst-32485	151	15	,	,	PUNCT
ajst-32485	151	16	tlr	tlr	PROPN
ajst-32485	151	17	agonists	agonist	NOUN
ajst-32485	151	18	,	,	PUNCT
ajst-32485	151	19	sting	ste	VERB
ajst-32485	151	20	activators	activator	NOUN
ajst-32485	151	21	)	)	PUNCT
ajst-32485	151	22	,	,	PUNCT
ajst-32485	151	23	may	may	AUX
ajst-32485	151	24	further	far	ADV
ajst-32485	151	25	amplify	amplify	VERB
ajst-32485	151	26	dc	dc	PROPN
ajst-32485	151	27	activation	activation	NOUN
ajst-32485	151	28	and	and	CCONJ
ajst-32485	151	29	t	t	NOUN
ajst-32485	151	30	-	-	PUNCT
ajst-32485	151	31	cell	cell	NOUN
ajst-32485	151	32	priming	priming	NOUN
ajst-32485	151	33	.	.	PUNCT
ajst-32485	152	1	multi	multi	ADJ
ajst-32485	152	2	-	-	ADJ
ajst-32485	152	3	target	target	ADJ
ajst-32485	152	4	composite	composite	ADJ
ajst-32485	152	5	delivery	delivery	NOUN
ajst-32485	152	6	using	use	VERB
ajst-32485	152	7	a	a	DET
ajst-32485	152	8	dualtargeting	dualtargeting	NOUN
ajst-32485	152	9	strategy	strategy	NOUN
ajst-32485	152	10	can	can	AUX
ajst-32485	152	11	also	also	ADV
ajst-32485	152	12	be	be	AUX
ajst-32485	152	13	considered	consider	VERB
ajst-32485	152	14	;	;	PUNCT
ajst-32485	152	15	for	for	ADP
ajst-32485	152	16	instance	instance	NOUN
ajst-32485	152	17	,	,	PUNCT
ajst-32485	152	18	co	co	VERB
ajst-32485	152	19	-	-	VERB
ajst-32485	152	20	delivering	deliver	VERB
ajst-32485	152	21	neoantigens	neoantigen	NOUN
ajst-32485	152	22	and	and	CCONJ
ajst-32485	152	23	sting	ste	VERB
ajst-32485	152	24	agonists	agonist	NOUN
ajst-32485	152	25	(	(	PUNCT
ajst-32485	152	26	such	such	ADJ
ajst-32485	152	27	as	as	ADP
ajst-32485	152	28	cgamp	cgamp	ADJ
ajst-32485	152	29	)	)	PUNCT
ajst-32485	152	30	can	can	AUX
ajst-32485	152	31	simultaneously	simultaneously	ADV
ajst-32485	152	32	activate	activate	VERB
ajst-32485	152	33	innate	innate	ADJ
ajst-32485	152	34	immunity	immunity	NOUN
ajst-32485	152	35	(	(	PUNCT
ajst-32485	152	36	type	type	NOUN
ajst-32485	152	37	i	i	PRON
ajst-32485	152	38	ifn	ifn	VERB
ajst-32485	152	39	)	)	PUNCT
ajst-32485	152	40	and	and	CCONJ
ajst-32485	152	41	adaptive	adaptive	ADJ
ajst-32485	152	42	immunity	immunity	NOUN
ajst-32485	152	43	.	.	PUNCT
ajst-32485	153	1	besides	besides	SCONJ
ajst-32485	153	2	,	,	PUNCT
ajst-32485	153	3	overcoming	overcome	VERB
ajst-32485	153	4	the	the	DET
ajst-32485	153	5	immunosuppressive	immunosuppressive	ADJ
ajst-32485	153	6	tme	tme	NOUN
ajst-32485	153	7	is	be	AUX
ajst-32485	153	8	also	also	ADV
ajst-32485	153	9	considered	consider	VERB
ajst-32485	153	10	an	an	DET
ajst-32485	153	11	essential	essential	ADJ
ajst-32485	153	12	future	future	ADJ
ajst-32485	153	13	direction	direction	NOUN
ajst-32485	153	14	.	.	PUNCT
ajst-32485	154	1	dual	dual	ADJ
ajst-32485	154	2	targeting	targeting	NOUN
ajst-32485	154	3	of	of	ADP
ajst-32485	154	4	stromal	stromal	ADJ
ajst-32485	154	5	barriers	barrier	NOUN
ajst-32485	154	6	:	:	PUNCT
ajst-32485	154	7	pancreatic	pancreatic	ADJ
ajst-32485	154	8	tumors	tumor	NOUN
ajst-32485	154	9	are	be	AUX
ajst-32485	154	10	rich	rich	ADJ
ajst-32485	154	11	in	in	ADP
ajst-32485	154	12	immunosuppressive	immunosuppressive	ADJ
ajst-32485	154	13	cells	cell	NOUN
ajst-32485	154	14	(	(	PUNCT
ajst-32485	154	15	tregs	treg	NOUN
ajst-32485	154	16	,	,	PUNCT
ajst-32485	154	17	cafs	cafs	NOUN
ajst-32485	154	18	)	)	PUNCT
ajst-32485	154	19	and	and	CCONJ
ajst-32485	154	20	dense	dense	ADJ
ajst-32485	154	21	stroma	stroma	NOUN
ajst-32485	154	22	.	.	PUNCT
ajst-32485	155	1	combining	combine	VERB
ajst-32485	155	2	neoantigen	neoantigen	ADJ
ajst-32485	155	3	vaccines	vaccine	NOUN
ajst-32485	155	4	with	with	ADP
ajst-32485	155	5	msln	msln	NOUN
ajst-32485	155	6	-	-	PUNCT
ajst-32485	155	7	targeted	target	VERB
ajst-32485	155	8	antibodies	antibody	NOUN
ajst-32485	155	9	to	to	PART
ajst-32485	155	10	deplete	deplete	VERB
ajst-32485	155	11	antigen	antigen	ADV
ajst-32485	155	12	-	-	PUNCT
ajst-32485	155	13	presenting	present	VERB
ajst-32485	155	14	cafs	cafs	NOUN
ajst-32485	155	15	(	(	PUNCT
ajst-32485	155	16	apcafs	apcafs	PROPN
ajst-32485	155	17	)	)	PUNCT
ajst-32485	155	18	(	(	PUNCT
ajst-32485	155	19	cai	cai	X
ajst-32485	155	20	et	et	PROPN
ajst-32485	155	21	al	al	PROPN
ajst-32485	155	22	.	.	PROPN
ajst-32485	155	23	,	,	PUNCT
ajst-32485	155	24	2025	2025	NUM
ajst-32485	155	25	)	)	PUNCT
ajst-32485	155	26	.	.	PUNCT
ajst-32485	156	1	cd40	cd40	PROPN
ajst-32485	156	2	agonists	agonist	NOUN
ajst-32485	156	3	or	or	CCONJ
ajst-32485	156	4	cxcr4	cxcr4	NOUN
ajst-32485	156	5	inhibitors	inhibitor	NOUN
ajst-32485	156	6	to	to	PART
ajst-32485	156	7	remodel	remodel	VERB
ajst-32485	156	8	the	the	DET
ajst-32485	156	9	tme	tme	NOUN
ajst-32485	156	10	and	and	CCONJ
ajst-32485	156	11	enhance	enhance	VERB
ajst-32485	156	12	t	t	PROPN
ajst-32485	156	13	-	-	PUNCT
ajst-32485	156	14	cell	cell	NOUN
ajst-32485	156	15	infiltration	infiltration	NOUN
ajst-32485	156	16	.	.	PUNCT
ajst-32485	157	1	checkpoint	checkpoint	NOUN
ajst-32485	157	2	inhibitor	inhibitor	NOUN
ajst-32485	157	3	synergy	synergy	NOUN
ajst-32485	157	4	:	:	PUNCT
ajst-32485	157	5	pd-1	pd-1	ADJ
ajst-32485	157	6	/	/	SYM
ajst-32485	157	7	ctla-4	ctla-4	NOUN
ajst-32485	157	8	blockade	blockade	NOUN
ajst-32485	157	9	may	may	AUX
ajst-32485	157	10	rescue	rescue	VERB
ajst-32485	157	11	exhausted	exhausted	ADJ
ajst-32485	157	12	t	t	NOUN
ajst-32485	157	13	cells	cell	NOUN
ajst-32485	157	14	,	,	PUNCT
ajst-32485	157	15	as	as	SCONJ
ajst-32485	157	16	seen	see	VERB
ajst-32485	157	17	in	in	ADP
ajst-32485	157	18	partial	partial	ADJ
ajst-32485	157	19	responders	responder	NOUN
ajst-32485	157	20	(	(	PUNCT
ajst-32485	157	21	rojas	rojas	PROPN
ajst-32485	157	22	et	et	PROPN
ajst-32485	157	23	al	al	PROPN
ajst-32485	157	24	.	.	PROPN
ajst-32485	157	25	,	,	PUNCT
ajst-32485	157	26	2023	2023	NUM
ajst-32485	157	27	)	)	PUNCT
ajst-32485	157	28	.	.	PUNCT
ajst-32485	158	1	improving	improve	VERB
ajst-32485	158	2	neoantigen	neoantigen	PROPN
ajst-32485	158	3	selection	selection	NOUN
ajst-32485	158	4	&	&	CCONJ
ajst-32485	158	5	design	design	NOUN
ajst-32485	158	6	is	be	AUX
ajst-32485	158	7	also	also	ADV
ajst-32485	158	8	an	an	DET
ajst-32485	158	9	objective	objective	NOUN
ajst-32485	158	10	,	,	PUNCT
ajst-32485	158	11	including	include	VERB
ajst-32485	158	12	multi	multi	ADJ
ajst-32485	158	13	-	-	ADJ
ajst-32485	158	14	epitope	epitope	ADJ
ajst-32485	158	15	vaccines	vaccine	NOUN
ajst-32485	158	16	and	and	CCONJ
ajst-32485	158	17	inclusion	inclusion	NOUN
ajst-32485	158	18	of	of	ADP
ajst-32485	158	19	shared	shared	ADJ
ajst-32485	158	20	neoantigens	neoantigen	NOUN
ajst-32485	158	21	.	.	PUNCT
ajst-32485	159	1	prioritizing	prioritize	VERB
ajst-32485	159	2	neoantigens	neoantigen	NOUN
ajst-32485	159	3	with	with	ADP
ajst-32485	159	4	high	high	ADJ
ajst-32485	159	5	mhc	mhc	NOUN
ajst-32485	159	6	-	-	PUNCT
ajst-32485	159	7	binding	bind	VERB
ajst-32485	159	8	affinity	affinity	NOUN
ajst-32485	159	9	and	and	CCONJ
ajst-32485	159	10	immunogenicity	immunogenicity	NOUN
ajst-32485	159	11	(	(	PUNCT
ajst-32485	159	12	e.g.	e.g.	ADV
ajst-32485	159	13	,	,	PUNCT
ajst-32485	159	14	via	via	ADP
ajst-32485	159	15	ai	ai	AUX
ajst-32485	159	16	-	-	PUNCT
ajst-32485	159	17	predicted	predict	VERB
ajst-32485	159	18	tcr	tcr	PROPN
ajst-32485	159	19	recognition	recognition	PROPN
ajst-32485	159	20	)	)	PUNCT
ajst-32485	159	21	.	.	PUNCT
ajst-32485	160	1	targeting	target	VERB
ajst-32485	160	2	recurrent	recurrent	ADJ
ajst-32485	160	3	mutations	mutation	NOUN
ajst-32485	160	4	(	(	PUNCT
ajst-32485	160	5	e.g.	e.g.	ADV
ajst-32485	160	6	,	,	PUNCT
ajst-32485	160	7	kras	kra	NOUN
ajst-32485	160	8	g12d	g12d	NOUN
ajst-32485	160	9	)	)	PUNCT
ajst-32485	160	10	could	could	AUX
ajst-32485	160	11	enable	enable	VERB
ajst-32485	160	12	"	"	PUNCT
ajst-32485	160	13	off	off	ADP
ajst-32485	160	14	-	-	PUNCT
ajst-32485	160	15	the	the	DET
ajst-32485	160	16	-	-	PUNCT
ajst-32485	160	17	shelf	shelf	NOUN
ajst-32485	160	18	"	"	PUNCT
ajst-32485	160	19	vaccines	vaccine	NOUN
ajst-32485	160	20	for	for	ADP
ajst-32485	160	21	subsets	subset	NOUN
ajst-32485	160	22	of	of	ADP
ajst-32485	160	23	patients	patient	NOUN
ajst-32485	160	24	(	(	PUNCT
ajst-32485	160	25	rojas	rojas	PROPN
ajst-32485	160	26	et	et	PROPN
ajst-32485	160	27	al	al	PROPN
ajst-32485	160	28	.	.	PROPN
ajst-32485	160	29	,	,	PUNCT
ajst-32485	160	30	2023	2023	NUM
ajst-32485	160	31	)	)	PUNCT
ajst-32485	160	32	.	.	PUNCT
ajst-32485	161	1	moreover	moreover	ADV
ajst-32485	161	2	,	,	PUNCT
ajst-32485	161	3	biomarker	biomarker	NOUN
ajst-32485	161	4	-	-	PUNCT
ajst-32485	161	5	driven	drive	VERB
ajst-32485	161	6	personalization	personalization	NOUN
ajst-32485	161	7	,	,	PUNCT
ajst-32485	161	8	msln	msln	NOUN
ajst-32485	161	9	expression	expression	NOUN
ajst-32485	161	10	screening	screening	NOUN
ajst-32485	161	11	has	have	AUX
ajst-32485	161	12	always	always	ADV
ajst-32485	161	13	been	be	AUX
ajst-32485	161	14	a	a	DET
ajst-32485	161	15	pivotal	pivotal	ADJ
ajst-32485	161	16	study	study	NOUN
ajst-32485	161	17	for	for	ADP
ajst-32485	161	18	neoantigen	neoantigen	PROPN
ajst-32485	161	19	.	.	PUNCT
ajst-32485	162	1	patient	patient	ADJ
ajst-32485	162	2	stratification	stratification	NOUN
ajst-32485	162	3	based	base	VERB
ajst-32485	162	4	on	on	ADP
ajst-32485	162	5	msln	msln	NOUN
ajst-32485	162	6	levels	level	NOUN
ajst-32485	162	7	may	may	AUX
ajst-32485	162	8	predict	predict	VERB
ajst-32485	162	9	response	response	NOUN
ajst-32485	162	10	to	to	ADP
ajst-32485	162	11	targeted	target	VERB
ajst-32485	162	12	vaccine	vaccine	NOUN
ajst-32485	162	13	delivery	delivery	NOUN
ajst-32485	162	14	(	(	PUNCT
ajst-32485	162	15	cai	cai	X
ajst-32485	162	16	et	et	PROPN
ajst-32485	162	17	al	al	PROPN
ajst-32485	162	18	.	.	PROPN
ajst-32485	162	19	,	,	PUNCT
ajst-32485	162	20	2025	2025	NUM
ajst-32485	162	21	)	)	PUNCT
ajst-32485	162	22	.	.	PUNCT
ajst-32485	163	1	dynamic	dynamic	ADJ
ajst-32485	163	2	immune	immune	ADJ
ajst-32485	163	3	monitoring	monitoring	NOUN
ajst-32485	163	4	:	:	PUNCT
ajst-32485	163	5	tracking	track	VERB
ajst-32485	163	6	neoantigenspecific	neoantigenspecific	ADJ
ajst-32485	163	7	t	t	PROPN
ajst-32485	163	8	-	-	PUNCT
ajst-32485	163	9	cell	cell	NOUN
ajst-32485	163	10	clonality	clonality	NOUN
ajst-32485	163	11	and	and	CCONJ
ajst-32485	163	12	memory	memory	NOUN
ajst-32485	163	13	formation	formation	NOUN
ajst-32485	163	14	(	(	PUNCT
ajst-32485	163	15	e.g.	e.g.	ADV
ajst-32485	163	16	,	,	PUNCT
ajst-32485	163	17	cd69⁺	cd69⁺	NOUN
ajst-32485	163	18	cd8⁺	cd8⁺	NOUN
ajst-32485	163	19	t	t	NOUN
ajst-32485	163	20	cells	cell	NOUN
ajst-32485	163	21	)	)	PUNCT
ajst-32485	163	22	to	to	PART
ajst-32485	163	23	refine	refine	VERB
ajst-32485	163	24	vaccination	vaccination	NOUN
ajst-32485	163	25	schedules	schedule	NOUN
ajst-32485	163	26	.	.	PUNCT
ajst-32485	164	1	a	a	DET
ajst-32485	164	2	clinical	clinical	ADJ
ajst-32485	164	3	trial	trial	NOUN
ajst-32485	164	4	is	be	AUX
ajst-32485	164	5	one	one	NUM
ajst-32485	164	6	of	of	ADP
ajst-32485	164	7	the	the	DET
ajst-32485	164	8	critical	critical	ADJ
ajst-32485	164	9	factors	factor	NOUN
ajst-32485	164	10	in	in	ADP
ajst-32485	164	11	the	the	DET
ajst-32485	164	12	development	development	NOUN
ajst-32485	164	13	of	of	ADP
ajst-32485	164	14	neoantigen	neoantigen	PROPN
ajst-32485	164	15	vaccines	vaccine	NOUN
ajst-32485	164	16	.	.	PUNCT
ajst-32485	165	1	earlier	early	ADJ
ajst-32485	165	2	intervention	intervention	NOUN
ajst-32485	165	3	,	,	PUNCT
ajst-32485	165	4	which	which	PRON
ajst-32485	165	5	is	be	AUX
ajst-32485	165	6	testing	test	VERB
ajst-32485	165	7	vaccines	vaccine	NOUN
ajst-32485	165	8	in	in	ADP
ajst-32485	165	9	resectable	resectable	ADJ
ajst-32485	165	10	or	or	CCONJ
ajst-32485	165	11	minimal	minimal	ADJ
ajst-32485	165	12	residual	residual	ADJ
ajst-32485	165	13	disease	disease	NOUN
ajst-32485	165	14	(	(	PUNCT
ajst-32485	165	15	mrd	mrd	ADJ
ajst-32485	165	16	)	)	PUNCT
ajst-32485	165	17	settings	setting	NOUN
ajst-32485	165	18	,	,	PUNCT
ajst-32485	165	19	where	where	SCONJ
ajst-32485	165	20	the	the	DET
ajst-32485	165	21	tme	tme	NOUN
ajst-32485	165	22	is	be	AUX
ajst-32485	165	23	less	less	ADJ
ajst-32485	165	24	suppressive	suppressive	NOUN
ajst-32485	165	25	.	.	PUNCT
ajst-32485	166	1	people	people	NOUN
ajst-32485	166	2	should	should	AUX
ajst-32485	166	3	also	also	ADV
ajst-32485	166	4	be	be	AUX
ajst-32485	166	5	aware	aware	ADJ
ajst-32485	166	6	of	of	ADP
ajst-32485	166	7	rational	rational	ADJ
ajst-32485	166	8	combination	combination	NOUN
ajst-32485	166	9	therapy	therapy	NOUN
ajst-32485	166	10	as	as	ADP
ajst-32485	166	11	a	a	DET
ajst-32485	166	12	control	control	NOUN
ajst-32485	166	13	factor	factor	NOUN
ajst-32485	166	14	in	in	ADP
ajst-32485	166	15	clinical	clinical	ADJ
ajst-32485	166	16	trials	trial	NOUN
ajst-32485	166	17	.	.	PUNCT
ajst-32485	167	1	sequential	sequential	ADJ
ajst-32485	167	2	or	or	CCONJ
ajst-32485	167	3	concurrent	concurrent	ADJ
ajst-32485	167	4	therapy	therapy	NOUN
ajst-32485	167	5	with	with	ADP
ajst-32485	167	6	chemotherapy	chemotherapy	NOUN
ajst-32485	167	7	(	(	PUNCT
ajst-32485	167	8	e.g.	e.g.	ADV
ajst-32485	167	9	,	,	PUNCT
ajst-32485	167	10	mfolfirinox	mfolfirinox	NOUN
ajst-32485	167	11	)	)	PUNCT
ajst-32485	167	12	,	,	PUNCT
ajst-32485	167	13	radiotherapy	radiotherapy	NOUN
ajst-32485	167	14	,	,	PUNCT
ajst-32485	167	15	or	or	CCONJ
ajst-32485	167	16	adoptive	adoptive	ADJ
ajst-32485	167	17	cell	cell	NOUN
ajst-32485	167	18	therapy	therapy	NOUN
ajst-32485	167	19	(	(	PUNCT
ajst-32485	167	20	tcr	tcr	PROPN
ajst-32485	167	21	-	-	PUNCT
ajst-32485	167	22	t	t	PROPN
ajst-32485	167	23	/	/	SYM
ajst-32485	167	24	car	car	NOUN
ajst-32485	167	25	-	-	PUNCT
ajst-32485	167	26	t	t	NOUN
ajst-32485	167	27	)	)	PUNCT
ajst-32485	167	28	,	,	PUNCT
ajst-32485	167	29	as	as	ADV
ajst-32485	167	30	well	well	ADV
ajst-32485	167	31	as	as	ADP
ajst-32485	167	32	an	an	DET
ajst-32485	167	33	increasing	increase	VERB
ajst-32485	167	34	amount	amount	NOUN
ajst-32485	167	35	of	of	ADP
ajst-32485	167	36	large	large	ADJ
ajst-32485	167	37	-	-	PUNCT
ajst-32485	167	38	scale	scale	NOUN
ajst-32485	167	39	clinical	clinical	ADJ
ajst-32485	167	40	trials	trial	NOUN
ajst-32485	167	41	and	and	CCONJ
ajst-32485	167	42	translational	translational	ADJ
ajst-32485	167	43	medical	medical	ADJ
ajst-32485	167	44	research	research	NOUN
ajst-32485	167	45	.	.	PUNCT
ajst-32485	168	1	in	in	ADP
ajst-32485	168	2	the	the	DET
ajst-32485	168	3	future	future	NOUN
ajst-32485	168	4	,	,	PUNCT
ajst-32485	168	5	it	it	PRON
ajst-32485	168	6	is	be	AUX
ajst-32485	168	7	necessary	necessary	ADJ
ajst-32485	168	8	to	to	PART
ajst-32485	168	9	verify	verify	VERB
ajst-32485	168	10	the	the	DET
ajst-32485	168	11	efficacy	efficacy	NOUN
ajst-32485	168	12	and	and	CCONJ
ajst-32485	168	13	safety	safety	NOUN
ajst-32485	168	14	in	in	ADP
ajst-32485	168	15	a	a	DET
ajst-32485	168	16	larger	large	ADJ
ajst-32485	168	17	sample	sample	NOUN
ajst-32485	168	18	(	(	PUNCT
ajst-32485	168	19	rojas	rojas	PROPN
ajst-32485	168	20	et	et	PROPN
ajst-32485	168	21	al	al	PROPN
ajst-32485	168	22	.	.	PROPN
ajst-32485	168	23	,	,	PUNCT
ajst-32485	168	24	2023	2023	NUM
ajst-32485	168	25	)	)	PUNCT
ajst-32485	168	26	.	.	PUNCT
ajst-32485	169	1	6	6	X
ajst-32485	169	2	.	.	X
ajst-32485	169	3	conclusion	conclusion	NOUN
ajst-32485	169	4	the	the	DET
ajst-32485	169	5	highly	highly	ADV
ajst-32485	169	6	immunosuppressive	immunosuppressive	ADJ
ajst-32485	169	7	tme	tme	NOUN
ajst-32485	169	8	of	of	ADP
ajst-32485	169	9	pancreatic	pancreatic	ADJ
ajst-32485	169	10	cancer	cancer	NOUN
ajst-32485	169	11	is	be	AUX
ajst-32485	169	12	still	still	ADV
ajst-32485	169	13	the	the	DET
ajst-32485	169	14	core	core	ADJ
ajst-32485	169	15	obstacle	obstacle	NOUN
ajst-32485	169	16	restricting	restrict	VERB
ajst-32485	169	17	neoantigen	neoantigen	PROPN
ajst-32485	169	18	vaccines	vaccine	NOUN
ajst-32485	169	19	’	'	PUNCT
ajst-32485	169	20	clinical	clinical	ADJ
ajst-32485	169	21	efficacy	efficacy	NOUN
ajst-32485	169	22	.	.	PUNCT
ajst-32485	170	1	the	the	DET
ajst-32485	170	2	dense	dense	ADJ
ajst-32485	170	3	stromal	stromal	ADJ
ajst-32485	170	4	structure	structure	NOUN
ajst-32485	170	5	not	not	PART
ajst-32485	170	6	only	only	ADV
ajst-32485	170	7	hinders	hinder	VERB
ajst-32485	170	8	the	the	DET
ajst-32485	170	9	infiltration	infiltration	NOUN
ajst-32485	170	10	of	of	ADP
ajst-32485	170	11	immune	immune	ADJ
ajst-32485	170	12	cells	cell	NOUN
ajst-32485	170	13	and	and	CCONJ
ajst-32485	170	14	effective	effective	ADJ
ajst-32485	170	15	antigen	antigen	ADJ
ajst-32485	170	16	delivery	delivery	NOUN
ajst-32485	170	17	but	but	CCONJ
ajst-32485	170	18	also	also	ADV
ajst-32485	170	19	makes	make	VERB
ajst-32485	170	20	it	it	PRON
ajst-32485	170	21	difficult	difficult	ADJ
ajst-32485	170	22	for	for	SCONJ
ajst-32485	170	23	t	t	NOUN
ajst-32485	170	24	cells	cell	NOUN
ajst-32485	170	25	to	to	PART
ajst-32485	170	26	penetrate	penetrate	VERB
ajst-32485	170	27	the	the	DET
ajst-32485	170	28	tumor	tumor	NOUN
ajst-32485	170	29	tissues	tissue	NOUN
ajst-32485	170	30	.	.	PUNCT
ajst-32485	171	1	as	as	ADP
ajst-32485	171	2	a	a	DET
ajst-32485	171	3	result	result	NOUN
ajst-32485	171	4	,	,	PUNCT
ajst-32485	171	5	the	the	DET
ajst-32485	171	6	accumulation	accumulation	NOUN
ajst-32485	171	7	of	of	ADP
ajst-32485	171	8	immunosuppressive	immunosuppressive	ADJ
ajst-32485	171	9	cells	cell	NOUN
ajst-32485	171	10	such	such	ADJ
ajst-32485	171	11	as	as	ADP
ajst-32485	171	12	tregs	treg	NOUN
ajst-32485	171	13	and	and	CCONJ
ajst-32485	171	14	mdscs	mdsc	NOUN
ajst-32485	171	15	,	,	PUNCT
ajst-32485	171	16	as	as	ADV
ajst-32485	171	17	well	well	ADV
ajst-32485	171	18	as	as	ADP
ajst-32485	171	19	the	the	DET
ajst-32485	171	20	elevated	elevated	ADJ
ajst-32485	171	21	expression	expression	NOUN
ajst-32485	171	22	of	of	ADP
ajst-32485	171	23	checkpoint	checkpoint	NOUN
ajst-32485	171	24	molecules	molecule	NOUN
ajst-32485	171	25	including	include	VERB
ajst-32485	171	26	pd	pd	NOUN
ajst-32485	171	27	-	-	PUNCT
ajst-32485	171	28	l1	l1	PROPN
ajst-32485	171	29	,	,	PUNCT
ajst-32485	171	30	makes	make	VERB
ajst-32485	171	31	it	it	PRON
ajst-32485	171	32	difficult	difficult	ADJ
ajst-32485	171	33	for	for	SCONJ
ajst-32485	171	34	t	t	NOUN
ajst-32485	171	35	cells	cell	NOUN
ajst-32485	171	36	to	to	PART
ajst-32485	171	37	kill	kill	VERB
ajst-32485	171	38	efficiently	efficiently	ADV
ajst-32485	171	39	even	even	ADV
ajst-32485	171	40	though	though	SCONJ
ajst-32485	171	41	they	they	PRON
ajst-32485	171	42	have	have	AUX
ajst-32485	171	43	already	already	ADV
ajst-32485	171	44	been	be	AUX
ajst-32485	171	45	activated	activate	VERB
ajst-32485	171	46	.	.	PUNCT
ajst-32485	172	1	a	a	DET
ajst-32485	172	2	more	more	ADV
ajst-32485	172	3	troublesome	troublesome	ADJ
ajst-32485	172	4	problem	problem	NOUN
ajst-32485	172	5	is	be	AUX
ajst-32485	172	6	that	that	SCONJ
ajst-32485	172	7	the	the	DET
ajst-32485	172	8	general	general	ADJ
ajst-32485	172	9	limitations	limitation	NOUN
ajst-32485	172	10	on	on	ADP
ajst-32485	172	11	apcs	apc	NOUN
ajst-32485	172	12	’	'	PUNCT
ajst-32485	172	13	quantity	quantity	NOUN
ajst-32485	172	14	and	and	CCONJ
ajst-32485	172	15	function	function	NOUN
ajst-32485	172	16	directly	directly	ADV
ajst-32485	172	17	lead	lead	VERB
ajst-32485	172	18	to	to	ADP
ajst-32485	172	19	poor	poor	ADJ
ajst-32485	172	20	vaccine	vaccine	NOUN
ajst-32485	172	21	-	-	PUNCT
ajst-32485	172	22	induced	induce	VERB
ajst-32485	172	23	immune	immune	ADJ
ajst-32485	172	24	responses	response	NOUN
ajst-32485	172	25	.	.	PUNCT
ajst-32485	173	1	mesothelin	mesothelin	NOUN
ajst-32485	173	2	-	-	PUNCT
ajst-32485	173	3	targeted	target	VERB
ajst-32485	173	4	delivery	delivery	NOUN
ajst-32485	173	5	strategies	strategy	NOUN
ajst-32485	173	6	have	have	AUX
ajst-32485	173	7	been	be	AUX
ajst-32485	173	8	proposed	propose	VERB
ajst-32485	173	9	in	in	ADP
ajst-32485	173	10	recent	recent	ADJ
ajst-32485	173	11	years	year	NOUN
ajst-32485	173	12	and	and	CCONJ
ajst-32485	173	13	have	have	AUX
ajst-32485	173	14	shown	show	VERB
ajst-32485	173	15	great	great	ADJ
ajst-32485	173	16	potential	potential	NOUN
ajst-32485	173	17	for	for	ADP
ajst-32485	173	18	improving	improve	VERB
ajst-32485	173	19	antigen	antigen	ADJ
ajst-32485	173	20	presentation	presentation	NOUN
ajst-32485	173	21	efficiency	efficiency	NOUN
ajst-32485	173	22	and	and	CCONJ
ajst-32485	173	23	t	t	NOUN
ajst-32485	173	24	cell	cell	NOUN
ajst-32485	173	25	infiltration	infiltration	NOUN
ajst-32485	173	26	in	in	ADP
ajst-32485	173	27	preclinical	preclinical	ADJ
ajst-32485	173	28	studies	study	NOUN
ajst-32485	173	29	.	.	PUNCT
ajst-32485	174	1	however	however	ADV
ajst-32485	174	2	,	,	PUNCT
ajst-32485	174	3	problems	problem	NOUN
ajst-32485	174	4	such	such	ADJ
ajst-32485	174	5	as	as	ADP
ajst-32485	174	6	high	high	ADJ
ajst-32485	174	7	dependence	dependence	NOUN
ajst-32485	174	8	on	on	ADP
ajst-32485	174	9	high	high	ADJ
ajst-32485	174	10	mesothelin	mesothelin	NOUN
ajst-32485	174	11	expression	expression	NOUN
ajst-32485	174	12	levels	level	NOUN
ajst-32485	174	13	in	in	ADP
ajst-32485	174	14	tumor	tumor	NOUN
ajst-32485	174	15	tissues	tissue	NOUN
ajst-32485	174	16	and	and	CCONJ
ajst-32485	174	17	the	the	DET
ajst-32485	174	18	complex	complex	ADJ
ajst-32485	174	19	interference	interference	NOUN
ajst-32485	174	20	brought	bring	VERB
ajst-32485	174	21	by	by	ADP
ajst-32485	174	22	immunosuppressive	immunosuppressive	ADJ
ajst-32485	174	23	microenvironment	microenvironment	NOUN
ajst-32485	174	24	highlight	highlight	VERB
ajst-32485	174	25	the	the	DET
ajst-32485	174	26	necessity	necessity	NOUN
ajst-32485	174	27	for	for	ADP
ajst-32485	174	28	multifaceted	multifaceted	ADJ
ajst-32485	174	29	optimization	optimization	NOUN
ajst-32485	174	30	.	.	PUNCT
ajst-32485	175	1	the	the	DET
ajst-32485	175	2	combined	combined	ADJ
ajst-32485	175	3	application	application	NOUN
ajst-32485	175	4	is	be	AUX
ajst-32485	175	5	expected	expect	VERB
ajst-32485	175	6	to	to	PART
ajst-32485	175	7	break	break	VERB
ajst-32485	175	8	through	through	ADP
ajst-32485	175	9	the	the	DET
ajst-32485	175	10	immune	immune	ADJ
ajst-32485	175	11	resistance	resistance	NOUN
ajst-32485	175	12	barrier	barrier	NOUN
ajst-32485	175	13	and	and	CCONJ
ajst-32485	175	14	improve	improve	VERB
ajst-32485	175	15	the	the	DET
ajst-32485	175	16	therapeutic	therapeutic	ADJ
ajst-32485	175	17	effect	effect	NOUN
ajst-32485	175	18	of	of	ADP
ajst-32485	175	19	pancreatic	pancreatic	ADJ
ajst-32485	175	20	cancer	cancer	NOUN
ajst-32485	175	21	.	.	PUNCT
ajst-32485	176	1	127	127	NUM
ajst-32485	176	2	references	reference	NOUN
ajst-32485	176	3	[	[	X
ajst-32485	176	4	1	1	NUM
ajst-32485	176	5	]	]	X
ajst-32485	176	6	cai	cai	X
ajst-32485	176	7	,	,	PUNCT
ajst-32485	176	8	z.	z.	PROPN
ajst-32485	176	9	,	,	PUNCT
ajst-32485	176	10	li	li	PROPN
ajst-32485	176	11	,	,	PUNCT
ajst-32485	176	12	z.	z.	PROPN
ajst-32485	176	13	,	,	PUNCT
ajst-32485	176	14	zhong	zhong	PROPN
ajst-32485	176	15	,	,	PUNCT
ajst-32485	176	16	w.	w.	PROPN
ajst-32485	176	17	,	,	PUNCT
ajst-32485	176	18	lin	lin	PROPN
ajst-32485	176	19	,	,	PUNCT
ajst-32485	176	20	f.	f.	PROPN
ajst-32485	176	21	,	,	PUNCT
ajst-32485	176	22	dong	dong	PROPN
ajst-32485	176	23	,	,	PUNCT
ajst-32485	176	24	x.	x.	NOUN
ajst-32485	176	25	,	,	PUNCT
ajst-32485	176	26	ye	ye	PROPN
ajst-32485	176	27	,	,	PUNCT
ajst-32485	176	28	h.	h.	PROPN
ajst-32485	176	29	,	,	PUNCT
ajst-32485	176	30	guo	guo	PROPN
ajst-32485	176	31	,	,	PUNCT
ajst-32485	176	32	y.	y.	PROPN
ajst-32485	176	33	,	,	PUNCT
ajst-32485	176	34	chen	chen	PROPN
ajst-32485	176	35	,	,	PUNCT
ajst-32485	176	36	g.	g.	PROPN
ajst-32485	176	37	,	,	PUNCT
ajst-32485	176	38	yu	yu	PROPN
ajst-32485	176	39	,	,	PUNCT
ajst-32485	176	40	x.	x.	PROPN
ajst-32485	176	41	,	,	PUNCT
ajst-32485	176	42	yu	yu	PROPN
ajst-32485	176	43	,	,	PUNCT
ajst-32485	176	44	h.	h.	PROPN
ajst-32485	176	45	,	,	PUNCT
ajst-32485	176	46	tang	tang	PROPN
ajst-32485	176	47	,	,	PUNCT
ajst-32485	176	48	r.	r.	PROPN
ajst-32485	176	49	,	,	PUNCT
ajst-32485	176	50	&	&	CCONJ
ajst-32485	176	51	liu	liu	PROPN
ajst-32485	176	52	,	,	PUNCT
ajst-32485	176	53	x.	x.	NOUN
ajst-32485	176	54	(	(	PUNCT
ajst-32485	176	55	2025	2025	NUM
ajst-32485	176	56	)	)	PUNCT
ajst-32485	176	57	.	.	PUNCT
ajst-32485	177	1	targeting	target	VERB
ajst-32485	177	2	mesothelin	mesothelin	NOUN
ajst-32485	177	3	enhances	enhance	NOUN
ajst-32485	177	4	personalized	personalize	VERB
ajst-32485	177	5	neoantigen	neoantigen	NOUN
ajst-32485	177	6	vaccine	vaccine	NOUN
ajst-32485	177	7	-	-	PUNCT
ajst-32485	177	8	induced	induce	VERB
ajst-32485	177	9	antitumor	antitumor	PROPN
ajst-32485	177	10	immune	immune	ADJ
ajst-32485	177	11	response	response	NOUN
ajst-32485	177	12	in	in	ADP
ajst-32485	177	13	orthotopic	orthotopic	ADJ
ajst-32485	177	14	pancreatic	pancreatic	ADJ
ajst-32485	177	15	cancer	cancer	NOUN
ajst-32485	177	16	mouse	mouse	NOUN
ajst-32485	177	17	models	model	NOUN
ajst-32485	177	18	.	.	PUNCT
ajst-32485	178	1	advanced	advanced	ADJ
ajst-32485	178	2	science	science	NOUN
ajst-32485	178	3	.	.	PUNCT
ajst-32485	179	1	https://doi.org/	https://doi.org/	PROPN
ajst-32485	179	2	10	10	NUM
ajst-32485	179	3	.	.	PUNCT
ajst-32485	180	1	1002/	1002/	NUM
ajst-32485	180	2	advs.202407976	advs.202407976	NOUN
ajst-32485	180	3	.	.	PUNCT
ajst-32485	181	1	[	[	X
ajst-32485	181	2	2	2	NUM
ajst-32485	181	3	]	]	X
ajst-32485	181	4	kleeff	kleeff	PROPN
ajst-32485	181	5	,	,	PUNCT
ajst-32485	181	6	j.	j.	PROPN
ajst-32485	181	7	,	,	PUNCT
ajst-32485	181	8	korc	korc	NOUN
ajst-32485	181	9	,	,	PUNCT
ajst-32485	181	10	m.	m.	NOUN
ajst-32485	181	11	,	,	PUNCT
ajst-32485	181	12	apte	apte	PROPN
ajst-32485	181	13	,	,	PUNCT
ajst-32485	181	14	m.	m.	NOUN
ajst-32485	181	15	,	,	PUNCT
ajst-32485	181	16	la	la	PROPN
ajst-32485	181	17	vecchia	vecchia	PROPN
ajst-32485	181	18	,	,	PUNCT
ajst-32485	181	19	c.	c.	PROPN
ajst-32485	181	20	,	,	PUNCT
ajst-32485	181	21	johnson	johnson	PROPN
ajst-32485	181	22	,	,	PUNCT
ajst-32485	181	23	c.	c.	PROPN
ajst-32485	181	24	d.	d.	PROPN
ajst-32485	181	25	,	,	PUNCT
ajst-32485	181	26	biankin	biankin	PROPN
ajst-32485	181	27	,	,	PUNCT
ajst-32485	181	28	a.	a.	PROPN
ajst-32485	181	29	v.	v.	PROPN
ajst-32485	181	30	,	,	PUNCT
ajst-32485	181	31	neale	neale	PROPN
ajst-32485	181	32	,	,	PUNCT
ajst-32485	181	33	r.	r.	PROPN
ajst-32485	181	34	e.	e.	PROPN
ajst-32485	181	35	,	,	PUNCT
ajst-32485	181	36	tempero	tempero	NOUN
ajst-32485	181	37	,	,	PUNCT
ajst-32485	181	38	m.	m.	NOUN
ajst-32485	181	39	,	,	PUNCT
ajst-32485	181	40	tuveson	tuveson	NOUN
ajst-32485	181	41	,	,	PUNCT
ajst-32485	181	42	d.	d.	PROPN
ajst-32485	181	43	a.	a.	PROPN
ajst-32485	181	44	,	,	PUNCT
ajst-32485	181	45	hruban	hruban	PROPN
ajst-32485	181	46	,	,	PUNCT
ajst-32485	181	47	r.	r.	PROPN
ajst-32485	181	48	h.	h.	PROPN
ajst-32485	181	49	,	,	PUNCT
ajst-32485	181	50	&	&	CCONJ
ajst-32485	181	51	neoptolemos	neoptolemos	PROPN
ajst-32485	181	52	,	,	PUNCT
ajst-32485	181	53	j.	j.	PROPN
ajst-32485	181	54	p.	p.	PROPN
ajst-32485	181	55	(	(	PUNCT
ajst-32485	181	56	2016	2016	NUM
ajst-32485	181	57	)	)	PUNCT
ajst-32485	181	58	.	.	PUNCT
ajst-32485	182	1	pancreatic	pancreatic	ADJ
ajst-32485	182	2	cancer	cancer	NOUN
ajst-32485	182	3	.	.	PUNCT
ajst-32485	183	1	nature	nature	NOUN
ajst-32485	183	2	reviews	review	NOUN
ajst-32485	183	3	disease	disease	NOUN
ajst-32485	183	4	primers	primer	NOUN
ajst-32485	183	5	,	,	PUNCT
ajst-32485	183	6	2(1	2(1	NUM
ajst-32485	183	7	)	)	PUNCT
ajst-32485	183	8	.	.	PUNCT
ajst-32485	184	1	https://doi.org/10.1038/nrdp.2016.22	https://doi.org/10.1038/nrdp.2016.22	NOUN
ajst-32485	184	2	.	.	PUNCT
ajst-32485	185	1	[	[	X
ajst-32485	185	2	3	3	NUM
ajst-32485	185	3	]	]	X
ajst-32485	185	4	nci	nci	X
ajst-32485	185	5	.	.	PUNCT
ajst-32485	185	6	(	(	PUNCT
ajst-32485	185	7	2018	2018	NUM
ajst-32485	185	8	)	)	PUNCT
ajst-32485	185	9	.	.	PUNCT
ajst-32485	186	1	cancer	cancer	NOUN
ajst-32485	186	2	of	of	ADP
ajst-32485	186	3	the	the	DET
ajst-32485	186	4	pancreas	pancreas	NOUN
ajst-32485	186	5	cancer	cancer	NOUN
ajst-32485	186	6	stat	stat	PROPN
ajst-32485	186	7	facts	fact	VERB
ajst-32485	186	8	.	.	PUNCT
ajst-32485	187	1	seer	seer	NOUN
ajst-32485	187	2	;	;	PUNCT
ajst-32485	187	3	national	national	PROPN
ajst-32485	187	4	cancer	cancer	PROPN
ajst-32485	187	5	institute	institute	PROPN
ajst-32485	187	6	.	.	PUNCT
ajst-32485	188	1	https://	https://	PROPN
ajst-32485	188	2	seer	seer	NOUN
ajst-32485	188	3	.	.	PUNCT
ajst-32485	189	1	cancer	cancer	NOUN
ajst-32485	189	2	.	.	PUNCT
ajst-32485	190	1	gov	gov	NOUN
ajst-32485	190	2	/	/	SYM
ajst-32485	190	3	statfacts	statfact	NOUN
ajst-32485	190	4	/	/	SYM
ajst-32485	190	5	html	html	NOUN
ajst-32485	190	6	/	/	SYM
ajst-32485	190	7	pancreas.html	pancreas.html	NOUN
ajst-32485	190	8	.	.	PUNCT
ajst-32485	191	1	[	[	X
ajst-32485	191	2	4	4	NUM
ajst-32485	191	3	]	]	X
ajst-32485	191	4	nci	nci	X
ajst-32485	191	5	.	.	PUNCT
ajst-32485	192	1	(	(	PUNCT
ajst-32485	192	2	2022	2022	NUM
ajst-32485	192	3	)	)	PUNCT
ajst-32485	192	4	.	.	PUNCT
ajst-32485	193	1	seer*explorer	seer*explorer	NUM
ajst-32485	193	2	application	application	NOUN
ajst-32485	193	3	.	.	PUNCT
ajst-32485	194	1	cancer.gov	cancer.gov	X
ajst-32485	194	2	.	.	PUNCT
ajst-32485	195	1	https://seer.cancer.gov/statistics-network/	https://seer.cancer.gov/statistics-network/	ADV
ajst-32485	195	2	explorer	explorer	NOUN
ajst-32485	195	3	/	/	SYM
ajst-32485	195	4	application.html?site=40&data_type=4&graph_type=2&compareby	application.html?site=40&data_type=4&graph_type=2&compareby	ADJ
ajst-32485	195	5	=	=	SYM
ajst-32485	195	6	sex&chk_sex_3=3&chk	sex&chk_sex_3=3&chk	NOUN
ajst-32485	195	7	_	_	PRON
ajst-32485	195	8	sex_2=2&relative_survival_interval=5&race=1&age_range=1&stage=101&advopt_precision=1&advop	sex_2=2&relative_survival_interval=5&race=1&age_range=1&stage=101&advopt_precision=1&advop	ADJ
ajst-32485	195	9	t_show_ci	t_show_ci	PROPN
ajst-32485	195	10	=	=	SYM
ajst-32485	195	11	on&hdn_view=1&advopt_sh	on&hdn_view=1&advopt_sh	NOUN
ajst-32485	195	12	.	.	PUNCT
ajst-32485	196	1	[	[	X
ajst-32485	196	2	5	5	NUM
ajst-32485	196	3	]	]	SYM
ajst-32485	196	4	nih	nih	PROPN
ajst-32485	196	5	,	,	PUNCT
ajst-32485	196	6	&	&	CCONJ
ajst-32485	196	7	genentech	genentech	PROPN
ajst-32485	196	8	,	,	PUNCT
ajst-32485	196	9	inc	inc	PROPN
ajst-32485	196	10	.	.	PROPN
ajst-32485	196	11	(	(	PUNCT
ajst-32485	196	12	2023	2023	NUM
ajst-32485	196	13	,	,	PUNCT
ajst-32485	196	14	december	december	PROPN
ajst-32485	196	15	18	18	NUM
ajst-32485	196	16	)	)	PUNCT
ajst-32485	196	17	.	.	PUNCT
ajst-32485	197	1	phase	phase	NOUN
ajst-32485	197	2	1	1	NUM
ajst-32485	197	3	clinical	clinical	ADJ
ajst-32485	197	4	trial	trial	NOUN
ajst-32485	197	5	of	of	ADP
ajst-32485	197	6	personalized	personalize	VERB
ajst-32485	197	7	neoantigen	neoantigen	PROPN
ajst-32485	197	8	tumor	tumor	NOUN
ajst-32485	197	9	vaccines	vaccine	NOUN
ajst-32485	197	10	and	and	CCONJ
ajst-32485	197	11	programmed	program	VERB
ajst-32485	197	12	death	death	NOUN
ajst-32485	197	13	-	-	PUNCT
ajst-32485	197	14	ligand	ligand	NOUN
ajst-32485	197	15	1	1	NUM
ajst-32485	197	16	(	(	PUNCT
ajst-32485	197	17	pd	pd	NOUN
ajst-32485	197	18	-	-	PUNCT
ajst-32485	197	19	l1	l1	NOUN
ajst-32485	197	20	)	)	PUNCT
ajst-32485	197	21	blockade	blockade	NOUN
ajst-32485	197	22	in	in	ADP
ajst-32485	197	23	patients	patient	NOUN
ajst-32485	197	24	with	with	ADP
ajst-32485	197	25	surgically	surgically	ADV
ajst-32485	197	26	resected	resect	VERB
ajst-32485	197	27	pancreatic	pancreatic	ADJ
ajst-32485	197	28	cancer	cancer	NOUN
ajst-32485	197	29	.	.	PUNCT
ajst-32485	198	1	clinicaltrials.gov	clinicaltrials.gov	X
ajst-32485	198	2	.	.	PUNCT
ajst-32485	199	1	https://clinicaltrials.gov/study/nct04161755	https://clinicaltrials.gov/study/nct04161755	PROPN
ajst-32485	199	2	.	.	PUNCT
ajst-32485	200	1	[	[	X
ajst-32485	200	2	6	6	NUM
ajst-32485	200	3	]	]	X
ajst-32485	200	4	peng	peng	PROPN
ajst-32485	200	5	,	,	PUNCT
ajst-32485	200	6	m.	m.	NOUN
ajst-32485	200	7	,	,	PUNCT
ajst-32485	200	8	mo	mo	PROPN
ajst-32485	200	9	,	,	PUNCT
ajst-32485	200	10	y.	y.	PROPN
ajst-32485	200	11	,	,	PUNCT
ajst-32485	200	12	wang	wang	PROPN
ajst-32485	200	13	,	,	PUNCT
ajst-32485	200	14	y.	y.	PROPN
ajst-32485	200	15	,	,	PUNCT
ajst-32485	200	16	wu	wu	PROPN
ajst-32485	200	17	,	,	PUNCT
ajst-32485	200	18	p.	p.	PROPN
ajst-32485	200	19	,	,	PUNCT
ajst-32485	200	20	zhang	zhang	PROPN
ajst-32485	200	21	,	,	PUNCT
ajst-32485	200	22	y.	y.	PROPN
ajst-32485	200	23	,	,	PUNCT
ajst-32485	200	24	xiong	xiong	PROPN
ajst-32485	200	25	,	,	PUNCT
ajst-32485	200	26	f.	f.	PROPN
ajst-32485	200	27	,	,	PUNCT
ajst-32485	200	28	guo	guo	PROPN
ajst-32485	200	29	,	,	PUNCT
ajst-32485	200	30	c.	c.	PROPN
ajst-32485	200	31	,	,	PUNCT
ajst-32485	200	32	wu	wu	PROPN
ajst-32485	200	33	,	,	PUNCT
ajst-32485	200	34	x.	x.	PROPN
ajst-32485	200	35	,	,	PUNCT
ajst-32485	200	36	li	li	PROPN
ajst-32485	200	37	,	,	PUNCT
ajst-32485	200	38	y.	y.	PROPN
ajst-32485	200	39	,	,	PUNCT
ajst-32485	200	40	li	li	PROPN
ajst-32485	200	41	,	,	PUNCT
ajst-32485	200	42	x.	x.	PROPN
ajst-32485	200	43	,	,	PUNCT
ajst-32485	200	44	li	li	PROPN
ajst-32485	200	45	,	,	PUNCT
ajst-32485	200	46	g.	g.	PROPN
ajst-32485	200	47	,	,	PUNCT
ajst-32485	200	48	xiong	xiong	PROPN
ajst-32485	200	49	,	,	PUNCT
ajst-32485	200	50	w.	w.	PROPN
ajst-32485	200	51	,	,	PUNCT
ajst-32485	200	52	&	&	CCONJ
ajst-32485	200	53	zeng	zeng	PROPN
ajst-32485	200	54	,	,	PUNCT
ajst-32485	200	55	z.	z.	PROPN
ajst-32485	200	56	(	(	PUNCT
ajst-32485	200	57	2019	2019	NUM
ajst-32485	200	58	)	)	PUNCT
ajst-32485	200	59	.	.	PUNCT
ajst-32485	201	1	neoantigen	neoantigen	PROPN
ajst-32485	201	2	vaccine	vaccine	NOUN
ajst-32485	201	3	:	:	PUNCT
ajst-32485	201	4	an	an	DET
ajst-32485	201	5	emerging	emerge	VERB
ajst-32485	201	6	tumor	tumor	NOUN
ajst-32485	201	7	immunotherapy	immunotherapy	NOUN
ajst-32485	201	8	.	.	PUNCT
ajst-32485	202	1	molecular	molecular	ADJ
ajst-32485	202	2	cancer	cancer	NOUN
ajst-32485	202	3	,	,	PUNCT
ajst-32485	202	4	18(1	18(1	NOUN
ajst-32485	202	5	)	)	PUNCT
ajst-32485	202	6	.	.	PUNCT
ajst-32485	203	1	https://doi.org/10.1186/s12943-019-1055-6	https://doi.org/10.1186/s12943-019-1055-6	PROPN
ajst-32485	203	2	.	.	PUNCT
ajst-32485	204	1	[	[	X
ajst-32485	204	2	7	7	X
ajst-32485	204	3	]	]	ADJ
ajst-32485	204	4	program	program	NOUN
ajst-32485	204	5	guide	guide	NOUN
ajst-32485	204	6	–	–	PUNCT
ajst-32485	204	7	asco	asco	NOUN
ajst-32485	204	8	meeting	meeting	NOUN
ajst-32485	204	9	program	program	NOUN
ajst-32485	204	10	guide	guide	NOUN
ajst-32485	204	11	.	.	PUNCT
ajst-32485	205	1	(	(	PUNCT
ajst-32485	205	2	2025	2025	NUM
ajst-32485	205	3	)	)	PUNCT
ajst-32485	205	4	.	.	PUNCT
ajst-32485	206	1	asco.org	asco.org	X
ajst-32485	206	2	.	.	PUNCT
ajst-32485	207	1	https://meetings	https://meeting	NOUN
ajst-32485	207	2	.	.	PUNCT
ajst-32485	208	1	asco.org/abstractspresentations/223019	asco.org/abstractspresentations/223019	PROPN
ajst-32485	208	2	.	.	PUNCT
ajst-32485	209	1	[	[	X
ajst-32485	209	2	8	8	NUM
ajst-32485	209	3	]	]	X
ajst-32485	209	4	rojas	rojas	PROPN
ajst-32485	209	5	,	,	PUNCT
ajst-32485	209	6	l.	l.	PROPN
ajst-32485	209	7	a.	a.	PROPN
ajst-32485	209	8	,	,	PUNCT
ajst-32485	209	9	sethna	sethna	NOUN
ajst-32485	209	10	,	,	PUNCT
ajst-32485	209	11	z.	z.	PROPN
ajst-32485	209	12	,	,	PUNCT
ajst-32485	209	13	soares	soares	PROPN
ajst-32485	209	14	,	,	PUNCT
ajst-32485	209	15	k.	k.	PROPN
ajst-32485	209	16	c.	c.	PROPN
ajst-32485	209	17	,	,	PUNCT
ajst-32485	209	18	olcese	olcese	PROPN
ajst-32485	209	19	,	,	PUNCT
ajst-32485	209	20	c.	c.	NOUN
ajst-32485	209	21	,	,	PUNCT
ajst-32485	209	22	pang	pang	NOUN
ajst-32485	209	23	,	,	PUNCT
ajst-32485	209	24	n.	n.	NOUN
ajst-32485	209	25	,	,	PUNCT
ajst-32485	209	26	patterson	patterson	PROPN
ajst-32485	209	27	,	,	PUNCT
ajst-32485	209	28	e.	e.	PROPN
ajst-32485	209	29	,	,	PUNCT
ajst-32485	209	30	lihm	lihm	PROPN
ajst-32485	209	31	,	,	PUNCT
ajst-32485	209	32	j.	j.	PROPN
ajst-32485	209	33	,	,	PUNCT
ajst-32485	209	34	ceglia	ceglia	PROPN
ajst-32485	209	35	,	,	PUNCT
ajst-32485	209	36	n.	n.	NOUN
ajst-32485	209	37	,	,	PUNCT
ajst-32485	209	38	guasp	guasp	NOUN
ajst-32485	209	39	,	,	PUNCT
ajst-32485	209	40	p.	p.	PROPN
ajst-32485	209	41	,	,	PUNCT
ajst-32485	209	42	chu	chu	PROPN
ajst-32485	209	43	,	,	PUNCT
ajst-32485	209	44	a.	a.	PROPN
ajst-32485	209	45	,	,	PUNCT
ajst-32485	209	46	yu	yu	PROPN
ajst-32485	209	47	,	,	PUNCT
ajst-32485	209	48	r.	r.	PROPN
ajst-32485	209	49	,	,	PUNCT
ajst-32485	209	50	chandra	chandra	PROPN
ajst-32485	209	51	,	,	PUNCT
ajst-32485	209	52	a.	a.	PROPN
ajst-32485	209	53	k.	k.	PROPN
ajst-32485	209	54	,	,	PUNCT
ajst-32485	209	55	waters	water	NOUN
ajst-32485	209	56	,	,	PUNCT
ajst-32485	209	57	t.	t.	PROPN
ajst-32485	209	58	,	,	PUNCT
ajst-32485	209	59	ruan	ruan	PROPN
ajst-32485	209	60	,	,	PUNCT
ajst-32485	209	61	j.	j.	PROPN
ajst-32485	209	62	,	,	PUNCT
ajst-32485	209	63	amisaki	amisaki	ADV
ajst-32485	209	64	,	,	PUNCT
ajst-32485	209	65	m.	m.	NOUN
ajst-32485	209	66	,	,	PUNCT
ajst-32485	209	67	zebboudj	zebboudj	PROPN
ajst-32485	209	68	,	,	PUNCT
ajst-32485	209	69	a.	a.	NOUN
ajst-32485	209	70	,	,	PUNCT
ajst-32485	209	71	odgerel	odgerel	PROPN
ajst-32485	209	72	,	,	PUNCT
ajst-32485	209	73	z.	z.	PROPN
ajst-32485	209	74	,	,	PUNCT
ajst-32485	209	75	payne	payne	PROPN
ajst-32485	209	76	,	,	PUNCT
ajst-32485	209	77	g.	g.	PROPN
ajst-32485	209	78	,	,	PUNCT
ajst-32485	209	79	derhovanessian	derhovanessian	PROPN
ajst-32485	209	80	,	,	PUNCT
ajst-32485	209	81	e.	e.	PROPN
ajst-32485	209	82	,	,	PUNCT
ajst-32485	209	83	&	&	CCONJ
ajst-32485	209	84	müller	müller	PROPN
ajst-32485	209	85	,	,	PUNCT
ajst-32485	209	86	f.	f.	PROPN
ajst-32485	209	87	(	(	PUNCT
ajst-32485	209	88	2023	2023	NUM
ajst-32485	209	89	)	)	PUNCT
ajst-32485	209	90	.	.	PUNCT
ajst-32485	210	1	personalized	personalize	VERB
ajst-32485	210	2	rna	rna	PROPN
ajst-32485	210	3	neoantigen	neoantigen	PROPN
ajst-32485	210	4	vaccines	vaccine	NOUN
ajst-32485	210	5	stimulate	stimulate	VERB
ajst-32485	210	6	t	t	NOUN
ajst-32485	210	7	cells	cell	NOUN
ajst-32485	210	8	in	in	ADP
ajst-32485	210	9	pancreatic	pancreatic	ADJ
ajst-32485	210	10	cancer	cancer	NOUN
ajst-32485	210	11	.	.	PUNCT
ajst-32485	211	1	nature	nature	NOUN
ajst-32485	211	2	,	,	PUNCT
ajst-32485	211	3	618(7963	618(7963	NUM
ajst-32485	211	4	)	)	PUNCT
ajst-32485	211	5	,	,	PUNCT
ajst-32485	211	6	1–7	1–7	X
ajst-32485	211	7	.	.	PUNCT
ajst-32485	212	1	https://doi.org/10.1038/s41586-023-06063-y	https://doi.org/10.1038/s41586-023-06063-y	NOUN
ajst-32485	212	2	.	.	PUNCT
ajst-32485	213	1	[	[	X
ajst-32485	213	2	9	9	NUM
ajst-32485	213	3	]	]	PUNCT
ajst-32485	213	4	who	who	PRON
ajst-32485	213	5	.	.	PUNCT
ajst-32485	213	6	(	(	PUNCT
ajst-32485	213	7	2025	2025	NUM
ajst-32485	213	8	)	)	PUNCT
ajst-32485	213	9	.	.	PUNCT
ajst-32485	214	1	who	who	PRON
ajst-32485	214	2	.	.	PUNCT
ajst-32485	215	1	www.who.int	www.who.int	NOUN
ajst-32485	215	2	.	.	PUNCT
ajst-32485	216	1	https://www.who.int/data/data-collection-tools/who-mortalitydatabase	https://www.who.int/data/data-collection-tools/who-mortalitydatabase	NOUN
ajst-32485	216	2	.	.	PUNCT